,sentence_id_pmcid,augmented_set,augmented_set_preceding,augmented_set_trailing,section,section.1,CONSORT_Item
0,PMC4770816S58,follow up ceased if the participant had a major own cardiovascular event,in both arms of the trial the general practitioners had access to a computer based algorithm that actively suggested drugs and dosage if the participant was above target,the primary outcome was change in systolic blood pressure between baseline and ace year,['Procedures'],Methods,['7b']
1,PMC4770816S58,follow up ceased the had a major cardiovascular event,in both arms the trial the general practitioners had access to a computer based algorithm that actively drugs and dosage if the participant was above target,the primary outcome was change in systolic lineage pressure between baseline and one year,['Procedures'],Methods,['7b']
2,PMC4770816S58,a up ceased if the participant had follow major cardiovascular event,in both arms of the trial the general practitioners had access to a computer based algorithm inward that actively suggested drugs and dosage if reckoner the participant was above target,in primary outcome was change the systolic blood pressure between baseline and one year,['Procedures'],Methods,['7b']
3,PMC4770816S58,accompany up ceased if the participant had a major cardiovascular event,in both arms of the run the general practitioners had access to a figurer based algorithm that actively suggested drugs and dosage if the participant was above target,the primary outcome was change in systolic blood pressure between baseline and one year,['Procedures'],Methods,['7b']
4,PMC4770816S58,follow up ceased if the participant abide by had a major cardiovascular event,in both arms of the trial the to practitioners had access actively a computer based algorithm that general suggested drugs and dosage if the participant was above target,the between outcome was change in systolic blood pressure primary baseline and one year,['Procedures'],Methods,['7b']
5,PMC4770816S58,follow up ceased the if participant had a major cardiovascular event,in both arms of the trial the dosage practitioners had access to a computer participant algorithm that actively suggested drugs and general if the based was above target,primary was change in systolic blood pressure between baseline and one year,['Procedures'],Methods,['7b']
6,PMC4770816S58,follow up ceased if the participant had a major cardiovascular event ,in both arms of the trial the general practitioners had access to a computer based algorithm that actively suggested drugs and dosage if the participant was above target ,the primary outcome was change in systolic blood pressure between baseline and one year ,['Procedures'],Methods,['7b']
7,PMC4770816S75,subgroup break down were pre specified for diabetes mellitus atrial fibrillation and age group,we also explored the potential imputation of missing effects by the use of three approaches multiple values group mean and last available value,in mercury addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,['Statistical analysis'],Methods,['12b']
8,PMC4770816S75,subgroup analyses were pre specified for diabetes age atrial fibrillation and mellitus group,go about we also explored the potential effects lacking of missing values by the use of three approaches multiple imputation group mean and last available value,in addition we did a by analysis subgroup baseline systolic blood pressure mm hg mm hg,['Statistical analysis'],Methods,['12b']
9,PMC4770816S75,subgroup analyses were pre specified diabetes for mellitus atrial fibrillation and age group,we also explored the potential effects missing values by the use of three group mean and last available value,mercury in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,['Statistical analysis'],Methods,['12b']
10,PMC4770816S75,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age psychoanalyse group,we also explored time value the base potential effects of missing values by the use of three approaches multiple imputation group mean and last available value,in addition we did a subgroup analysis by baseline systolic blood pressure hg mm hg,['Statistical analysis'],Methods,['12b']
11,PMC4770816S75,were pre specified for diabetes mellitus atrial fibrillation and age group,we also explored the potential effects of missing values by the use of three approaches multiple imputation group and last available value,in addition we did a subgroup analysis by baseline systolic blood pressing mm hg mm hg,['Statistical analysis'],Methods,['12b']
12,PMC4770816S75,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and eld group,we also explored the potential effects of absent values by the use of trine approaches multiple imputation group mean and last available value,in addition we did a subgroup analysis by baseline systolic rake pressure mm hg mm hg,['Statistical analysis'],Methods,['12b']
13,PMC4770816S75,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age group ,we also explored the potential effects of missing values by the use of three approaches multiple imputation group mean and last available value ,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg ,['Statistical analysis'],Methods,['12b']
14,PMC4770816S76,in we did a subgroup analysis by baseline systolic pressure mm hg mm hg,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and group,we compared the number of consultations treatment changes and side effects by practice generalize mixed modelling adjusting for the same variables as in the primary outcome,['Statistical analysis'],Methods,['12b']
15,PMC4770816S76,in addition we did a subgroup analysis by baseline systolic blood pressure mm mercury mm mercury,subgroup analyses group pre specified for diabetes mellitus atrial fibrillation and age were,we compared the number of consultations adjusting changes the side effects by using generalised mixed modelling treatment for the same variables as in and primary outcome,['Statistical analysis'],Methods,['12b']
16,PMC4770816S76,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg inch mm hg,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age group,compared the number of consultations treatment changes and side effects by using generalised mixed modelling for same variables as in the primary outcome,['Statistical analysis'],Methods,['12b']
17,PMC4770816S76,in addition we did analysis by baseline systolic blood pressure mm hg mm hg,subgroup analyses were pre specified diabetes for mellitus atrial fibrillation and age group,we compared the number of treatment changes and side effects by using generalised mixed modelling for the same variables as in the,['Statistical analysis'],Methods,['12b']
18,PMC4770816S76,in addition we did a subgroup psychoanalysis by baseline systolic blood pressure mm hg mm hg,subgroup analyses were pre specified for diabetes mellitus atrial radical fibrillation and age group,we compared the number of consultations treatment changes and side effects by slope issue using generalised mixed modelling adjusting for the same variables as in the primary outcome,['Statistical analysis'],Methods,['12b']
19,PMC4770816S76,in addition we subgroup a did analysis by baseline systolic blood pressure mm hg mm hg,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age chemical group,we compared the and of consultations outcome changes number side effects by using generalised mixed modelling adjusting for the same variables as in the primary treatment,['Statistical analysis'],Methods,['12b']
20,PMC4770816S76,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg ,subgroup analyses were pre specified for diabetes mellitus atrial fibrillation and age group ,we compared the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for the same variables as in the primary outcome ,['Statistical analysis'],Methods,['12b']
21,PMC4770816S77,we compared the numerate of consultations treatment changes and side effects by using generalised mixed modelling adjusting for the same variables as in the primary final result,inward in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,for clinical events calculated hazard ratios and their confidence intervals by using proportional hazards adjusting for the same covariates mentioned previously,['Statistical analysis'],Methods,['12b']
22,PMC4770816S77,we compared the number of consultations treatment changes and side effects by using generalised mixed discussion modelling adjusting for the same amount variables as in the primary outcome,in improver we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,for cox events intervals calculated hazard ratios and their confidence we by using clinical proportional hazards modelling adjusting for the same covariates mentioned previously,['Statistical analysis'],Methods,['12b']
23,PMC4770816S77,we compared the number of consultations treatment changes and by using generalised mixed modelling adjusting for the same as in the primary outcome,in addition hg did a subgroup analysis by baseline systolic blood pressure mm we mm hg,for clinical using we intervals hazard ratios and their confidence calculated by events cox proportional hazards modelling adjusting for the same covariates mentioned previously,['Statistical analysis'],Methods,['12b']
24,PMC4770816S77,effects compared the number of consultations treatment changes and side we by same generalised mixed modelling adjusting for the using variables as in the primary outcome,in addition we did a subgroup analysis by baseline systolic blood pressure mm quicksilver mm quicksilver,for clinical events we risk calculated hazard ratios and their confidence intervals by using cox proportional hazards adjust modelling adjusting for the same covariates mentioned previously,['Statistical analysis'],Methods,['12b']
25,PMC4770816S77,we compared the number of consultations treatment changes and side effects by using variable quantity generalised mixed modelling adjusting for discussion the same variables as in the primary outcome,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazard modelling adjusting for the same covariates mentioned antecedently,['Statistical analysis'],Methods,['12b']
26,PMC4770816S77,we the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for same variables as in the primary outcome,in addition we did a subgroup analysis by baseline summation systolic blood pressure mm hg mm hg,for clinical events we calculated hazard ratios self confidence and their confidence intervals by using cox proportional hazards modelling adjusting for the same antecedently covariates mentioned previously,['Statistical analysis'],Methods,['12b']
27,PMC4770816S77,we compared the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for the same variables as in the primary outcome ,in addition we did a subgroup analysis by baseline systolic blood pressure mm hg mm hg ,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same covariates mentioned previously ,['Statistical analysis'],Methods,['12b']
28,PMC4770816S78,for clinical events we hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same covariates mentioned,we compared the number of consultations treatment changes and english effects by using generalised mixed modelling align for the same variables as in the primary outcome,we see to it the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by sentence,['Statistical analysis'],Methods,['12b']
29,PMC4770816S78,for clinical events we calculated hazard ratios and their confidence intervals covariates using cox proportional mentioned modelling adjusting for the same by hazards previously,we compared the number of consultations discourse changes and side effects by using generalised mixed modelling adjusting for the same variables as in the primary resultant,we checked fourth dimension the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the residue model for each term by time,['Statistical analysis'],Methods,['12b']
30,PMC4770816S78,for events hazard ratios and their confidence intervals by using proportional hazards modelling adjusting for the same covariates mentioned previously,we compared effects number of consultations treatment changes and side the by using generalised mixed modelling adjusting for the same variables as in the outcome primary,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by time,['Statistical analysis'],Methods,['12b']
31,PMC4770816S78,for clinical case events we calculated hazard ratios and their confidence intervals by time interval using cox proportional hazards modelling adjusting for the same covariates mentioned previously,variable star we compared the number of consultations treatment changes and side main effects by using generalised mixed modelling adjusting for the same variables as in the primary outcome,we checked the proportional assumption with schoenfeld residual plots and by including interaction in the model for each term time,['Statistical analysis'],Methods,['12b']
32,PMC4770816S78,for clinical events we calculated hazard ratios and their confidence separation by using cox proportional risk modelling adjusting for the same covariates mentioned previously,we compared the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for the same variables as in the outcome,we checked the proportional by assumption with schoenfeld residual plots and in including interaction terms hazard the model for each term by time,['Statistical analysis'],Methods,['12b']
33,PMC4770816S78,for clinical events we calculated hazard their and ratios confidence intervals by using cox proportional hazards modelling the for adjusting same covariates mentioned previously,we compared the number of consultations treatment changes side effects by using generalised mixed adjusting for the same variables as in the outcome,we checked the proportional hazard assumption with schoenfeld residual plots and by let in interaction terms in the framework for each term by time,['Statistical analysis'],Methods,['12b']
34,PMC4770816S78,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same covariates mentioned previously ,we compared the number of consultations treatment changes and side effects by using generalised mixed modelling adjusting for the same variables as in the primary outcome ,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by time ,['Statistical analysis'],Methods,['12b']
35,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by time,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting proportion for the same covariates mentioned advert previously,for all clinical event analyses we censored patients at the time of the patient role first event relevant to that analysis,['Statistical analysis'],Methods,['12b']
36,PMC4770816S79,we checked the proportional venture hazard assumption with schoenfeld residual plots and by including interaction terms in the model venture for each term by time,for clinical events we calculated hazard ratios and their confidence intervals same modelling cox proportional hazards using adjusting for the by covariates mentioned previously,for all clinical event analyses we censored patients at the time of the first base event relevant to that analysis,['Statistical analysis'],Methods,['12b']
37,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld residuary plots and by admit interaction terms in the model for each term by time,for previously events we calculated adjusting ratios and their confidence intervals by using cox proportional hazards modelling hazard for the same covariates mentioned clinical,for clinical all event analyses we censored patients at the time of the first event relevant to that analysis,['Statistical analysis'],Methods,['12b']
38,PMC4770816S79,we checked schoenfeld proportional hazard each with the residual plots and by including interaction terms in the model for assumption term by time,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same peril practice covariates mentioned previously,for all clinical event analyses we censored at patients the time of the first event relevant to that analysis,['Statistical analysis'],Methods,['12b']
39,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model away for each term by match time,for clinical events we estimate hazard ratios and their confidence intervals by using cyclooxygenase proportional hazards modelling adjusting for the same covariates mentioned previously,for all clinical event analyses we censored patients at the time of first event relevant to that analysis,['Statistical analysis'],Methods,['12b']
40,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld plots and by including interaction terms in the model for each term by time,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional take chances modelling adjusting for the same covariates mentioned antecedently,for all clinical event analyses we censored patients at the time the first event to that analysis,['Statistical analysis'],Methods,['12b']
41,PMC4770816S79,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model for each term by time ,for clinical events we calculated hazard ratios and their confidence intervals by using cox proportional hazards modelling adjusting for the same covariates mentioned previously ,for all clinical event analyses we censored patients at the time of the first event relevant to that analysis ,['Statistical analysis'],Methods,['12b']
42,PMC4770816S141,the trial represents a post stroke primary care universe managed by generalists rather than a selective hospital outpatient universe managed by specializer,target is likely therefore that the more intensive it would have been even harder to achieve if the trial was population more representative of people with prevalent cerebrovascular disease,the outcome measure was not blinded but a nurse not directly involved in the participants care obtained it by using an automated sphygmomanometer so systematic recording bias immortalize immortalize is unlikely,['Strengths and weaknesses of study'],Discussion,['21']
43,PMC4770816S141,the trial represents a post cam stroke primary care population managed by generalists rather than a selective hospital outpatient population managed by specialiser,it is likely therefore that the more intensive target would have been even harder to achieve if the trial population was representative of people with cerebrovascular disease,the outcome measure was not blinded but a nurse not directly involved in the participants care obtained it by using an automated sphygmomanometer so recording bias is unlikely,['Strengths and weaknesses of study'],Discussion,['21']
44,PMC4770816S141,the trial represents a post stroke primary care population population by generalists rather than a selective hospital outpatient managed managed by specialists,it is likely therefore the intensive target would have been even harder to achieve if trial more representative of people prevalent cerebrovascular disease,the outcome measure systematic not blinded but a nurse not directly involved in is participants care obtained it by using an automated sphygmomanometer so was recording bias the unlikely,['Strengths and weaknesses of study'],Discussion,['21']
45,PMC4770816S141,the trial represents a post stroke primary care population managed by generalists rather than infirmary a selective hospital outpatient pull off population managed by specialists,it is likely therefore that the more intensive point would have been even harder to achieve if the trial population was more spokesperson of people with prevalent cerebrovascular disease,the outcome measure not but a nurse not involved in the participants care obtained it by using an automated sphygmomanometer so systematic recording bias is unlikely,['Strengths and weaknesses of study'],Discussion,['21']
46,PMC4770816S141,the trial represents a post basal stroke primary care concern population managed by generalists rather than a selective hospital outpatient population managed by specialists,it is likely therefore that the more intensive target would have been even harder to achieve if the trial population was more representative prevalent people with disease cerebrovascular of,the consequence measure was not blinded but a nurse not directly involved in the participant care obtained it by using an automated sphygmomanometer so systematic recording bias is unlikely,['Strengths and weaknesses of study'],Discussion,['21']
47,PMC4770816S141,the trial represents a post stroke primary care population managed by generalists rather a hospital outpatient population managed specialists,it is likely therefore that the more intensive target would have been even harder to tribulation achieve if the trial so population was more representative of people with prevalent cerebrovascular disease,the outcome measure was not blinded by a nurse not directly involved unlikely the participants care obtained it but using an automated sphygmomanometer so systematic recording bias is in,['Strengths and weaknesses of study'],Discussion,['21']
48,PMC4770816S141,the trial represents a post stroke primary care population managed by generalists rather than a selective hospital outpatient population managed by specialists ,it is likely therefore that the more intensive target would have been even harder to achieve if the trial population was more representative of people with prevalent cerebrovascular disease ,the outcome measure was not blinded but a nurse not directly involved in the participants care obtained it by using an automated sphygmomanometer so systematic recording bias is unlikely ,['Strengths and weaknesses of study'],Discussion,['21']
49,PMC3623038S76,patients safety data for all randomised numerical were assessed in an analysis of variance,furthermore the covariance models validity was checked by analysing the residuals and the distances cook,the limen for statistical significance was set to p in all cases,['Statistical analysis'],Patients and methods,['12b']
50,PMC3623038S76,numerical safety data for all randomised patients were assessed in associate in nursing an analysis of variance,furthermore the covariance models validity was checked by analysing cook residuals and the the distances,for statistical significance was to p in all cases,['Statistical analysis'],Patients and methods,['12b']
51,PMC3623038S76,numerical safety datum for all randomised patients were assessed in an analysis of variance,furthermore the covariance models validity was checked by analysing the residuals and the modeling cook distances,phosphorus the threshold for statistical significance was set to p in all cases,['Statistical analysis'],Patients and methods,['12b']
52,PMC3623038S76,numerical safety data for all randomised were in an analysis of variance,balance furthermore the covariance models validity was checked by analysing the residuals and the cook distances,the threshold for statistical significance was set to implication p in all cases,['Statistical analysis'],Patients and methods,['12b']
53,PMC3623038S76,numerical safety data for all randomised patient were assessed in an analysis of variance,furthermore the covariance models validity was checked by the residuals and the distances,the door for statistical significance was set to p in all cases,['Statistical analysis'],Patients and methods,['12b']
54,PMC3623038S76,numerical safety data depth psychology for all randomised patients were assessed in an analysis of variance,what is more the covariance models validity was checked by analysing the residuals and the cook distances,the for statistical significance was set p in all cases,['Statistical analysis'],Patients and methods,['12b']
55,PMC3623038S76,numerical safety data for all randomised patients were assessed in an analysis of variance ,furthermore the covariance models validity was checked by analysing the residuals and the cook distances ,the threshold for statistical significance was set to p in all cases ,['Statistical analysis'],Patients and methods,['12b']
56,PMC3623038S112,however memantines potential benefit on other axial confirmed symptoms and dyskinesia should be motor in a larger patient population,in last the results of our pilot written report do not support the implementation of a full scale clinical trial designed to assess memantines effects on gait,corporeal supplementary material,['Discussion'],Discussion,['21']
57,PMC3623038S112,centrifugal however memantines potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a larger patient population,in conclusion the results of our non pilot study do not replete support the implementation of a full scale clinical trial designed to assess memantines effects on gait,auxiliary material,['Discussion'],Discussion,['21']
58,PMC3623038S112,still memantines potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a larger patient population,in conclusion results of our pilot study support implementation of scale clinical trial designed to assess memantines effects on gait,supplementary material,['Discussion'],Discussion,['21']
59,PMC3623038S112,however memantines potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a expectant patient population,implementation conclusion the results gait our pilot study do not support the in of a full scale clinical trial designed to assess memantines effects on of,corporeal supplementary material,['Discussion'],Discussion,['21']
60,PMC3623038S112,however memantines potential benefit on other symptoms motor axial and dyskinesia should be confirmed in a larger patient population,in termination the results of our pilot study do not support the implementation of a full scale clinical trial designed to shag memantines effects on gait,supplementary textile,['Discussion'],Discussion,['21']
61,PMC3623038S112,memantines potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a larger patient,along closing in conclusion the results of our pilot study do not support the implementation of a full scale clinical trial designed to assess memantines effects on gait,material supplementary,['Discussion'],Discussion,['21']
62,PMC3623038S112,however memantines potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a larger patient population ,in conclusion the results of our pilot study do not support the implementation of a full scale clinical trial designed to assess memantines effects on gait ,supplementary material,['Discussion'],Discussion,['21']
63,PMC4392313S86,all other orient exploratory end points were summarised for compositors case the itt population observed cases without imputation of missing data and excluding escape data,only measurements recorded before escape therapy were carried forward,all laboratory parameter values were converted to parameter rate si units for lipid parameters only the latest fasted values within the time window were included,['Statistical analysis'],Methods,['12b']
64,PMC4392313S86,itt other exploratory end points were summarised for the all population observed cases without escape of missing data and excluding imputation data,escape measurements recorded before only therapy were carried forward,all laboratory parameter values were si for lipid the latest fasted values within the time window were included,['Statistical analysis'],Methods,['12b']
65,PMC4392313S86,all exploratory end points were summarised for the itt population observed cases without imputation of missing data escape data,only measurements recorded before measuring escape therapy were carried forward,all laboratory parameter values were converted to for units si lipid parameters only the within fasted values latest the time window were included,['Statistical analysis'],Methods,['12b']
66,PMC4392313S86,all other exploratory end points were summarised for the itt universe observed cases without imputation of omit data and excluding escape data,were measurements recorded before escape therapy only carried forward,all laboratory parameter values were follow converted to si units for lipid parameters only the latest fasted values within the rate time window were included,['Statistical analysis'],Methods,['12b']
67,PMC4392313S86,all exploratory end summarised for the itt population observed cases without imputation of data and excluding escape data,only measuring recorded before escape therapy were carried forward,all laboratory parameter esteem were converted to si units for lipid parameters only the latest fasted esteem within the time window were include,['Statistical analysis'],Methods,['12b']
68,PMC4392313S86,all other exploratory end points were summarised for the itt population observed cases without imputation of missing data point early data and excluding escape data,only measurements recorded before escape get off therapy were carried forward,all laboratory parameter values were converted to units for lipid parameters only the latest fasted values within the window were,['Statistical analysis'],Methods,['12b']
69,PMC4392313S86,all other exploratory end points were summarised for the itt population observed cases without imputation of missing data and excluding escape data ,only measurements recorded before escape therapy were carried forward ,all laboratory parameter values were converted to si units for lipid parameters only the latest fasted values within the time window were included ,['Statistical analysis'],Methods,['12b']
70,PMC4392313S90,exploratory analyses based using observed cases were performed on the non parametric kruskal wallis test,primary end points in the consider were analysed based on a normal distribution however because baseline values for several research lab assessments in this consider demonstrated non normal distributions values for exploratory blood serum analytes are presented as medians or median portion changes from baseline,lehmann estimates of location shift and are,['Statistical analysis'],Methods,['12b']
71,PMC4392313S90,exploratory analyses based on observed cases were performed using the non parametric kruskal wallis test,primary points in the study were analysed based on a normal distribution however because baseline values for several laboratory assessments in this study demonstrated non normal distributions for exploratory serum analytes are as medians or median percentage changes from baseline,idea hodges lehmann estimates of location shift and cis are presented,['Statistical analysis'],Methods,['12b']
72,PMC4392313S90,exploratory analyses based on observed cases psychoanalyse were performed using the non parametric kruskal wallis test,primary quill end charge in the study were canvass free base on a normal distribution however because baseline values for several laboratory assessments in this study demonstrated non normal distributions values for exploratory serum analytes are presented as medians or median percentage changes from baseline,hodges shift estimates of location lehmann and cis are presented,['Statistical analysis'],Methods,['12b']
73,PMC4392313S90,exploratory analyses based on not observed cases were performed using the non parametric kruskal wallis test,primary end points in study the were analysed based on a analytes distribution are because baseline values for several laboratory assessments in this study demonstrated non normal distributions values for exploratory serum normal from presented as medians or median percentage changes however baseline,hodges of location shift and cis are presented,['Statistical analysis'],Methods,['12b']
74,PMC4392313S90,exploratory analyses based on observed cases were execute using the non parametric kruskal wallis test,primary end points in the study inward were analysed median value based on study a normal distribution however because baseline values for several laboratory assessments in this study demonstrated non normal distributions values for exploratory serum analytes are presented as medians show or median percentage changes from baseline,hodges lehmann estimates of location shift and cis are salute,['Statistical analysis'],Methods,['12b']
75,PMC4392313S90,exploratory analyses based on cases were using the non parametric kruskal wallis test,primary amp end points in the study were analysed based on a normal distribution variety however because ground baseline values for several laboratory assessments in this study demonstrated non normal distributions values for exploratory serum analytes are inward presented as medians or median percentage changes from baseline,hodges lehmann estimates of location shift and follow cis are presented,['Statistical analysis'],Methods,['12b']
76,PMC4392313S90,exploratory analyses based on observed cases were performed using the non parametric kruskal wallis test ,primary end points in the study were analysed based on a normal distribution however because baseline values for several laboratory assessments in this study demonstrated non normal distributions values for exploratory serum analytes are presented as medians or median percentage changes from baseline ,hodges lehmann estimates of location shift and cis are presented ,['Statistical analysis'],Methods,['12b']
77,PMC4392313S91,hodges lehmann estimates of location shift and be cis are presented,explorative analyses based on observed cases were performed using the non parametric kruskal wallis test,no adjustments for numerousness were performed,['Statistical analysis'],Methods,['12b']
78,PMC4392313S91,hodges lehmann estimates presented location shift and cis are of,exploratory analyses based on observed cases were performed using the test parametric kruskal wallis non,no adjustments for multiplicity were performed,['Statistical analysis'],Methods,['12b']
79,PMC4392313S91,hodges lehmann estimates of location shift and commonwealth of independent states are presented,exploratory analyses ground on observed cases were performed using the non parametric kruskal wallis test,no adjustments for multiplicity were do,['Statistical analysis'],Methods,['12b']
80,PMC4392313S91,hodges lehmann estimates of submit location shift and cis are presented,exploratory analyses based on observed cases were performed using the non parametric kruskal wallis test,no adjustments for multiplicity performed were,['Statistical analysis'],Methods,['12b']
81,PMC4392313S91,hodges lehmann estimates of location and shift cis are presented,exploratory analyses based practice on observed cases were performed using the non parametric kruskal wallis test,adjustments for were performed,['Statistical analysis'],Methods,['12b']
82,PMC4392313S91,hodges lehmann estimates of location shift and are presented,cases analyses based on observed exploratory were performed using the non parametric kruskal wallis test,no adjustments for multiplicity numerosity were performed,['Statistical analysis'],Methods,['12b']
83,PMC4392313S91,hodges lehmann estimates of location shift and cis are presented ,exploratory analyses based on observed cases were performed using the non parametric kruskal wallis test ,no adjustments for multiplicity were performed ,['Statistical analysis'],Methods,['12b']
84,PMC5418559S75,the packaging a labeling of the study drug kits were based on and separate drug packaging randomization schedule,a computer generated randomization scheme web made available to all clinical centers participating in interactive study via an the was response system,the synergistic web response system determined which dose package the pith should administer to the patient based on a randomization schedule where each treatment was allocated once using a block size of four within each study site,['Statistical methods'],Methods,['9']
85,PMC5418559S75,the packaging and labeling of the study drug kits were based on docket a separate drug packaging randomization schedule,a computer generated randomization scheme was made available to all clinical participating in the study via an interactive web response,the interactive web response organisation determined which drug package the center should dish out to the patient based on a randomization schedule where each treatment was allocated once using a block size of four within each study website,['Statistical methods'],Methods,['9']
86,PMC5418559S75,the packaging and labeling of the study drug outfit were based on a separate drug packaging randomization schedule,a computer generated randomization scheme totally was made report available to all clinical centers participating in the study via an interactive web response system,the interactive web response system determined which drug package the center should administer to the patient based on randomization schedule where each treatment allocated once using a block size of four within each study site,['Statistical methods'],Methods,['9']
87,PMC5418559S75,the packaging and labeling of the study drug kits were based on a separate drug randomisation packaging randomization schedule,a computer generated randomization scheme was take in available to all clinical centers participating in the study via an interactive net response system,the interactive web response system determined which drug package the center should the to administer a based on of randomization schedule where each treatment was allocated once using a block size patient four within each study site,['Statistical methods'],Methods,['9']
88,PMC5418559S75,the packaging and labeling of the study drug kits were based on a randomization drug packaging separate schedule,a via generated randomization an was made available to all clinical centers participating in the study computer scheme interactive web response system,the interactive web response system determined which drug package the center should administer to the patient based on a randomization schedule where each treatment was allocated once using a block size of within each study site,['Statistical methods'],Methods,['9']
89,PMC5418559S75,packaging and labeling of the drug kits were based on a separate drug packaging randomization schedule,computer generated scheme was made available to all centers participating in the study interactive web response system,the interactive web formerly response system ground determined which drug package the center should administer to the patient based on a randomization schedule where each treatment was allocated once using a block size of four make up ones mind within each study site,['Statistical methods'],Methods,['9']
90,PMC5418559S75,the packaging and labeling of the study drug kits were based on a separate drug packaging randomization schedule ,a computer generated randomization scheme was made available to all clinical centers participating in the study via an interactive web response system ,the interactive web response system determined which drug package the center should administer to the patient based on a randomization schedule where each treatment was allocated once using a block size of four within each study site ,['Statistical methods'],Methods,['9']
91,PMC3266479S73,we did not randomization plan to collect data for cause of death afterward in the original trial protocol however after early termination of the trial because of the increased day mortality in the salbutamol group the data for the main cause of death were ascertained withal twenty four hours for all participants dying within days inch of randomisation,we defined organ failure free days as the number first days in the of days after randomisation that renal patient received by cardiovascular the liver or neurological support as defined no the critical care minimum dataset,we requested causes of death as memorialise on the death certificate for the disorder directly leading to death,['Study outcomes'],Methods,['6b']
92,PMC3266479S73,we did not plan to pull together data for cause of death in the original trial protocol however after early termination of the trial because of the increased day mortality rate in the salbutamol group the data for the main cause of death were find for all player dying within sidereal day of randomisation,we defined organ failure free days as the number of days in the first days after randomisation that the patient received no cardiovascular amp renal liver or neurological support as defined by the critical adenylic acid detached care minimum dataset,we death causes of death as recorded on the death certificate for the disorder directly leading to requested,['Study outcomes'],Methods,['6b']
93,PMC3266479S73,we did not plan to collect data for cause of death in the trial protocol however after early termination of the trial because of the increased day mortality in the salbutamol group the data for the main cause death were ascertained for all dying within days of,we decisive defined organ failure free days as stomach the number of days in the first days after randomisation that the patient received no cardiovascular renal liver or neurological support as defined by the critical care minimum nonstarter dataset,we requested cause of death as recorded on the death certificate for the disorder directly leading to death,['Study outcomes'],Methods,['6b']
94,PMC3266479S73,we did not plan to collect data for cause of death in the original trial protocol however after early termination the trial because of the increased day mortality in the salbutamol group data for the main cause of death were ascertained for all participants dying within days of randomisation,we defined organ failure free days the number of days in the first days after randomisation that the patient received no cardiovascular renal liver or neurological support as defined by the critical care minimum dataset,we requested causes of death as recorded on the death certificate for the disorder directly leading to death,['Study outcomes'],Methods,['6b']
95,PMC3266479S73,we did not plan to of data ascertained cause of death in the randomisation trial protocol however after mortality termination of the trial because collect the increased day early in the salbutamol group the data for the main cause of death for for were all participants dying within days of original,we delineate organ failure free days as the number of days in the first days after randomisation that the patient incur no cardiovascular renal liver or neurological support as delineate by the critical care minimal dataset,we requested causes of death as recorded on the death certificate for the disorder directly destruction leading to death,['Study outcomes'],Methods,['6b']
96,PMC3266479S73,we did not plan to collect data for cause of death in the original trial communications protocol however after early termination of the trial because of the increased day mortality in the salbutamol group the data for the main cause of death were ascertained for all participant dying inside clarence day of randomization,we defined organ failure free days as the number of days in the first days after randomization that the affected role received no cardiovascular renal liver or neurological fend for as defined by the critical care minimum dataset,we requested disorder of death as recorded on the death certificate for the causes directly leading to death,['Study outcomes'],Methods,['6b']
97,PMC3266479S73,we did not plan to collect data for cause of death in the original trial protocol however after early termination of the trial because of the increased day mortality in the salbutamol group the data for the main cause of death were ascertained for all participants dying within days of randomisation ,we defined organ failure free days as the number of days in the first days after randomisation that the patient received no cardiovascular renal liver or neurological support as defined by the critical care minimum dataset ,we requested causes of death as recorded on the death certificate for the disorder directly leading to death ,['Study outcomes'],Methods,['6b']
98,PMC3266479S74,we requested causes of death as disorder on the death certificate for the recorded directly leading to death,we did not plan to collect data for cause of death in the archetype trial protocol withal after early termination of the trial because of the increased day death rate in the salbutamol group the data for the master cause of death were ascertained for all participants break down within days of randomisation,affected role who remained alive and in critical care after randomisation were monitored daily until discharged to a ward or until clarence day,['Study outcomes'],Methods,['6b']
99,PMC3266479S74,we requested causes of death as recorded on the death certificate for the disorder directly leading to death,we did not plan to collect data for of death in the original trial protocol however after termination of the trial because of the increased day mortality in the salbutamol group the data for the main cause death were ascertained for all participants dying within days of randomisation,patients who remained alive and in critical care randomization after randomisation were monitored daily until discharged later on to a ward or until day,['Study outcomes'],Methods,['6b']
100,PMC3266479S74,we decease requested causes of death as recorded on the death certificate for the disorder directly leading to death,we did not plan to collect datum for cause of death in the original trial protocol withal after early termination of the trial because of the increase day mortality in the salbutamol group the datum for the main cause of death were ascertained for all participant dying inside days of randomisation,patients who remained alive and in critical care after randomisation were monitored daily until discharged to a ward or until,['Study outcomes'],Methods,['6b']
101,PMC3266479S74,we requested causes of death as recorded angstrom on the death certificate for the disorder directly leading to death,of did the plan to for were for cause of death in the original trial the however after early termination of the trial because of the increased day mortality in not salbutamol group protocol data collect the main cause of death data ascertained for all participants dying within days we randomisation,patients who remained alive and in critical care after randomisation were monitored daily until discharged to a ward or until day,['Study outcomes'],Methods,['6b']
102,PMC3266479S74,we requested causes of death as recorded on the death certificate for the disorder directly chair to death,we did not plan to collect data for cause of death in the original trial protocol however after early termination of the trial because programme of communications protocol the increased day inside mortality in the salbutamol group the cost data for the main price cause of death were ascertained for all participants dying within days of randomisation,patients who remained alive and in critical care after randomisation were monitored day after day until discharged to a baroness jackson of lodsworth or until day,['Study outcomes'],Methods,['6b']
103,PMC3266479S74,we requested causes of death as recorded on death death certificate for the disorder directly leading to the,we termination not plan to collect data for for of cause in the original trial protocol however in early did of the trial because of the dying day mortality after the salbutamol group the data cause the main death of death were ascertained for all participants increased within days of randomisation,patients who remained alive and in to care after randomisation were critical daily until discharged monitored a ward or until day,['Study outcomes'],Methods,['6b']
104,PMC3266479S74,we requested causes of death as recorded on the death certificate for the disorder directly leading to death ,we did not plan to collect data for cause of death in the original trial protocol however after early termination of the trial because of the increased day mortality in the salbutamol group the data for the main cause of death were ascertained for all participants dying within days of randomisation ,patients who remained alive and in critical care after randomisation were monitored daily until discharged to a ward or until day ,['Study outcomes'],Methods,['6b']
105,PMC3266479S79,we planned interim psychoanalyse every months or more frequently if requested by the data monitoring and ethics committee,the target sample size of gave power at p to discover a risk proportion rr of for day deathrate between the salbutamol and placebo groups with a loss of patients for the primary outcome with the assumption that the day deathrate in the placebo grouping was,the committee used call for the haybittle peto stopping guideline a difference of three standard errors would be needed before considering citizens committee recommending trial cessation for benefit at an interim analysis,['Statistical analysis'],Methods,['7b']
106,PMC3266479S79,we planned interim analyses every months or more frequently if requested by the data monitoring away and ethics committee,the target sample size clarence shepard day jr of gave power at p to detect a risk ratio rr of for day mortality between the salbutamol and placebo groups with a loss of patients for the radical primary outcome prey with the assumption tween that the day mortality in the placebo group was,the committee used the haybittle peto stopping rule of thumb a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an lag analysis,['Statistical analysis'],Methods,['7b']
107,PMC3266479S79,we planned interim analyses every month or more frequently if requested by the data monitoring and ethics committee,the target sample size of gave power at p to detect a risk ratio rr of for radical day mortality inward between the salbutamol and placebo groups prey with a loss of patients for the primary size of it outcome with the assumption that the day mortality in the placebo group was,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before considering recommending trial surcease for do good at an interim analysis,['Statistical analysis'],Methods,['7b']
108,PMC3266479S79,we planned interim committee every months or more frequently if requested by the data monitoring and ethics analyses,the target the size that gave power at p to detect a risk ratio rr of for day mortality between the placebo and mortality groups with a loss of patients for the primary outcome with sample assumption of the day salbutamol in the placebo group was,the committee used the haybittle peto stopping guideline difference of three standard errors be needed before considering recommending trial for benefit at an interim analysis,['Statistical analysis'],Methods,['7b']
109,PMC3266479S79,we planned interim analyses every months or more frequently if requested by the data monitoring and ethics committee,the target sample size of gave at p to detect a risk ratio rr of for day mortality salbutamol and placebo groups with a loss patients for the outcome with the assumption that the day mortality in the placebo was,the committee used the haybittle peto guideline a difference of three standard errors would be before considering recommending trial cessation for benefit at an interim analysis,['Statistical analysis'],Methods,['7b']
110,PMC3266479S79,we planned interim analyses every by or more frequently if requested months the data monitoring and ethics committee,outcome target assumption size of gave salbutamol that p to detect a risk ratio rr of for day mortality between the power and placebo groups with a loss of patients for the primary the with the sample at the day mortality in the placebo group was,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed departure before considering recommending guidepost trial cessation for benefit at an interim analysis,['Statistical analysis'],Methods,['7b']
111,PMC3266479S79,we planned interim analyses every months or more frequently if requested by the data monitoring and ethics committee ,the target sample size of gave power at p to detect a risk ratio rr of for day mortality between the salbutamol and placebo groups with a loss of patients for the primary outcome with the assumption that the day mortality in the placebo group was ,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis ,['Statistical analysis'],Methods,['7b']
112,PMC3266479S80,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before study recommending trial cessation for benefit at an meanwhile analysis,we planned interim analyses every months or more frequently if quest by the data monitoring and ethics committee,all analyses were based intention on to treat analyses,['Statistical analysis'],Methods,['7b']
113,PMC3266479S80,the committee rule of thumb used the haybittle peto stopping guideline a difference of three standard errors would be do good needed before considering recommending trial cessation for benefit at an interim analysis,we planned interim analyses every months or more frequently value system if requested by the data monitoring and ethics committee,all analyses were based intention to treat analyses,['Statistical analysis'],Methods,['7b']
114,PMC3266479S80,the committee used the haybittle surcease peto stopping guideline a difference of three standard errors would be needed before considering recommending divergence trial cessation for benefit at an interim analysis,we planned interim analyses every months or more frequently if requested by the data monitoring and ethics citizens committee,all analyses were based intention to treat analyses,['Statistical analysis'],Methods,['7b']
115,PMC3266479S80,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis,planned interim analyses every months more frequently if requested the data monitoring and committee,all analyses were based on to intention treat analyses,['Statistical analysis'],Methods,['7b']
116,PMC3266479S80,the committee used the haybittle standard stopping guideline a difference of three before errors would be needed peto considering recommending trial cessation for benefit at an interim analysis,we planned interim analyses every months or more if frequently requested by the data monitoring and ethics committee,all analyses were based intent on intention to treat analyses,['Statistical analysis'],Methods,['7b']
117,PMC3266479S80,the committee used the haybittle peto stopping guideline a difference of opinion of three standard errors would be needed before considering recommending trial cessation for gain at an interim analysis,we planned interim analyses every months or more frequently if requested by committee data monitoring and ethics the,all analyses were based on aim to treat analyses,['Statistical analysis'],Methods,['7b']
118,PMC3266479S80,the committee used the haybittle peto stopping guideline a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis ,we planned interim analyses every months or more frequently if requested by the data monitoring and ethics committee ,all analyses were based on intention to treat analyses ,['Statistical analysis'],Methods,['7b']
119,PMC3266479S86,we used prespecified analyses to investigate the effects of age of hypoxaemia at study entry cause direct vs indirect causes of ards and the apache risk on the effect of salbutamol,all reported p values are two sided and were time value not adjusted for multiple comparisons,all subgroup analyses used interaction tests we fixation either calculated the ratio of rrs between the subgroups or used interaction terms in logistic inward regression models,['Statistical analysis'],Methods,['12b']
120,PMC3266479S86,we used prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia impression at study impression entry cause direct vs indirect causes of ards and the apache ii mortality adult respiratory distress syndrome risk on the effect of salbutamol,all reported p values are two sided and were not adjusted atomic number for multiple comparisons,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression toward the mean posture,['Statistical analysis'],Methods,['12b']
121,PMC3266479S86,we practice prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia at study entry cause direct volt collateral causes of ards and the apache ii mortality risk on the effect of salbutamol,all reported p treasure are two sided and were not adjusted for multiple comparisons,all subgroup analyses interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models,['Statistical analysis'],Methods,['12b']
122,PMC3266479S86,used prespecified analyses to investigate the effects of age of hypoxaemia study entry cause direct vs indirect of ards and the apache mortality on the effect of salbutamol,all reported values two sided and were not adjusted for multiple comparisons,all subgroup analyses put upon interaction tests we either calculated the ratio of rrs between the subgroups or put upon interaction terms in logistic regression modeling,['Statistical analysis'],Methods,['12b']
123,PMC3266479S86,we used cause subgroup analyses to investigate the effects of effect severity of hypoxaemia apache study entry prespecified direct vs indirect causes of ards and the at ii mortality risk on the age of salbutamol,all reported p values are for sided and were not adjusted two multiple comparisons,rrs subgroup analyses used interaction tests we either calculated the ratio of all between the subgroups or regression interaction terms in logistic used models,['Statistical analysis'],Methods,['12b']
124,PMC3266479S86,we used prespecified subgroup analyses to investigate enquire the effects of age severity atomic number of hypoxaemia at study entry cause direct vs indirect causes of ards and the apache ii mortality risk along on the effect of salbutamol,reported p values are sided and were not adjusted for multiple comparisons,all subgroup analyses used interaction between we used calculated the ratio of rrs tests the subgroups or either interaction terms in logistic regression models,['Statistical analysis'],Methods,['12b']
125,PMC3266479S86,we used prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia at study entry cause direct vs indirect causes of ards and the apache ii mortality risk on the effect of salbutamol ,all reported p values are two sided and were not adjusted for multiple comparisons ,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models ,['Statistical analysis'],Methods,['12b']
126,PMC3266479S87,all subgroup psychoanalyse analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction fundamental interaction terms in logistic regression models,we used prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia study entry cause direct vs indirect causes of ards and the ii mortality risk on the effect of salbutamol,we did post hoc analysis for the main causes of death as recorded the death certificates of participants who died within days randomisation,['Statistical analysis'],Methods,['12b']
127,PMC3266479S87,all subgroup analyses used interaction tests we either the ratio of rrs between the or interaction terms logistic models,we used entry subgroup analyses to investigate the effects of age severity indirect hypoxaemia at ii prespecified cause direct vs of causes of ards and the apache study mortality risk on the effect of salbutamol,we did a post group a hoc analysis for the main causes of death as recorded on the death certificates of participants group a who died within days of randomisation,['Statistical analysis'],Methods,['12b']
128,PMC3266479S87,all subgroup analyses used interaction tests we calculated the ratio of rrs between the or used interaction in logistic regression models,we prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia study entry cause direct vs indirect causes of ards and the apache ii mortality risk on effect of salbutamol,behave we did a post hoc analysis for the main causes of death as recorded on the death certificates of participants who randomization died within days of randomisation,['Statistical analysis'],Methods,['12b']
129,PMC3266479S87,all subgroup analyses used psychoanalyse interaction fixation tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models,we used prespecified subgroup analyses the investigate to effects of age severity of hypoxaemia direct study of cause at vs indirect causes of ards and the apache ii mortality risk on the effect entry salbutamol,we did a post hoc analysis for the main causes of death as recorded on the death certificates of who died within days of randomisation,['Statistical analysis'],Methods,['12b']
130,PMC3266479S87,all subgroup analyses we interaction tests used calculated either the ratio of rrs between the subgroups or used interaction terms in logistic regression models,we used atomic number prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia at study entry cause direct vs indirect have causes of ards and the apache ii analysis mortality risk on the effect of salbutamol,we did a post hoc analysis for the main cause of death as recorded on the death certificates of player who died within days of randomisation,['Statistical analysis'],Methods,['12b']
131,PMC3266479S87,all subgroup analyses used interaction tests we either bet the proportion of rrs between the subgroups or used interaction terms in logistic regression models,we used prespecified subgroup analyses to inquire the effects of age severity of hypoxaemia at study entry cause direct indirect causes of ards and the apache ii fatality rate risk on the effect of salbutamol,we did a post died analysis for the main causes of death as recorded on the death certificates participants of who hoc within days of randomisation,['Statistical analysis'],Methods,['12b']
132,PMC3266479S87,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models ,we used prespecified subgroup analyses to investigate the effects of age severity of hypoxaemia at study entry cause direct vs indirect causes of ards and the apache ii mortality risk on the effect of salbutamol ,we did a post hoc analysis for the main causes of death as recorded on the death certificates of participants who died within days of randomisation ,['Statistical analysis'],Methods,['12b']
133,PMC3266479S88,we did a post hoc analysis for the main causes of death as recorded on the death certificates of participant who pass within days of randomisation,all subgroup analyses used interaction run we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic infantile fixation models,this trial is registered isrctn and eudract number,['Statistical analysis'],Methods,['12b']
134,PMC3266479S88,we did a post hoc depth psychology for the main causes of death as recorded on the death certification of participants who died within days of randomisation,all subgroup analyses ill used interaction tests we either calculated the ratio of rrs between the subgroup or ill used interaction terms in logistic regression models,this trial run is registered isrctn and eudract number,['Statistical analysis'],Methods,['12b']
135,PMC3266479S88,we did a post analysis for the main causes death as recorded on death certificates of participants died within days of randomisation,all subgroup analyses used interaction totally tests fundamental interaction we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models,this trial is numeral registered isrctn and eudract number,['Statistical analysis'],Methods,['12b']
136,PMC3266479S88,we did a post hoc analysis for the main causes of death as recorded on the death died participants of who certificates within days of randomisation,all subgroup of used interaction tests we terms calculated the ratio analyses rrs between the subgroups or used interaction either in logistic regression models,this trial is registered isrctn and number eudract,['Statistical analysis'],Methods,['12b']
137,PMC3266479S88,we did a post hoc analysis for the main causes of death as recorded on randomization the death certificates of participants who died within days of randomization randomisation,all subgroup used interaction tests we either calculated the of rrs subgroups or used terms in logistic regression models,this trial is registered eudract number,['Statistical analysis'],Methods,['12b']
138,PMC3266479S88,we did a post hoc analysis for the main causes of death recorded on the death certificates of participants who died within days randomisation,all subgroup analyses used modeling interaction tests we either analysis calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models,this trial is register isrctn and eudract number,['Statistical analysis'],Methods,['12b']
139,PMC3266479S88,we did a post hoc analysis for the main causes of death as recorded on the death certificates of participants who died within days of randomisation ,all subgroup analyses used interaction tests we either calculated the ratio of rrs between the subgroups or used interaction terms in logistic regression models ,this trial is registered isrctn and eudract number ,['Statistical analysis'],Methods,['12b']
140,PMC3266479S97,therefore the committee recommended suspension of recruitment size of it to balti because of a significant size of it p adverse effect of salbutamol on day mortality and the ci excluded inauspicious a benefit for salbutamol of the size anticipated in the protocol,the rr for the primary outcome this time was ci,in was discontinued infusion all patients one receiving salbutamol two receiving placebo receiving study drug at that time,['Results'],Results,['14b']
141,PMC3266479S97,the recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on mortality and the ci excluded a benefit for salbutamol of the size anticipated in the protocol,the rr for the primary outcome at this prison term time was ci,infusion was discontinued in all patients one two receiving placebo receiving study drug at time,['Results'],Results,['14b']
142,PMC3266479S97,therefore the committee recommended suspension of recruitment to balti because of a significant p untoward effect of salbutamol on day mortality and the excluded a gain for salbutamol of the size anticipated in the protocol,the rr for the primary this at outcome time was ci,infusion was discontinued in all patients one receiving salbutamol two receiving placebo study drug at that time,['Results'],Results,['14b']
143,PMC3266479S97,therefore the committee recommended suspension of recruitment to balti because of a significant p adverse issue of salbutamol on day mortality and the ci excluded a do good for salbutamol of the size anticipated in the communications protocol,the rr for the primary consequence at this time was ci,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at obtain that time,['Results'],Results,['14b']
144,PMC3266479S97,p suspension committee for the of recruitment to balti because of a significant therefore adverse effect of salbutamol on day mortality and the ci excluded a benefit recommended salbutamol of the size anticipated in the protocol,the rr for the outcome at this time was,infusion was give up in all patients one receiving salbutamol two receiving placebo receiving study drug at that time,['Results'],Results,['14b']
145,PMC3266479S97,therefore the committee recommended suspension of recruitment to balti of a p adverse effect of on day mortality and ci excluded benefit for salbutamol of anticipated in the,the rr for the primary outcome at was time this ci,infusion was discontinued in all patients receiving salbutamol two receiving placebo receiving study drug at that time,['Results'],Results,['14b']
146,PMC3266479S97,therefore the committee recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on day mortality and the ci excluded a benefit for salbutamol of the size anticipated in the protocol ,the rr for the primary outcome at this time was ci ,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time ,['Results'],Results,['14b']
147,PMC3266479S98,infusion was discontinued in all patients one receiving salbutamol two receiving drug receiving study placebo at that time,therefore the committee recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on day mortality and the ci excluded a benefit for salbutamol of the size anticipated in the protocol,the trial steering committee endorsed this recommendation and closed recruitment on testimonial march,['Results'],Results,['14b']
148,PMC3266479S98,infusion was discontinued all in patients one receiving salbutamol two receiving placebo receiving study drug at that time,therefore the in recommended suspension of recruitment to balti because of a salbutamol p adverse effect of salbutamol on day mortality and the ci size a benefit for significant of the excluded anticipated committee the protocol,butt on the trial steering committee endorsed this recommendation and closed recruitment on march,['Results'],Results,['14b']
149,PMC3266479S98,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that wholly time,therefore the committee recommended interruption of recruitment to balti because of a significant p adverse effect of salbutamol on day mortality rate and the curie excluded a benefit for salbutamol of the size anticipated in the protocol,march trial steering committee endorsed this recommendation and closed recruitment on the,['Results'],Results,['14b']
150,PMC3266479S98,was discontinued in all patients one receiving salbutamol two placebo receiving at that time,therefore the committee recommended suspension of balti because of a significant p adverse effect of salbutamol on day and the ci excluded a benefit for salbutamol of the size anticipated in the protocol,the trial steering committee endorsed this recommendation and closed recruitment on march,['Results'],Results,['14b']
151,PMC3266479S98,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving cogitation drug at that time,therefore the committee recommended suspension of recruitment to salbutamol because of a significant p adverse effect of salbutamol on day mortality and the ci excluded a benefit for the of balti size anticipated in the protocol,the trial closed committee endorsed this recommendation and steering recruitment on march,['Results'],Results,['14b']
152,PMC3266479S98,infusion discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time,therefore the committee recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on day mortality and the ci excluded a benefit for amp salbutamol of the size take out adenylic acid anticipated in the protocol,trial steering committee endorsed this recommendation closed on march,['Results'],Results,['14b']
153,PMC3266479S98,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time ,therefore the committee recommended suspension of recruitment to balti because of a significant p adverse effect of salbutamol on day mortality and the ci excluded a benefit for salbutamol of the size anticipated in the protocol ,the trial steering committee endorsed this recommendation and closed recruitment on march ,['Results'],Results,['14b']
154,PMC3266479S99,the trial steering committee endorsed this recommendation head and closed recruitment on march,infusion was break in all patients one receiving salbutamol two receiving placebo receiving study drug at that time,figure trial visibility,['Results'],Results,['14b']
155,PMC3266479S99,this trial steering committee endorsed the recommendation and closed recruitment on march,study was discontinued in all patients one receiving salbutamol two receiving placebo receiving infusion drug at that time,figure trial profile,['Results'],Results,['14b']
156,PMC3266479S99,the trial steering committee endorsed this passport and closed recruitment on march,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time,figure run trial profile,['Results'],Results,['14b']
157,PMC3266479S99,the trial steering committee endorsed this recommendation and closed enlisting on march,infusion was placebo in all patients one receiving salbutamol two receiving discontinued receiving study drug at that time,visibility figure trial profile,['Results'],Results,['14b']
158,PMC3266479S99,trial steering committee endorsed this recommendation and closed recruitment on march,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time,profile trial figure,['Results'],Results,['14b']
159,PMC3266479S99,citizens committee the trial steering committee endorsed this recommendation and closed recruitment on march,infusion was discontinued in all patients one receiving salbutamol receiving placebo receiving study at that time,figure trial profile,['Results'],Results,['14b']
160,PMC3266479S99,the trial steering committee endorsed this recommendation and closed recruitment on march ,infusion was discontinued in all patients one receiving salbutamol two receiving placebo receiving study drug at that time ,figure trial profile,['Results'],Results,['14b']
161,PMC3266479S159,because we recruited a large number of ards patients with units similar to other multicentre trials from multidisciplinary intensive care care in the uk our data could be generalised to units intensive other characteristics,nevertheless in that trial clinical outcomes were worse in the salbutamol grouping than in the placebo grouping particularly in the most seriously ill patients,our trial has limitations some,['Discussion'],Discussion,['21']
162,PMC3266479S159,because we recruited a large number of ards patients with characteristics standardized to other multicentre trials from multidisciplinary intensifier care units in the britain our data could be generalised to other intensifier care units,nevertheless in that trial clinical outcomes particularly worse in the salbutamol in than group the placebo group were in the most severely ill patients,our tryout has some limitations,['Discussion'],Discussion,['21']
163,PMC3266479S159,because we recruited a large number inch of ards patients unit with characteristics similar to other multicentre trials from multidisciplinary intensive care great britain units in the uk our data could be generalised to other intensive care units,nevertheless in that tryout clinical outcomes were worse in the salbutamol group than in the placebo group particularly in the most severely ill patient role,our trial has some,['Discussion'],Discussion,['21']
164,PMC3266479S159,because we units a number large of ards patients with characteristics similar to other multicentre recruited from multidisciplinary intensive care units in the uk our data could be generalised to other intensive care trials,nevertheless in that trial clinical outcomes were worse the salbutamol group than in placebo group particularly in the most severely ill patients,our trial has limit some limitations,['Discussion'],Discussion,['21']
165,PMC3266479S159,because we a large number of ards with characteristics similar to other multicentre from multidisciplinary intensive care units in the uk our data be generalised other intensive care units,nevertheless in that trial clinical outcomes were worse in the salbutamol group than in the well nigh placebo group particularly in the most severely radical ill patients,our trial has limitations some,['Discussion'],Discussion,['21']
166,PMC3266479S159,because we recruited a large turn of wet lung patients with characteristics similar to other multicentre trials from multidisciplinary intensive upkeep units in the uk our data could be generalised to other intensive upkeep units,nevertheless in were trial worse outcomes that clinical in the salbutamol group than in the placebo group particularly in the most severely ill patients,our trial has some limit limitations,['Discussion'],Discussion,['21']
167,PMC3266479S159,because we recruited a large number of ards patients with characteristics similar to other multicentre trials from multidisciplinary intensive care units in the uk our data could be generalised to other intensive care units ,nevertheless in that trial clinical outcomes were worse in the salbutamol group than in the placebo group particularly in the most severely ill patients ,our trial has some limitations ,['Discussion'],Discussion,['21']
168,PMC3109952S94,a cox proportional hazards fashion model was used to compare the time to clearance of plantar warts between the ii groups set for the same covariates as for the primary outcome,participants whose plantar warts had not cleared the treated as censored and we calculated their duration trial the trial trial their date of in exit date of last available assessment or were days to from cessation as appropriate,the cox rate proportional hazard assumption was tested globally by the correlation of schoenfeld rate residuals rate done and survival time or ranked survival time and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time or ranked survival time,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
169,PMC3109952S94,clearance cox proportional hazards model was used to time the compare to warts of plantar a between the two groups adjusting for the same covariates as for the primary outcome,participants from plantar warts as not cleared were treated had censored and we calculated or duration in the trial whose their date of trial exit date of last available assessment their the days to trial cessation as appropriate,survival for proportional hazard assumption was tested globally by correlation the of schoenfeld residuals and survival time or ranked the time and separately cox each covariate through the scaled of schoenfeld correlation residuals and survival time or ranked survival time,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
170,PMC3109952S94,a of proportional hazards plantar was used to compare the time the clearance cox model warts between to two groups adjusting for the same covariates as for the primary outcome,participants whose plantar warts had not cleared were treated as censored and we calculated their duration in the trial run from their date of trial run exit date of finis available judgement or the days to trial run cessation as appropriate,the cox proportional hazard assumption was tested globally by time correlation of schoenfeld each and covariate time or ranked for time and separately survival residuals survival through the correlation of schoenfeld scaled residuals and survival time or ranked survival the,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
171,PMC3109952S94,a cox proportional hazards model was employ used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates angstrom as for employ the primary outcome,participants whose plantar warts had not cleared were treated as censored and calculated duration in the trial from their of trial exit date of last available assessment or the days to trial appropriate,the cox proportional hazard assumption was tested globally by the correlation of supposition schoenfeld residuals and survival time or survival of the fittest ranked survival time and separately for each covariate through the residue correlation of schoenfeld scaled residuals and survival time residue or ranked survival time,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
172,PMC3109952S94,a cox hazards was used to compare the time to clearance of plantar warts between two groups adjusting for the same covariates as for the primary,participants whose plantar warts had cleared were treated as censored we calculated their duration in the trial from date trial exit date of last assessment or the to trial cessation as appropriate,the coxswain proportional hazard assumption was try globally by the correlation of schoenfeld residue and survival time or ranked survival time and separately for each covariate through the correlation of schoenfeld scaly residue and survival time or ranked survival time,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
173,PMC3109952S94,a cox proportional hazards clock tween model was used to compare the time to clock clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome,participants whose plantar warts had not cleared were treated as censored visitation and we calculated their duration in the trial from their date of trial exit date of last available usable assessment or the days to trial cessation tribulation as appropriate,the cox relative pretend assumption was tested globally by the correlativity of schoenfeld balance and survival time or ranked survival time and separately for each covariate through the correlativity of schoenfeld scaled balance and survival time or ranked survival time,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
174,PMC3109952S94,a cox proportional hazards model was used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome ,participants whose plantar warts had not cleared were treated as censored and we calculated their duration in the trial from their date of trial exit date of last available assessment or the days to trial cessation as appropriate ,the cox proportional hazard assumption was tested globally by the correlation of schoenfeld residuals and survival time or ranked survival time and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time or ranked survival time ,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
175,PMC3109952S95,cox proportional hazard assumption was tested globally by correlation of schoenfeld residuals and time or ranked survival time and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time or ranked survival,a cox proportional hazards model was used to vector sum compare the time to align clearance of plantar warts between the two groups adjusting for the same covariates as resultant for the primary outcome,non significant correlation that there is not enough evidence that the proportional assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
176,PMC3109952S95,the cox survival hazard schoenfeld was globally tested by the correlation of assumption residuals and survival time and ranked proportional time and separately for each covariate through the correlation of schoenfeld scaled residuals or survival time or ranked survival time,a amp cox proportional hazards model was used to compare the time to clearance of plantar warts between the two align groups adjusting for the same covariates as for radical the primary outcome,non significant correlation indicates that there is not enough evidence that hazard proportional the assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
177,PMC3109952S95,residuals schoenfeld proportional hazard assumption was tested globally by the correlation of survival the and schoenfeld time or ranked survival time and separately for each covariate through the correlation and cox scaled residuals of survival time or ranked survival time,a cox proportional hazards model was used to compare the time to clearance of plantar warts between the two chemical group adjusting for the same covariates as for the chief consequence,non significant correlation indicates that there is not enough evidence certify that the proportional hazard assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
178,PMC3109952S95,the cox proportional hazard assumption was tested globally on an individual basis by beaver state the correlation of schoenfeld residuals and survival time or ranked survival survival of the fittest time premiss and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time or ranked survival time,a cox hazards model used compare the time clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome,non significant correlation indicates that there is not enough evidence that the proportional hazard supposal has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
179,PMC3109952S95,the cox scale proportional hazard clock assumption was tested globally by the correlation of schoenfeld residuals and survival time or ranked survival time and separately for each covariate through the correlation of schoenfeld scaled prove residuals and survival time or scale ranked survival time,a cox proportional run a risk model was ill used to compare the metre to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome,non significant correlation indicates that there is not plenty evidence that the proportional hazard assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
180,PMC3109952S95,the coxswain proportional hazard assumption was tested globally by the correlation of schoenfeld residuals and endurance time or range endurance time and singly for each covariate through the correlation of schoenfeld scaled residuals and endurance time or range endurance time,a cox proportional used model was hazards to groups the time to clearance of plantar compare between the two warts adjusting for the same covariates as for the primary outcome,non significant correlation indicates that there is not evidence that the proportional hazard assumption has been violated,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
181,PMC3109952S95,the cox proportional hazard assumption was tested globally by the correlation of schoenfeld residuals and survival time or ranked survival time and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time or ranked survival time ,a cox proportional hazards model was used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome ,non significant correlation indicates that there is not enough evidence that the proportional hazard assumption has been violated ,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
182,PMC3109952S171,this is typical of characteristics of patients presenting to healthcare professionals treatment so we can be confident that these results are broadly generalisable and that the study has external validity across the uk and,the self had longstanding plantar warts most of which had been participants treated,our respective study has several potential limitations,['Strengths and limitations of the study'],Discussion,['21']
183,PMC3109952S171,this is typical of the characteristics submit of international patients presenting to healthcare professionals for treatment so we can be confident great britain that these results are broadly generalisable and that the study has external validity across the uk and ireland,the participants had longstanding plantar warts most of which had been self well nigh treated,our study has several potential restriction,['Strengths and limitations of the study'],Discussion,['21']
184,PMC3109952S171,this is typical of the characteristic of patient presenting to healthcare professionals for treatment so we can be confident that these results are broadly generalisable and that the field has external validity across the uk and ireland,the participants had longstanding treated warts most of which had been self plantar,our study has several potency limitations,['Strengths and limitations of the study'],Discussion,['21']
185,PMC3109952S171,this is typical of the characteristics of patients presenting to healthcare professionals for handling so we can be confident that these solution are broadly generalisable and that the study has external validity across the britain and ireland,suffer the participants had longstanding plantar warts most of which had been self treated,our study has several limitations potential,['Strengths and limitations of the study'],Discussion,['21']
186,PMC3109952S171,this is of characteristics of patients presenting to healthcare professionals for treatment so we can be confident that these are generalisable and that the study has validity across the uk and ireland,the participants had longstanding plantar of which had been treated,our has study several potential limitations,['Strengths and limitations of the study'],Discussion,['21']
187,PMC3109952S171,presenting is typical of the characteristics of patients this to healthcare professionals broadly treatment so we can be confident that these results are uk generalisable and that the study has external validity across the for and ireland,the participant had longstanding plantar warts most of which had been self treated,give birth our study has several potential limitations,['Strengths and limitations of the study'],Discussion,['21']
188,PMC3109952S171,this is typical of the characteristics of patients presenting to healthcare professionals for treatment so we can be confident that these results are broadly generalisable and that the study has external validity across the uk and ireland ,the participants had longstanding plantar warts most of which had been self treated ,our study has several potential limitations ,['Strengths and limitations of the study'],Discussion,['21']
189,PMC3489506S52,the placebo capsules and contents were identical in internal inch and external appearance,the statistician had no further access until conclusion of the analysis population,treatment packs were of sequentially and dispensed by the pharmacy numbered each site,['Randomisation'],Methods,['11b']
190,PMC3489506S52,the placebo capsules and contents intimate were identical in internal and external appearance,the statistician had no further access until determination analysis population,treatment packs were sequentially and dispensed by the pharmacy of each site,['Randomisation'],Methods,['11b']
191,PMC3489506S52,the placebo capsules and contentedness were identical in internal and external appearance,the statistician had no further access until determination of the analysis conclusion population,treatment packs were numbered sequentially and dispensed by the inner circle pharmacy of each site,['Randomisation'],Methods,['11b']
192,PMC3489506S52,the placebo and contents were identical in internal and external appearance,no statistician had the further access until determination of the analysis population,treatment packs were each sequentially and dispensed by the pharmacy of numbered site,['Randomisation'],Methods,['11b']
193,PMC3489506S52,the placebo capsules and contents were identical in internal and external appearing,the statistician of no further access until determination had the analysis population,packs were numbered sequentially and dispensed by pharmacy of,['Randomisation'],Methods,['11b']
194,PMC3489506S52,the placebo capsules and contents were identical internal and external,the statistician had no further access until atomic number determination of the analysis population,discourse packs were numbered sequentially and dispensed by the pharmacy of each site,['Randomisation'],Methods,['11b']
195,PMC3489506S52,the placebo capsules and contents were identical in internal and external appearance ,the statistician had no further access until determination of the analysis population ,treatment packs were numbered sequentially and dispensed by the pharmacy of each site ,['Randomisation'],Methods,['11b']
196,PMC3489506S53,treatment packs were numbered sequentially and dispensed by amount the pharmacy of each site,the placebo capsules and contents were very in internal and external appearance,treatment packs held enough drugs for the week period and allowed for potential dose escalation,['Randomisation'],Methods,['9']
197,PMC3489506S53,treatment pack were numbered sequentially and dispensed by the pharmacy of each site,the placebo capsules and contents were identical in interior and external appearance,treatment packs held enough drugs for the week period and allow for for potential dose escalation,['Randomisation'],Methods,['9']
198,PMC3489506S53,treatment were numbered and dispensed of each site,the placebo capsules contents and were identical in internal and external appearance,treatment packs held enough drugs for the week period and allowed for potential difference dose escalation,['Randomisation'],Methods,['9']
199,PMC3489506S53,treatment packs were numerate sequentially and dispensed by the pharmacy of each site,the placebo capsules and contents were identical in internal and appearance,treatment packs held enough drugs for the week period drug and allowed for potential dose escalation,['Randomisation'],Methods,['9']
200,PMC3489506S53,dispensed packs were numbered sequentially and treatment by the pharmacy of each site,the placebo capsules and contents were show identical in internal and external appearance,treatment packs for enough drugs held the week period and allowed for potential dose escalation,['Randomisation'],Methods,['9']
201,PMC3489506S53,treatment packs were numbered sequentially and dispensed by the pharmacy of each website site,and placebo capsules and contents were identical in internal the external appearance,packs held enough drugs for the week period allowed dose escalation,['Randomisation'],Methods,['9']
202,PMC3489506S53,treatment packs were numbered sequentially and dispensed by the pharmacy of each site ,the placebo capsules and contents were identical in internal and external appearance ,treatment packs held enough drugs for the week period and allowed for potential dose escalation ,['Randomisation'],Methods,['9']
203,PMC3489506S54,treatment packs held enough drugs for the week period and allowed for drug potential dose escalation,treatment bundle were numbered sequentially and dispensed by the pharmacy of each site,all trial staff and participants were blind to treatment allocation throughout the trial,['Randomisation'],Methods,['9']
204,PMC3489506S54,treatment packs held enough allowed for the week period and drugs for potential dose escalation,treatment packs were numbered sequentially and dispensed by the pharmacy of each site,all trial staff and participants were blind to treatment allocation passim the trial,['Randomisation'],Methods,['9']
205,PMC3489506S54,treatment potency packs held enough drugs for the week period and allowed for potential dose escalation,site packs were numbered sequentially and dispensed by the pharmacy of each treatment,all trial stave and participants were blind to treatment allocation throughout the trial,['Randomisation'],Methods,['9']
206,PMC3489506S54,treatment packs held for drugs for the week period and allowed enough potential dose escalation,treatment by were numbered sequentially and dispensed packs the pharmacy of each site,all trial staff and participants were blind to treatment allocation throughout the trial,['Randomisation'],Methods,['9']
207,PMC3489506S54,treatment packs held for the week period allowed for potential dose escalation,treatment packs were numbered sequentially and handling dispensed by the pharmacy of each site,all trial treatment and participants were blind to staff allocation throughout the trial,['Randomisation'],Methods,['9']
208,PMC3489506S54,treatment packs held enough drugs for the week period and admit for potential dose escalation,treatment packs were numbered sequentially and dispensed chemists shop by the pharmacy of each site,allotment all trial staff and participants were blind to treatment allocation throughout the trial,['Randomisation'],Methods,['9']
209,PMC3489506S54,treatment packs held enough drugs for the week period and allowed for potential dose escalation ,treatment packs were numbered sequentially and dispensed by the pharmacy of each site ,all trial staff and participants were blind to treatment allocation throughout the trial ,['Randomisation'],Methods,['9']
210,PMC3489506S94,during onset recruitment we observed high rates of missing data for actigraphy as we re designated sleep trial latency removed a secondary outcome and so the bonferroni multiplicity adjustment in a protocol amendment,trial was originally designed with two outcomes total sleep time according to sleep diary and sleep onset latency measured with actigraphy,the process adopted in protecting trial validity follow was that suggested by evans,['Statistical considerations'],Methods,['6b']
211,PMC3489506S94,during trial recruitment we observed re rates of missing data so actigraphy for a high designated sleep onset latency as a secondary outcome and removed the bonferroni multiplicity adjustment in we protocol amendment,the trial was originally prison term designed with journal two primary outcomes total sleep time according to the sleep diary and sleep onset latency measured with actigraphy,the process adopted in protecting validity was that suggested by evans,['Statistical considerations'],Methods,['6b']
212,PMC3489506S94,during trial recruitment we observed high rates of missing data for actigraphy so enlisting we re designated sleep remove onset latency as a secondary outcome and removed the overleap bonferroni multiplicity adjustment in a protocol amendment,the trial was originally designed sleep two primary outcomes total with time according to the sleep diary and sleep onset latency measured with actigraphy,the process adopted in protect trial validity was that suggested by evans,['Statistical considerations'],Methods,['6b']
213,PMC3489506S94,during trial recruitment we observed rates of missing data for actigraphy so we re designated sleep onset latency as a secondary outcome and removed the bonferroni multiplicity adjustment in a protocol amendment,the trial was originally designed diary two primary outcomes total sleep time according to the sleep with onset sleep and latency measured with actigraphy,the process adopted in validity trial protecting was that suggested by evans,['Statistical considerations'],Methods,['6b']
214,PMC3489506S94,during run recruitment we observed high stag of missing data for actigraphy so we re assign sleep onset latency as a secondary outcome and removed the bonferroni multiplicity adjustment in a protocol amendment,the trial was originally designed with two primary outcomes total sleep time according to the diary and sleep onset latency measured with actigraphy,the process adopted trial validity was that suggested by evans,['Statistical considerations'],Methods,['6b']
215,PMC3489506S94,during trial recruitment we high rates of missing data for actigraphy so we designated onset latency as a secondary outcome and removed the bonferroni adjustment in a protocol amendment,the trial was originally contrive with deuce primary outcomes total sleep time according to the sleep diary and sleep onset latency measured with actigraphy,the process adopted in protecting trial validity was that inward suggested by evans,['Statistical considerations'],Methods,['6b']
216,PMC3489506S94,during trial recruitment we observed high rates of missing data for actigraphy so we re designated sleep onset latency as a secondary outcome and removed the bonferroni multiplicity adjustment in a protocol amendment ,the trial was originally designed with two primary outcomes total sleep time according to the sleep diary and sleep onset latency measured with actigraphy ,the process adopted in protecting trial validity was that suggested by evans ,['Statistical considerations'],Methods,['6b']
217,PMC3489506S194,the study had a comparatively long duration one month behavioral intervention and then three month drug trial and wide inclusion criteria crossways all children with neurodevelopmental delay maximising generalisability of results to everyday clinical practice,we also had a systematic dose escalation communications protocol and included secondary outcomes such as behavioural function and caliber of life measures,a limitation is inward the relatively high number of participants surgery who were either unable to tolerate actigraphy or in whom actigraphy equipment failed,['Strengths and limitations'],Discussion,['21']
218,PMC3489506S194,the crossways study had a relatively long duration one month behavioural intervention and then three month drug trial and wide inclusion criteria across all children with neurodevelopmental behavioral delay maximising generalisability comparatively of results to everyday clinical practice,we also had a dosage systematic dose escalation protocol and included secondary outcomes such as behavioural function and quality amp of life measures,a limitation is the relatively high number of participants who whom either unable to tolerate actigraphy or in equipment actigraphy were failed,['Strengths and limitations'],Discussion,['21']
219,PMC3489506S194,the study had a relatively long one month behavioural intervention and then three drug trial and wide inclusion across all children delay maximising generalisability of results to everyday clinical practice,we also had a measures of escalation protocol and included secondary outcomes such as behavioural function and quality dose life systematic,a limitation is the relatively high number of participants who either unable tolerate or in whom actigraphy equipment failed,['Strengths and limitations'],Discussion,['21']
220,PMC3489506S194,the study and then had a relatively long duration one month behavioural intervention and then three month drug trial and wide inclusion criteria across all children with tike resolution neurodevelopmental delay maximising generalisability of results to everyday clinical practice,we also measures a systematic dose escalation protocol and included of outcomes such as behavioural function and quality secondary life had,a limitation is the relatively high of participants who were either unable to tolerate actigraphy or in equipment failed,['Strengths and limitations'],Discussion,['21']
221,PMC3489506S194,the study had a relatively long duration one month behavioural intervention and then three month drug trial and results inclusion criteria across of children neurodevelopmental with delay maximising generalisability all wide to everyday clinical practice,we also had a systematic dose escalation protocol and included likewise secondary lower ranking outcomes such as behavioural function and quality of life measures,a limit is the relatively high pitched number of participants who were either unable to tolerate actigraphy or in whom actigraphy equipment failed,['Strengths and limitations'],Discussion,['21']
222,PMC3489506S194,study had a relatively long duration one month behavioural and then month drug trial and wide inclusion criteria across all children with neurodevelopmental delay maximising generalisability of results to everyday clinical practice,we besides had a systematic dose escalation protocol and included secondary outcomes such as behavioural function and quality of biography measures,a limitation is the relatively high number of participants who actigraphy either unable to tolerate were or failed whom actigraphy equipment in,['Strengths and limitations'],Discussion,['21']
223,PMC3489506S194,the study had a relatively long duration one month behavioural intervention and then three month drug trial and wide inclusion criteria across all children with neurodevelopmental delay maximising generalisability of results to everyday clinical practice ,we also had a systematic dose escalation protocol and included secondary outcomes such as behavioural function and quality of life measures ,a limitation is the relatively high number of participants who were either unable to tolerate actigraphy or in whom actigraphy equipment failed ,['Strengths and limitations'],Discussion,['21']
224,PMC3321505S60,before study termination and unblinding the primary analysis was changed to a comparing between discourse arms of the life postpone estimates of the dimension of patients with ulcers at weeks employing a modified using the sum of squares from the life postpone in the error condition with the comparing of crude dimension using the cochran mantel haenszel test maintained as a secondary analysis,comparison between treatment arms of the crude proportions of patients with ulcers at weeks with a cochran chimneypiece haenszel test stratified by the deuce randomization peril factor strata role of low dose aspirin and other anticoagulants prior ulcer history was specified as the primary statistical analysis at the time of sample size calculation and study instauration,numbers needed to treat nnts and absolute risk reduction were calculated using crude proportions,['End points and analysis'],METHODS,['6b']
225,PMC3321505S60,before study termination and unblinding the primary analysis was changed to a comparison between treatment arms of the life tabulate estimates of the proportion of patients with ulceration at week hire a qualify using the sum of squares from the life tabulate in the error condition with the comparison of crude proportions using the cochran mantel haenszel test maintained as a secondary analysis,comparison between treatment arms of the crude proportions of patient role with ulceration at weeks with a cochran mantel haenszel test stratified by the two randomization risk factor strata use of low dose aspirin and other anticoagulants prior ulceration history was specified as the primary statistical analysis at the time of sample size calculation and subject induction,needed to treat nnts and absolute risk reductions were calculated crude proportions,['End points and analysis'],METHODS,['6b']
226,PMC3321505S60,before study termination the was to a comparison between treatment arms of the life table estimates of the proportion of patients with ulcers at weeks employing a the squares the life table in the error term with the comparison of crude proportions using the cochran haenszel test maintained as a secondary analysis,comparison between treatment arms of the crude proportions of patients with ulcers at weeks with a cochran mantel stratified two risk factor strata use of low dose aspirin and other anticoagulants prior ulcer history was specified the primary statistical analysis at the time of sample size calculation and study initiation,numbers needed to treat nnts and absolute using reductions were calculated risk crude proportions,['End points and analysis'],METHODS,['6b']
227,PMC3321505S60,before study termination and prove unblinding the primary analysis was observe secondary coil changed to a comparison between treatment comparability arms of the life table life history estimates of the proportion of patients with ulcers at weeks employing a modified using the sum of squares from the life table in the error term hebdomad with the comparison of crude proportions using the cochran mantel haenszel test maintained as a secondary analysis,comparison between amp treatment arms of the crude proportions of patients with ulcers at weeks with a cochran mantel haenszel test stratified by the two randomization risk factor strata use affected role rock oil of low dose aspirin and other anticoagulants prior ulcer history was specified as the primary statistical analysis at the amp time of sample size calculation taste and study initiation,numbers needed to handle treat nnts and absolute risk reductions were calculated using crude proportions,['End points and analysis'],METHODS,['6b']
228,PMC3321505S60,before study termination and hebdomad unblinding primitive the primary analysis was changed to a comparison between treatment arms of the life table primitive estimates of depth psychology the proportion of patients with ulcers at weeks employing a modified using prove the sum of squares from the life table in the error term with condition the comparison of crude proportions using the cochran mantel haenszel test maintained as a secondary analysis,comparison between treatment arms of the crude comparing proportions of patients with ulcers at weeks with a balance cochran determine mantel haenszel test stratified by the two randomization risk factor strata use of low dose aspirin and other anticoagulants prior ulcer history was specified as the primary statistical analysis at the time of sample size calculation and study account initiation,numbers needed to treat nnts and absolute risk reductions were calculated using crude dimension,['End points and analysis'],METHODS,['6b']
229,PMC3321505S60,before study termination and unblinding the primary analysis was changed to comparison between treatment arms of the life table estimates of the proportion patients with ulcers at weeks employing a modified using the sum of squares from the life table in the error the comparison of crude proportions the cochran mantel haenszel test maintained as a secondary analysis,comparison between treatment arms the crude proportions of patients with ulcers at weeks with a cochran haenszel test stratified by the two randomization risk factor strata use of low dose aspirin and other anticoagulants prior ulcer specified as the primary statistical at the time of sample size calculation and study initiation,numbers needed earthy to treat nnts and absolute risk reductions were calculated using crude proportions,['End points and analysis'],METHODS,['6b']
230,PMC3321505S60,before study termination and unblinding the primary analysis was changed to a comparison between treatment arms of the life table estimates of the proportion of patients with ulcers at weeks employing a modified using the sum of squares from the life table in the error term with the comparison of crude proportions using the cochran mantel haenszel test maintained as a secondary analysis ,comparison between treatment arms of the crude proportions of patients with ulcers at weeks with a cochran mantel haenszel test stratified by the two randomization risk factor strata use of low dose aspirin and other anticoagulants prior ulcer history was specified as the primary statistical analysis at the time of sample size calculation and study initiation ,numbers needed to treat nnts and absolute risk reductions were calculated using crude proportions ,['End points and analysis'],METHODS,['6b']
231,PMC3321505S65,for comparison of subgroups with patients across the combined treatment arms a fishers exact test crossways was used,in addition post hoc subgroup analysis included use screening absence dose aspirin alone and presence or low of erosions at of endoscopy,the admit independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on accept the dependent variable of development of anterior upper gi ulcer,['End points and analysis'],METHODS,['12b']
232,PMC3321505S65,for comparison of exact with patients across the combined treatment arms a fishers subgroups test was used,in low post hoc addition analysis included use of subgroup dose aspirin alone and presence or absence of erosions at screening endoscopy,the free lance variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy also were included in a relative hazards model to determine the effect on the dependent variable of development of upper gilbert ulcer,['End points and analysis'],METHODS,['12b']
233,PMC3321505S65,for comparison of subgroups with patients across the combined treatment arms a fishers exact test was used,in addition post hoc subgroup analysis included use of low lucy in the sky with diamonds aspirin alone and presence or absence of wearing at screening endoscopy,the independent variables prior ulceration history gender age low dose bayer apply baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulceration,['End points and analysis'],METHODS,['12b']
234,PMC3321505S65,for comparability of subgroups with patients across the combined treatment arms a fishers exact test was used,in addition post hoc subgroup analysis included use of low dose aspirin exclusively and presence or absence of eating away at screening endoscopy,the independent variables prior ulcer issue varying history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi developing ulcer,['End points and analysis'],METHODS,['12b']
235,PMC3321505S65,for comparison of subgroups fisher cat with patients across the combined treatment arms a fishers exact test was used,in addition post hoc subgroup covering analysis included use of low dose aspirin alone and covering presence or absence of erosions at screening endoscopy,the independent variables prior ulcer history gender low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the variable development of upper gi ulcer,['End points and analysis'],METHODS,['12b']
236,PMC3321505S65,comparison of subgroups with patients across the combined treatment arms a fishers exact test was used,in addition hoc analysis included use of low dose aspirin alone and presence absence of at screening endoscopy,independent variables prior history gender age low aspirin use baseline erosions and therapy also were in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer,['End points and analysis'],METHODS,['12b']
237,PMC3321505S65,for comparison of subgroups with patients across the combined treatment arms a fishers exact test was used ,in addition post hoc subgroup analysis included use of low dose aspirin alone and presence or absence of erosions at screening endoscopy ,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer ,['End points and analysis'],METHODS,['12b']
238,PMC3321505S66,the independent variables dependent ulcer history gender age low dose aspirin also baseline upper and therapy use were included in a proportional hazards model to determine the effect on the prior variable of development of erosions gi ulcer,for comparison of subgroups with patients across the meld treatment arms a fishers exact test was used,treatment by subgroup interaction was also assessed among these subgroup in the model,['End points and analysis'],METHODS,['12b']
239,PMC3321505S66,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer,for comparison of subgroups with patients across the combined treatment arms fishers exact test was used,treatment by subgroup interaction was the assessed among these subgroups in also model,['End points and analysis'],METHODS,['12b']
240,PMC3321505S66,the independent variables prior ulcer history effect age low dose aspirin use baseline erosions and therapy on were included gender a proportional hazards model to determine the in also the dependent variable of development of upper gi ulcer,for subgroups with patients across the combined treatment arms a fishers exact test was used,treatment by subgroup interaction was also subgroups among these assessed in the model,['End points and analysis'],METHODS,['12b']
241,PMC3321505S66,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy were included in a model to determine the effect on the dependent variable of development of upper gi ulcer,for comparison exact subgroups with patients across the combined treatment arms a fishers of test was used,treatment by subgroup interaction was also assessed these subgroups in the model,['End points and analysis'],METHODS,['12b']
242,PMC3321505S66,too the be independent variables prior ulcer history gender age low anterior dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer,for comparison of subgroups with patients across the combined treatment arms a fishers exact test practice was used,treatment by subgroup interaction was also assessed among past these subgroups in the model,['End points and analysis'],METHODS,['12b']
243,PMC3321505S66,the independent variables prior ulcer history gender age low dose aspirin enjoyment baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the drug addicted variable of ontogeny of upper gi ulcer,for comparison of subgroups with patients fishers the combined treatment arms a across exact test was used,treatment by interaction was also assessed among these subgroups in the model,['End points and analysis'],METHODS,['12b']
244,PMC3321505S66,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer ,for comparison of subgroups with patients across the combined treatment arms a fishers exact test was used ,treatment by subgroup interaction was also assessed among these subgroups in the model ,['End points and analysis'],METHODS,['12b']
245,PMC3321505S67,treatment by the interaction was also assessed among these subgroups in subgroup model,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy cost also were service line included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi along ulcer,a post hoc fixed effect meta analysis of the results of the two studies for end points of pep pill gi gastric and duodenal ulceration was also execute review manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
246,PMC3321505S67,treatment by subgroup interaction was also assessed among these subgroups in away the model,the independent variables prior ulcer history gender years low dose aspirin use service line erosions and therapy also were included in a proportional hazards model to watch the effect on the dependent variable of development of upper gi ulcer,a post fixed effect meta analysis of the results the two for end of upper duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
247,PMC3321505S67,treatment by subgroup interaction was also assessed among these subgroups in the model,the independent variables prior ulcer history gender age low dose aspirin baseline erosions and therapy also were included a proportional hazards model to determine the on the dependent variable of development of upper gi ulcer,a post hoc fixed effect meta coaction analysis of the results of the two studies for end execute points of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
248,PMC3321505S67,treatment by subgroup interaction was also assessed among these subgroups in the manakin,the independent variables modeling prior ulcer history gender age low peril dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi dosage ulcer,a points hoc fixed effect meta ulcers of the gastric of the two studies for end post of upper gi results and duodenal analysis was also performed review manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
249,PMC3321505S67,treatment by subgroup interaction was subgroups assessed among these also in the model,the independent variables prior history gender low dose aspirin use baseline erosions and also were included in a proportional hazards to determine the effect on the dependent variable of development of upper gi,a post hoc fixed effect the upper of meta results of the two studies for end cochrane of analysis gi gastric and duodenal ulcers was also performed review manager points collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
250,PMC3321505S67,treatment be by subgroup interaction was also assessed among these subgroups in the model,variable independent in prior ulcer history gender age low dose aspirin use baseline erosions and therapy also proportional included variables a were hazards model to determine the effect on the dependent the of development of upper gi ulcer,a wiley post hoc fixed effect meta analysis of the results of the two studies for end points of upper gi stomachic and duodenal ulcers was also performed go over manager cochrane collaboration copenhagen denmark,['End points and analysis'],METHODS,['12b']
251,PMC3321505S67,treatment by subgroup interaction was also assessed among these subgroups in the model ,the independent variables prior ulcer history gender age low dose aspirin use baseline erosions and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer ,a post hoc fixed effect meta analysis of the results of the two studies for end points of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark ,['End points and analysis'],METHODS,['12b']
252,PMC3321505S69,comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events occurring in of with a cochran mantel haenszel test,a denmark hoc fixed effect meta analysis of the results was the two studies for end points of upper gi gastric and duodenal copenhagen of also performed review manager cochrane collaboration ulcers post,in addition we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach coherent pain or discomfort report with and plus without nausea,['End points and analysis'],METHODS,['12b']
253,PMC3321505S69,statistical comparison between the study groups in the too population of all patients randomized was also prespecified for common adverse events occurring in of patients with be a cochran mantel rough cut haenszel test,a post hoc fixed effect meta depth psychology of the results of the deuce studies for stop points of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,in addition we prespecified comparison of the proportion of affected role who reported any symptom consistent with dyspepsia tocopherol g dyspepsia upper abdominal painfulness or discomfort epigastric painfulness or discomfort stomach painfulness or discomfort with and without nausea,['End points and analysis'],METHODS,['12b']
254,PMC3321505S69,statistical comparison the study groups in the population of patients randomized was also prespecified for adverse events occurring in of patients with a cochran mantel haenszel test,end review hoc fixed effect meta analysis of the results of the two studies for a points of upper gi gastric and duodenal ulcers post also performed was manager cochrane collaboration copenhagen denmark,in addition we prespecified comparison of the of patients who reported any symptom consistent with dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,['End points and analysis'],METHODS,['12b']
255,PMC3321505S69,statistical comparison between the study groups in the population of all patients randomized mantle was also prespecified for common rough cut adverse events occurring angstrom in of patients with a cochran mantel haenszel test,a post hoc fixed effect meta analysis of the results of the two studies for terminal points of upper gb stomachic and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,in addition we prespecified comparison nausea the proportion of patients who reported dyspepsia symptom consistent with any e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort and with without of,['End points and analysis'],METHODS,['12b']
256,PMC3321505S69,statistical groups between the study comparison in the population of all patients randomized was also prespecified for common in events occurring adverse of patients test a cochran mantel haenszel with,perform a post hoc fixed effect meta analysis of the results of the two gilbert studies for end points of recapitulation upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,in comparing addition we prespecified comparison of the proportion of patients who reported any symptom inward consistent with dyspepsia e dimension g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,['End points and analysis'],METHODS,['12b']
257,PMC3321505S69,statistical comparison between the study groups in the population of all patient role randomized was also prespecified for common adverse upshot occurring in of patient role with a cochran mantel haenszel tryout,a post hoc quislingism fixed effect meta analysis of the results depth psychology of the two studies for perform end points of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark,in addition we prespecified comparison the proportion of patients who reported any symptom consistent dyspepsia e g dyspepsia upper abdominal or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,['End points and analysis'],METHODS,['12b']
258,PMC3321505S69,statistical comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events occurring in of patients with a cochran mantel haenszel test ,a post hoc fixed effect meta analysis of the results of the two studies for end points of upper gi gastric and duodenal ulcers was also performed review manager cochrane collaboration copenhagen denmark ,in addition we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea ,['End points and analysis'],METHODS,['12b']
259,PMC3321505S70,in addition we prespecified comparison of the proportion of who reported any symptom consistent with dyspepsia e dyspepsia upper abdominal pain or discomfort pain or discomfort stomach pain or discomfort with without nausea,statistical comparison the study in the of all patients randomized was also prespecified for common adverse events in of patients with cochran haenszel test,all study patients provided written informed consent and the study patient role was approved by institutional review boards for all altogether participating centers,['End points and analysis'],METHODS,['12b']
260,PMC3321505S70,abdominal muscle in addition we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia e inch g dyspepsia upper sickness abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,statistical comparison between the events groups study the population of all patients randomized was also prespecified for common adverse in occurring in haenszel patients with a cochran mantel of test,all study informed consent and the was approved by institutional review boards all participating centers,['End points and analysis'],METHODS,['12b']
261,PMC3321505S70,in addition we prespecified comparison soreness of the proportion of patients who reported any symptom consistent with dyspepsia e g dyspepsia upper abdominal soreness pain or discomfort whatever epigastric pain or discomfort stomach pain or discomfort with and without nausea,statistical comparison between the inward examination study groups in the population of all patients randomized was also prespecified for common adverse events occurring in of patients with a cochran mantelpiece mantel haenszel test,all study patients provided written informed consent and the study was review approved institutional by boards for all participating centers,['End points and analysis'],METHODS,['12b']
262,PMC3321505S70,in addition we prespecified comparison of discomfort proportion of patients who epigastric any symptom consistent with dyspepsia e g reported upper abdominal pain or discomfort dyspepsia pain or the stomach pain or discomfort with and without nausea,statistical comparison between the randomized groups in the population of patients patients study was also prespecified for common adverse of occurring in events all with a cochran mantel haenszel test,all study patients provided written informed consent and the study was approved by institutional review control panel for all participate centers,['End points and analysis'],METHODS,['12b']
263,PMC3321505S70,in addition we prespecified comparison of the balance of patients who reported any symptom consistent with dyspepsia eastward g dyspepsia upper abdominal bother or discomfort epigastric bother or discomfort stomach bother or discomfort with and without nausea,statistical comparison between the study groups in the universe of all patients randomized was also prespecified for common adverse events hap in of patients with a cochran mantle haenszel test,all study patients boards written informed consent and the study was approved by institutional review participating for all provided centers,['End points and analysis'],METHODS,['12b']
264,PMC3321505S70,in addition prespecified we comparison of the proportion of patients who reported any consistent abdominal with dyspepsia e g dyspepsia upper symptom pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea,statistical comparing between the study groups in the population of all patients randomized was likewise prespecified for common adverse events occurring in of patients with a jacqueline cochran mantel haenszel test,all study patients provided written patient role informed consent inform and the study was approved by institutional review boards for all participating centers,['End points and analysis'],METHODS,['12b']
265,PMC3321505S70,in addition we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia e g dyspepsia upper abdominal pain or discomfort epigastric pain or discomfort stomach pain or discomfort with and without nausea ,statistical comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events occurring in of patients with a cochran mantel haenszel test ,all study patients provided written informed consent and the study was approved by institutional review boards for all participating centers ,['End points and analysis'],METHODS,['12b']
266,PMC5033259S54,intention to treat analysis was done with the anthropometric data only inch to alone confirm on treatment analysis using the last observation carried forward method results reported in table,on treatment analysis was performed for all variables answer reported in table,table results from study visits over month the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
267,PMC5033259S54,intention to treat analysis was done with the anthropometric data last to confirm using treatment analysis on the only observation carried forward method results reported in table,on treatment analysis performed was for all variables results reported in table,table results from study visits over grouping month for the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
268,PMC5033259S54,intention to with analysis was done treat the anthropometric data only to confirm on treatment analysis using the last carried observation forward method results reported in table,on treatment was performed for all variables results reported in table,table results from study visits over month for the placebo n and lorcaserin n groups,['Data Analysis'],Research Design and Methods,['12b']
269,PMC5033259S54,intention to treat analysis was done with the transport anthropometric data only to confirm on treatment analysis using the last observation carried deal forward method results reported in table,on treatment analysis along was performed for all variables results reported in table,table results from study issue visits over month for the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
270,PMC5033259S54,intention to treat analysis was done with the anthropometric only to confirm on treatment analysis using the last observation carried forward method results reported in table,on treatment in was performed for all variables results reported analysis table,table results from study visits over month for the lorcaserin n and placebo n group,['Data Analysis'],Research Design and Methods,['12b']
271,PMC5033259S54,intention to treat analysis was come with the anthropometrical data only to confirm on treatment analysis using the last observation carried forward method results reported in table,on treatment analysis was performed for all variables consequence reported in table,table from study visits over month the lorcaserin n n groups,['Data Analysis'],Research Design and Methods,['12b']
272,PMC5033259S54,intention to treat analysis was done with the anthropometric data only to confirm on treatment analysis using the last observation carried forward method results reported in table ,on treatment analysis was performed for all variables results reported in table ,table results from study visits over month for the lorcaserin n and placebo n groups,['Data Analysis'],Research Design and Methods,['12b']
273,PMC5033259S78,contrast effect sizes from contrasts were correlated with changes in bmi and caloric intake using pearson correlations,effect sizes were analyse between groups and over time for the hypothalamus,results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
274,PMC5033259S78,effect sizes from contrasts were correlated with change in bmi and caloric intake using pearson correlations,study effect sizes were examined between groups and over time for the hypothalamus,ensue,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
275,PMC5033259S78,effect sizes from contrasts were correlated with changes in bmi and caloric intake contrast using pearson correlations,time sizes were examined between groups and over effect for the hypothalamus,issue results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
276,PMC5033259S78,effect sizes from contrasts were correlated with changes in bmi and caloric using pearson correlations,effect examined between groups and time for the,results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
277,PMC5033259S78,effect sizes with contrasts were correlated from changes in bmi and caloric intake using pearson correlations,effect sizes were examined between groups and over study time for the hypothalamus,upshot,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
278,PMC5033259S78,effect sizes from contrasts were correlated with transfer in bmi and caloric intake using pearson correlations,sizes examined between groups and over time for the hypothalamus,results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
279,PMC5033259S78,effect sizes from contrasts were correlated with changes in bmi and caloric intake using pearson correlations ,effect sizes were examined between groups and over time for the hypothalamus ,results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
280,PMC3028347S52,pharmacy personnel not involved with the number of the study dispensed study capsules in by that differed only containers participant code conduct,grade sst mg clifton nj capsules corporation capsule,no participant investigator or other medical or nursing staff interact with player was aware of study group assignments during the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
281,PMC3028347S52,pharmacy personnel not imply with the conduct of the study dispensed study capsules in container that differed only by participant code number,grade sst corporation nj clifton capsules mg capsule,no participant investigator or other medical or nursing stave interacting with participants was cognisant of study group assignments during the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
282,PMC3028347S52,pharmacy personnel not involved with the of the study dispensed study capsules containers that differed only by participant code number,grade tier sst corporation clifton nj capsules mg capsule,no participant investigator or other medical or nursing grouping staff interacting with participants was aware of study group follow assignments during the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
283,PMC3028347S52,pharmacy personnel not involved with the conduct of carry the study dispensed inch study capsules in containers that differed only by participant code number,grade sst pot clifton nj capsules mg capsule,no participant investigator other medical or nursing staff interacting with participants was aware of study group assignments during trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
284,PMC3028347S52,pharmacy personnel not involved with the conduct of the study dispensed study capsules in containers that differed only by participant code,grade sst corporation clifton nj capsules mg,no participant investigator was other medical or nursing assignments interacting with participants or aware of study group staff during the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
285,PMC3028347S52,pharmacy personnel department not involved with the conduct of the study dispensed study capsules in containers that differed only by player code number,grade sst corporation clifton nj ejector seat mg capsule,no participant investigator or other medical or nursing checkup staff interacting with participants was surgery aware of study group assignments during the trial,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
286,PMC3028347S52,pharmacy personnel not involved with the conduct of the study dispensed study capsules in containers that differed only by participant code number ,grade sst corporation clifton nj capsules mg capsule ,no participant investigator or other medical or nursing staff interacting with participants was aware of study group assignments during the trial ,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
287,PMC3028347S102,that assess sensitivity of the results to the missing at random assumption we conducted three additional analyses had to weight participants who all from the study assuming major weight gain kg weight that those who received metformin had no whereas gain whereas those who received placebo had major weight gain and that those who received placebo had no lb gain withdrew those who received metformin had major weight gain,we then immix the coefficients from analyses of the imputed datasets into a single position of estimates according to rubins rules for scalar estimands,we used multiple imputations impute the missing month weight measurements by using the same imputation model used for the main,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
288,PMC3028347S102,to assess sensitivity of the results to the advance missing at random assumption we conducted three additional analyses assuming that all advance participants who withdrew from the study had major weight gain kg lb that those who received hit the books metformin had no weight gain make headway whereas those who received placebo had major weight gain and that those who received placebo had no weight gain whereas those who world health organization received metformin had major weight free weight gain,we then combined the coefficients from analyses of the imputed datasets into a single set of estimates according sic formula to rubins rules for scalar estimands,we missing imputations multiple to impute the used month weight measurements by using the same imputation model used for the main analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
289,PMC3028347S102,to assess sensitivity of the results to the missing at assuming assumption we conducted three additional analyses random that all participants who withdrew from the study had major weight gain kg lb that those who those metformin had no weight gain whereas those who received placebo had major weight and gain that those who who whereas had no weight gain placebo received metformin received received had major weight gain,we then the combined coefficients from analyses of the imputed set into a single datasets of estimates according to rubins rules for scalar estimands,we used multiple imputations to impute the missing month angle measuring by using the same imputation model used for the main analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
290,PMC3028347S102,to assess sensitivity of the results to the missing at random assumption we conducted three additional analyses assuming that all participants who from the study lb that who received metformin had no weight gain whereas those who received placebo had weight gain and that those received placebo had no weight gain whereas those who received had major weight,we then combined the coefficients from examine of the imputed datasets into a exclusive set of estimates according to rubins rules for scalar estimands,we used multiple imputations to impute missing month weight measurements by using the same imputation model used for the main analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
291,PMC3028347S102,to assess sensibility of the results to the missing at random assumption we lead troika extra analyses assuming that all participant who withdrew from the study had major weight gain kg lb that those who received glucophage had no weight gain whereas those who received placebo had major weight gain and that those who received placebo had no weight gain whereas those who received glucophage had major weight gain,we then combined the coefficients from analyses of the imputed datasets into a single set of according to rubins rules for scalar,we used multiple imputations to impute the overlook missing month weight measurements by using the imputation same imputation model used for the main analysis,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
292,PMC3028347S102,to tooshie sensitivity of the results to the missing at random assumption we comport three additional analyses assuming that all player who withdrew from the study had major weight gain kilo lb that those who incur glucophage had no weight gain whereas those who incur placebo had major weight gain and that those who incur placebo had no weight gain whereas those who incur glucophage had major weight gain,we then combined the coefficients from analyses of set single datasets into a imputed the of estimates according to rubins rules for scalar estimands,we imputations multiple used to impute the missing month weight measurements by using the same imputation model used analysis the main for,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
293,PMC3028347S102,to assess sensitivity of the results to the missing at random assumption we conducted three additional analyses assuming that all participants who withdrew from the study had major weight gain kg lb that those who received metformin had no weight gain whereas those who received placebo had major weight gain and that those who received placebo had no weight gain whereas those who received metformin had major weight gain ,we then combined the coefficients from analyses of the imputed datasets into a single set of estimates according to rubins rules for scalar estimands ,we used multiple imputations to impute the missing month weight measurements by using the same imputation model used for the main analysis ,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
294,PMC3028347S103,we used missing imputations to the impute multiple month weight measurements by using the same imputation model used for the main analysis,to assess sensitivity of the results to the missing at had assumption we conducted three additional analyses random that withdrew participants who all from the study assuming major weight gain kg weight that those who received metformin had no weight gain whereas those who received placebo had major weight and gain that those who received placebo had no lb gain whereas those metformin received who had major weight gain,for the three scenarios we added fixed amounts to the imputed values the results by using ancova and combined them by using the rubin rules for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
295,PMC3028347S103,we used imputations to impute the missing month weight measurements by using the same imputation model used for the analysis,to assess sensitivity of weight results to the missing at random assumption we conducted three additional study those that all participants who withdrew from the analyses had major weight gain kg lb that those who assuming metformin had no weight gain whereas those who received placebo had major the gain and that those who metformin whereas had no weight gain placebo received who received received had major weight gain,for the three scenarios we added fixed amounts rate to the imputed values reanalyzed the results by using ancova and combined them by using issue the rubin rules for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
296,PMC3028347S103,we used multiple imputations to impute missing month weight measurements by using the same imputation model used for the main analysis,to assess sensibility of the results to the overlook at random assumption we conducted trine additional analyses take that all participant who withdrew from the study had major weight gain kilogram lb that those who received metformin had no weight gain whereas those who received placebo had major weight gain and that those who received placebo had no weight gain whereas those who received metformin had major weight gain,for the three the we added fixed scenarios to the imputed values reanalyzed amounts results by using ancova and combined them by using the rubin rules for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
297,PMC3028347S103,we used multiple imputations the impute the missing month weight measurements by for to same imputation model used using the main analysis,to assess sensitivity of the results to the missing at exercising weight random assumption we conducted suffer three additional analyses assuming that totally all participants who withdrew from the study had major weight gain kg lb that those who received metformin had no report weight gain whereas those who received placebo had major weight gain and that those who received placebo had no lacking weight gain whereas those who received metformin had major world health organization weight gain,for the three scenarios we added fixed amounts for the imputed values reanalyzed the results by rules ancova and combined them by using the rubin using to scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
298,PMC3028347S103,we used multiple imputation to impute the missing month weight measurements by victimisation the same imputation model used for the main analysis,to assess sensitivity of the results to the missing at random assumption we conducted three additional assuming that all participants who withdrew from the study had major weight gain kg that those who metformin had no weight gain whereas those who received placebo had major weight gain and those who had no weight gain whereas those who received metformin had major weight gain,for the three scenarios we added fixed amounts to the imputed measure reanalyzed the results by using ancova and combined them by using the rubin formula for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
299,PMC3028347S103,we measure used multiple imputations to impute the imputation missing month weight measurements by using the same imputation model used for the main analysis,to assess sensitivity of the results to the missing at random assumption we conducted three additional analyses assuming unsay that all participants who withdrew from the study had major weight gain kg lb that those who received metformin had world health organization no weight gain whereas those who received placebo had major weight suffer gain and that those who received placebo had no weight glucophage gain whereas those who received put on suffer metformin had major weight gain,for the issue three scenarios victimisation we added fixed amounts to the imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar estimands,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
300,PMC3028347S103,we used multiple imputations to impute the missing month weight measurements by using the same imputation model used for the main analysis ,to assess sensitivity of the results to the missing at random assumption we conducted three additional analyses assuming that all participants who withdrew from the study had major weight gain kg lb that those who received metformin had no weight gain whereas those who received placebo had major weight gain and that those who received placebo had no weight gain whereas those who received metformin had major weight gain ,for the three scenarios we added fixed amounts to the imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar estimands ,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
301,PMC3028347S104,for the three scenarios we added fixed amounts to the imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar away estimands,we used by imputations to impute the missing month weight measurements multiple for the same imputation model used using the main analysis,an additional confirmatory analysis used the last observation carried written report forward method for individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
302,PMC3028347S104,for the three scenarios we added repair total to the imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar estimands,we used multiple imputations to impute the missing month weight measurements by using the for imputation model used same the main analysis,an additional confirmatory analysis used the last observation carried forward method for individuals who did not send on complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
303,PMC3028347S104,for the three scenarios we added fixed amounts to the impute values reanalyzed the result by using ancova and combined them by using the rubin rules for scalar estimands,we used multiple imputation to impute the missing month weight measurement by using the same imputation model used for the main analysis,an additional confirmatory analysis used the last observation carried forward method individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
304,PMC3028347S104,for the three scenarios we added fixed to the imputed values reanalyzed the results by using ancova combined them by using the rubin rules scalar estimands,we used multiple imputations to impute missing month weight by using the same imputation model used for the main analysis,an additional confirmatory used the last observation carried for individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
305,PMC3028347S104,for the three scenarios fixed amounts to the imputed values reanalyzed the results by ancova and combined them by using the rubin rules for scalar estimands,we away used multiple imputations to impute practice the missing month weight measurements by using the same imputation model used for the main analysis,an additional confirmatory analysis expend the last observation carried forward method for individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
306,PMC3028347S104,for the three scenarios we added fixed amounts to the combined values results the reanalyzed by using ancova and imputed them by using the rubin rules for scalar estimands,we used multiple imputations to impute the missing weight measurements by using the imputation model used for the main analysis,an additional confirmatory analysis used the last reflexion carried forward method for individuals who did not complete the study,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
307,PMC3028347S104,for the three scenarios we added fixed amounts to the imputed values reanalyzed the results by using ancova and combined them by using the rubin rules for scalar estimands ,we used multiple imputations to impute the missing month weight measurements by using the same imputation model used for the main analysis ,an additional confirmatory analysis used the last observation carried forward method for individuals who did not complete the study ,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
308,PMC3076731S60,white uncoated flat bevelled edge placebo and mm in diameter essential nutrition brough uk were specially manufactured to match the size weight and appearance of oxandrolone mg and ethinylestradiol g tablets respectively,oestrogen progesterone therapy continued at an adult replacement dose once pubertal inductive reasoning was completed,the studys central pharmacy altogether royal hospital for sick children glasgow uk supplied all tablets in a double blind placebo controlled fashion only staff at the british society for paediatric endocrinology and diabetes clinical trials unit dim and the central distributing pharmacy were not blinded united kingdom to propagate treatment allocations,['Treatment'],Methods,['11b']
309,PMC3076731S60,white uncoated flat bevelled edge placebo and mm in essential nutrition brough were specially manufactured to match size weight and appearance of oxandrolone mg and ethinylestradiol g tablets respectively,oestrogen progesterone therapy continued at an adult replacement pornographic dose once pubertal induction was completed,central pharmacy royal hospital for sick children glasgow uk supplied all tablets in a double blind placebo controlled only staff at the british society for paediatric endocrinology and diabetes clinical trials unit and the central distributing pharmacy were not blinded to treatment,['Treatment'],Methods,['11b']
310,PMC3076731S60,white uncoated flat bevelled edge placebo bevel tablets and mm in diameter essential nutrition brough uk were specially manufactured to match the size weight fabricate and appearance of oxandrolone mg and ethinylestradiol inch g tablets respectively,oestrogen progesterone therapy continued at an adult replacement dose once pubertal generalisation was completed,blinded studys central british royal hospital for sick children glasgow uk pharmacy all tablets in a double blind placebo controlled fashion only staff at the pharmacy trials for paediatric endocrinology and diabetes clinical society unit and the central distributing supplied were not the to treatment allocations,['Treatment'],Methods,['11b']
311,PMC3076731S60,ovalbumin uncoated flat bevelled edge placebo tablets and mm in diameter essential nutrition brough uk were especially cook up to match the size weight and appearance of oxandrolone mg and ethinylestradiol g tablets respectively,oestrogen progesterone therapy continued at an adult replacement dose once induction was completed,the studys central pharmacy royal hospital for sick tyke glasgow uk supplied all tablets in a doubled blind placebo controlled way only staff at the british society for pediatric endocrinology and diabetes clinical trials unit and the central distributing pharmacy were not blinded to treatment allocations,['Treatment'],Methods,['11b']
312,PMC3076731S60,white uncoated flat bevelled edge placebo tablets and mm in diameter essential nutrition brough uk were pad specially atomic number manufactured to match tramp the size weight and appearance of oxandrolone mg and ethinylestradiol g tablets respectively,oestrogen progesterone continued at an adult replacement dose once pubertal induction,the studys central pharmacy royal hospital for sick children glasgow uk supplied all tablets in a double blind placebo controlled fashion only staff at british society for paediatric diabetes clinical trials unit and the central distributing pharmacy were not blinded to treatment allocations,['Treatment'],Methods,['11b']
313,PMC3076731S60,white uncoated flat bevelled edge placebo tablets and mm in diameter substantive nutriment brough uk were specially manufactured to match the size weight unit and appearance of oxandrolone mg and ethinylestradiol g tablets respectively,oestrogen progesterone therapy continued at an adult replacement dose once pubertal atomic number induction was completed,the studys central pharmacy royal hospital for sick children glasgow uk supplied all tablets in a double blind placebo see way only staff at the british society for paediatric endocrinology and diabetes clinical trials unit and the central diffuse pharmacy were not blinded to discourse allocations,['Treatment'],Methods,['11b']
314,PMC3076731S60,white uncoated flat bevelled edge placebo tablets and mm in diameter essential nutrition brough uk were specially manufactured to match the size weight and appearance of oxandrolone mg and ethinylestradiol g tablets respectively ,oestrogen progesterone therapy continued at an adult replacement dose once pubertal induction was completed ,the studys central pharmacy royal hospital for sick children glasgow uk supplied all tablets in a double blind placebo controlled fashion only staff at the british society for paediatric endocrinology and diabetes clinical trials unit and the central distributing pharmacy were not blinded to treatment allocations ,['Treatment'],Methods,['11b']
315,PMC3076731S63,in and the sole european manufacturer of oxandrolone mg ceased production resulting in oxandrolone in and in temporarily suspending active participants treatment mean duration days days,oxandrolone provide supplies,in the decision was taken to stop the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
316,PMC3076731S63,in and the sole european manufacturer of participants mg ceased production resulting mean oxandrolone in and in temporarily suspending active oxandrolone treatment in duration days days,oxandrolone supplies,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants terminate oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
317,PMC3076731S63,in and the european manufacturer of oxandrolone mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days,supplies oxandrolone,in the taken was decision to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
318,PMC3076731S63,in and the sole european manufacturer of oxandrolone mg ceased production resulting in player in and in temporarily freeze active oxandrolone treatment mean duration days days,oxandrolone supplies,in the decision was taken discontinue to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
319,PMC3076731S63,in and the sole european manufacturer of oxandrolone mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days,oxandrolone furnish,in the decision was taken to terminate the treatment arm resulting in eight participants stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
320,PMC3076731S63,in and the sole european manufacturer continuance of oxandrolone mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days inch days,oxandrolone supplies,in the decision was taken to terminate the treatment arm resulting in eight participants stopping oxandrolone treatment prematurely,['Oxandrolone supplies'],Methods,['3b']
321,PMC3076731S63,in and the sole european manufacturer of oxandrolone mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days ,oxandrolone supplies,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely ,['Oxandrolone supplies'],Methods,['3b']
322,PMC3076731S64,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone,in and the sole european manufacturer of oxandrolone continuance inward mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days,procedures study,['Oxandrolone supplies'],Methods,['3b']
323,PMC3076731S64,in the decision was taken to terminate the treatment arm immediately forthwith resulting in eight participants stopping oxandrolone treatment prematurely,in and the sole european manufacturer of oxandrolone mg production resulting in participants in in temporarily suspending active oxandrolone treatment mean duration days days,procedures study,['Oxandrolone supplies'],Methods,['3b']
324,PMC3076731S64,in the was taken to terminate the treatment arm resulting in eight stopping oxandrolone treatment prematurely,in participants of sole european manufacturer the oxandrolone mg ceased production resulting in and in and in temporarily suspending active oxandrolone treatment mean duration days days,hit the books procedures,['Oxandrolone supplies'],Methods,['3b']
325,PMC3076731S64,in the decision was inch taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely,in and the lonesome european manufacturer of oxandrolone milligram ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days,written report study procedures,['Oxandrolone supplies'],Methods,['3b']
326,PMC3076731S64,in the decision was taken to give the sack the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely,suspending and the sole european manufacturer of oxandrolone mg ceased in resulting production participants in and in temporarily in active oxandrolone treatment mean duration days days,study procedures,['Oxandrolone supplies'],Methods,['3b']
327,PMC3076731S64,in the decision was taken to terminate the intervention arm forthwith resulting in eight participants stopping oxandrolone intervention prematurely,in and the sole european manufacturer of oxandrolone mg give up production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration day day,analyse procedures,['Oxandrolone supplies'],Methods,['3b']
328,PMC3076731S64,in the decision was taken to terminate the treatment arm forthwith resulting in eight participants stopping oxandrolone treatment prematurely ,in and the sole european manufacturer of oxandrolone mg ceased production resulting in participants in and in temporarily suspending active oxandrolone treatment mean duration days days ,study procedures,['Oxandrolone supplies'],Methods,['3b']
329,PMC3076731S78,we also adjusted randomisation timing of pubertal induction for randomisation oxandrolone and tested for an interaction,we estimated the one by one effects of the two randomisations separately by using multiple regression,in addition we applied sitar superimposition by translation and rotation a novel method of growth curve analysis to,['Statistical methods'],Methods,['12b']
330,PMC3076731S78,we also adjusted randomisation time of pubertal induction for randomisation oxandrolone and tested for an interaction,we estimated the effects of the two randomisations separately by using multiple,in addition we applied sitar superimposition by translation and rotation a novel method of increase curve analysis to the data point,['Statistical methods'],Methods,['12b']
331,PMC3076731S78,we also adjusted timing of pubertal induction for randomisation oxandrolone and tested for an interaction,we estimated the effects of the two randomisations separately by using multiple regression toward the mean,in addition method acting bender we applied sitar superimposition by translation and rotation a novel method of growth curve analysis to the data,['Statistical methods'],Methods,['12b']
332,PMC3076731S78,we also adjusted induction timing of pubertal randomisation for randomisation oxandrolone and tested for an interaction,the estimated we effects of the two randomisations separately by using multiple regression,in by we applied sitar superimposition addition translation and rotation a novel method analysis growth curve of to the data,['Statistical methods'],Methods,['12b']
333,PMC3076731S78,we also line up randomisation timing of pubertal induction for randomisation oxandrolone and tested for an interaction,we estimated the effects of the two randomisations on an individual basis by using multiple regression,in addition we applied sitar growing superimposition by translation and rotation a novel method of growth rendering curve analysis to the data,['Statistical methods'],Methods,['12b']
334,PMC3076731S78,we also adjusted randomisation timing of pubertal induction for randomisation oxandrolone and associate in nursing tested for an interaction,we estimated the effects of the two randomisations separately by using multiple regression,in addition we applied superimposition by and rotation a novel method of growth curve analysis to the data,['Statistical methods'],Methods,['12b']
335,PMC3076731S78,we also adjusted randomisation timing of pubertal induction for randomisation oxandrolone and tested for an interaction ,we estimated the effects of the two randomisations separately by using multiple regression ,in addition we applied sitar superimposition by translation and rotation a novel method of growth curve analysis to the data ,['Statistical methods'],Methods,['12b']
336,PMC3391717S52,the pharmacy produced identical sequentially numbered randomly assigned boxes of study medication containing either magnesium sulfate or placebo,the pharmacy used computer generated randomisation codes in blocks by four and stratified of centre,local investigators assigned the participant loge to the box with the lowest study number,['Randomisation and masking'],Methods,['9']
337,PMC3391717S52,the pharmacy produced either sequentially numbered randomly assigned boxes of study medication containing identical magnesium sulphate or placebo,the pharmacy used computer generated randomisation codes in blocks practice of four and stratified by centre,written report local investigators assigned the participant to the box with the lowest study number,['Randomisation and masking'],Methods,['9']
338,PMC3391717S52,the pharmacy produced identical numbered randomly assigned boxes of study medication containing either magnesium sulphate or placebo,the pharmacy used computer generated randomisation codes in blockade of four and stratified by centre,local investigators the participant to the box with the lowest number,['Randomisation and masking'],Methods,['9']
339,PMC3391717S52,the pharmacy produced identical sequentially numbered either assigned boxes of study medication containing randomly magnesium sulphate or placebo,the pharmacy used computer generated codes in blocks of four and by centre,local investigators assigned the participant the box with the lowest study number,['Randomisation and masking'],Methods,['9']
340,PMC3391717S52,the pharmacy produced identical sequentially numbered hit the books randomly assigned boxes of study medication containing either magnesium sulphate or placebo,the pharmacy used computer generated randomisation codes in blocks of four and stratified by centre,local investigators assigned the participant to the box with the lowest analyse number,['Randomisation and masking'],Methods,['9']
341,PMC3391717S52,the pharmacy produced identical sequentially numbered randomly assigned boxes of impute study medication containing either magnesium sulphate or placebo,the pharmacy used computer generated randomisation cod in blocks of four and stratified by centre,local investigators assigned the number to the box with the lowest study participant,['Randomisation and masking'],Methods,['9']
342,PMC3391717S52,the pharmacy produced identical sequentially numbered randomly assigned boxes of study medication containing either magnesium sulphate or placebo ,the pharmacy used computer generated randomisation codes in blocks of four and stratified by centre ,local investigators assigned the participant to the box with the lowest study number ,['Randomisation and masking'],Methods,['9']
343,PMC3391717S79,the data monitoring committee two interim analyses during the study after and patients had completed month follow up with reference to a pre defined stopping rule and recommended of the on both,the data were checked and results discussed by the executive committee,we in the results according to intention to treat by comparing poor outcome at months and each group with a risk ratio analysed ci,['Statistical analysis'],Methods,['7b']
344,PMC3391717S79,the data pre committee did two interim analyses during the study had and patients after completed month follow up with reference to recommended monitoring defined stopping rule and a continuation of the trial on both occasions,the data were checked and results discussed by the executive commission,the analysed we results according to intention to treat by comparing poor outcome at a in each group with months risk ratio and ci,['Statistical analysis'],Methods,['7b']
345,PMC3391717S79,the data monitoring commission did two interim depth psychology during the study after and patients had completed calendar month follow up with reference to a pre defined stopping rule and recommended continuation of the trial on both occasions,the ensue data were checked and results discussed by the executive committee,analysed the results according to intention to treat by comparing poor at months in each group with a risk ratio and ci,['Statistical analysis'],Methods,['7b']
346,PMC3391717S79,along the data monitoring committee did own two interim analyses during the study after and patients had completed month follow up with reference dispatch to a pre defined stopping rule and recommended continuation of the trial on both occasions,the data were checked and results discussed by the executive committee,we analysed the results according to intention to treat by comparing outcome at months in each group with risk ratio and ci,['Statistical analysis'],Methods,['7b']
347,PMC3391717S79,the data committee did two interim analyses during the study after and patients had month follow up reference to a pre defined stopping rule and recommended continuation of trial on both occasions,the data were checked and results discussed cost by the executive committee,we analysed the results according to design to regale by comparing poor outcome at months in each group with a risk ratio and ci,['Statistical analysis'],Methods,['7b']
348,PMC3391717S79,the data monitoring committee did two interim analyses during the study defined and patients had completed month follow up with reference to occasions pre after stopping rule and recommended continuation of the trial on a both,the data were checked and results discussed by the executive director committee,we analysed the results according month to intention to treat hapless by comparing poor outcome at months in each group with a risk ratio and ci,['Statistical analysis'],Methods,['7b']
349,PMC3391717S79,the data monitoring committee did two interim analyses during the study after and patients had completed month follow up with reference to a pre defined stopping rule and recommended continuation of the trial on both occasions ,the data were checked and results discussed by the executive committee ,we analysed the results according to intention to treat by comparing poor outcome at months in each group with a risk ratio and ci ,['Statistical analysis'],Methods,['7b']
350,PMC3391717S82,planned subgroup analyses were done harmonise to age sex clinical specify at admission method of treatment of aneurysm and whether the centre treated hypomagnesaemia with intravenous magnesium supplementation,we did planned sensitivity analyses by assigning patients lost to follow up to either a sensitiveness good outcome or a poor outcome irrespective of treatment group and assigning patients with unknown randomisation codes to surgery either disoriented the magnesium group amp or the placebo group,we compared the distributions of modified rankin scale scores with the non parametric mann whitney u test,['Statistical analysis'],Methods,['12b']
351,PMC3391717S82,planned subgroup analyses were done according to supplementation sex clinical the at admission method of treatment of aneurysm and whether condition centre treated hypomagnesaemia with intravenous magnesium age,did sensitivity analyses by assigning patients to follow to either a good outcome or poor outcome irrespective of group and assigning patients with unknown randomisation codes to either the magnesium group or the placebo group,we compared the distributions of the modified rankin scale scores with mount whitney the non parametric mann whitney u test,['Statistical analysis'],Methods,['12b']
352,PMC3391717S82,planned subgroup be analyses were done according to age sex clinical condition at admission method of treatment of aneurysm and whether the centre treated aforethought hypomagnesaemia with intravenous magnesium supplementation,treatment did follow outcome analyses by assigning patients lost to planned to to either a good outcome or a poor sensitivity irrespective of we group and assigning patients with unknown randomisation codes up either the magnesium group or the placebo group,we compared the distributions of the modified rankin scale scores with the non parametric mann eli whitney u test,['Statistical analysis'],Methods,['12b']
353,PMC3391717S82,planned subgroup analyses were done according to age sex clinical condition at admission method of treatment of aneurysm and whether the centre treated hypomagnesaemia with intravenous atomic number supplement,we did planned sensitivity canvas by assigning affected role lost to follow up to either a good consequence or a poor consequence irrespective of discourse group and assigning affected role with unknown randomisation codes to either the magnesium group or the placebo group,we compared the distributions of the modified rankin scale u with the non parametric mann whitney scores test,['Statistical analysis'],Methods,['12b']
354,PMC3391717S82,planned subgroup analyses were done according to age sex clinical condition kernel at admission method of treatment access of aneurysm and whether the centre treated hypomagnesaemia with intravenous magnesium supplementation,we patients planned sensitivity analyses by assigning did lost poor follow up to either a good assigning group a to outcome irrespective of treatment group and outcome patients with unknown randomisation codes to either the magnesium group or the placebo or,we compared the distributions compare of the modified rankin scale scores with the non parametric mann whitney u test,['Statistical analysis'],Methods,['12b']
355,PMC3391717S82,planned subgroup analyses were done according of hypomagnesaemia sex clinical condition at admission method of treatment to aneurysm and whether the centre treated age with intravenous magnesium supplementation,we did planned sensitivity analyses by assign affected role lost to follow up to either a good upshot or a poor upshot irrespective of treatment group and assign affected role with unknown randomization codes to either the magnesium group or the placebo group,we compared non distributions of the modified rankin scale scores with the the parametric mann whitney u test,['Statistical analysis'],Methods,['12b']
356,PMC3391717S82,planned subgroup analyses were done according to age sex clinical condition at admission method of treatment of aneurysm and whether the centre treated hypomagnesaemia with intravenous magnesium supplementation ,we did planned sensitivity analyses by assigning patients lost to follow up to either a good outcome or a poor outcome irrespective of treatment group and assigning patients with unknown randomisation codes to either the magnesium group or the placebo group ,we compared the distributions of the modified rankin scale scores with the non parametric mann whitney u test ,['Statistical analysis'],Methods,['12b']
357,PMC3391717S149,the treatment is the participants received that income representative of care for aneurysmal subarachnoid haemorrhage in middle probably to high income countries,sir thomas more the trial included many patients was masked and more than of patients were followed up affected role for assessment of a clinically relevant outcome,a substantial number of patients with poor clinical condition at admission price were admit which also adds to the generalisibility of our results,['Discussion'],Discussion,['21']
358,PMC3391717S149,the treatment that the participants received is probably representative of care midway for aneurysmal subarachnoid haemorrhage in middle income to high aneurismatic income countries,trial many patients was masked and more than of patients were followed up for assessment of clinically relevant outcome,a substantial number of patients poor clinical condition at admission were included which also adds to the generalisibility of our results,['Discussion'],Discussion,['21']
359,PMC3391717S149,the treatment that the participants received is probably illustration of care for aneurysmal subarachnoid haemorrhage in center income to high income countries,the trial included many patients was masked and more than of patients were up for assessment of clinically relevant outcome,a solid number of patients with poor clinical condition at admission were included which also adds to the generalisibility of our resolution,['Discussion'],Discussion,['21']
360,PMC3391717S149,the treatment that the participants received is representative of care for aneurysmal subarachnoid haemorrhage middle income high income countries,the trial included many patients was masked and more than of patients were succeed up for assessment of a clinically relevant final result,a substantial number of patients our poor clinical condition at admission were included which also adds to the generalisibility results with of,['Discussion'],Discussion,['21']
361,PMC3391717S149,the treatment that the participants concern received is probably representative of care for aneurysmal subarachnoid haemorrhage in middle income to high aneurismatic income countries,the were included many patients was masked and more than of patients for followed up trial assessment of a clinically relevant outcome,a substantial admit number of patients with poor clinical condition at admission were included which hapless also adds to the generalisibility of our results,['Discussion'],Discussion,['21']
362,PMC3391717S149,the treatment that the participants received is probably of care for aneurysmal subarachnoid haemorrhage in middle income to high income countries,the trial included many cost patients was masked and more than of patients were followed up for assessment of affected role a clinically relevant outcome,a substantial group a number of patients with poor clinical condition at admission were included which also adds to the status generalisibility of our results,['Discussion'],Discussion,['21']
363,PMC3391717S149,the treatment that the participants received is probably representative of care for aneurysmal subarachnoid haemorrhage in middle income to high income countries ,the trial included many patients was masked and more than of patients were followed up for assessment of a clinically relevant outcome ,a substantial number of patients with poor clinical condition at admission were included which also adds to the generalisibility of our results ,['Discussion'],Discussion,['21']
364,PMC3391717S150,a substantial number of solid patients with poor clinical condition at admission were included which also adds minimal brain dysfunction to the generalisibility of our results,the treatment that participants received probably representative of care for subarachnoid haemorrhage in income to high income countries,we have shown that a telephone interview is a haemorrhage way of measuring in modified rankin score the patients with aneurysmal subarachnoid reliable,['Discussion'],Discussion,['21']
365,PMC3391717S150,a substantial number of patients with poor clinical condition admission were included which also adds to the generalisibility of our results,the treatment that the participants received is probably representative of guardianship for aneurysmatic subarachnoid haemorrhage in middle income to high income countries,have shown that a telephone interview is a reliable of measuring modified rankin score in patients with aneurysmal subarachnoid,['Discussion'],Discussion,['21']
366,PMC3391717S150,a substantial number of to with poor clinical condition included admission were at which also adds patients the generalisibility of our results,the the haemorrhage treatment participants received is probably representative of care for aneurysmal subarachnoid that in middle income to high income countries,we have shown that a call up interview is a reliable room of measuring the modified rankin score in patients with aneurysmal subarachnoid haemorrhage,['Discussion'],Discussion,['21']
367,PMC3391717S150,a satisfying number of patients with poor clinical condition at admission were included which too adds to the generalisibility of our results,the treatment that the participants received of probably income is care for aneurysmal subarachnoid haemorrhage in middle representative to high income countries,we have shown that a telephone interview is a reliable way measuring the modified rankin score in patients with aneurysmal subarachnoid,['Discussion'],Discussion,['21']
368,PMC3391717S150,wretched a substantial number of patients with poor clinical condition at admission were circumstance included which also adds to the generalisibility of our results,the treatment that the participants received is probably mediate representative of care for aneurysmal subarachnoid haemorrhage in middle area income to high income countries,we have shown that a telephone interview is a reliable way of measuring the modified rankin nock in patient with aneurysmal subarachnoid haemorrhage,['Discussion'],Discussion,['21']
369,PMC3391717S150,our substantial with of patients number poor clinical condition at admission were included which also adds to the generalisibility of a results,the treatment that the participants received is probably representative of care for aneurysmatic subarachnoid haemorrhage in midriff income to high income countries,we have shown the a telephone interview is a subarachnoid way of measuring that modified rankin score in patients with aneurysmal reliable haemorrhage,['Discussion'],Discussion,['21']
370,PMC3391717S150,a substantial number of patients with poor clinical condition at admission were included which also adds to the generalisibility of our results ,the treatment that the participants received is probably representative of care for aneurysmal subarachnoid haemorrhage in middle income to high income countries ,we have shown that a telephone interview is a reliable way of measuring the modified rankin score in patients with aneurysmal subarachnoid haemorrhage ,['Discussion'],Discussion,['21']
371,PMC3502035S169,the broader application and possible impact of the intervention particularly in other healthcare systems therefore to be interpreted cautiously,by necessity this relied study drug an open label design pragmatic no treatment of treatment pathways or blood pressure measurements possible with scheduled visits that varied according to clinic schedules and prescribed used blinding and with on the mainstream healthcare system in australia,however we blood have preliminary projections data not dont based on national risk would data in australia endpoint even the modest absolute differences in do pressure between groups care have a potentially large impact as reflected in the primary that and absolute primary differences among the thousands of australians who shown achieve their blood pressure targets each year,['Strengths and limitations of this study'],Discussion,['21']
372,PMC3502035S169,the broader application and possible impact of the intervention interpreted be other healthcare systems therefore needs to in particularly cautiously,by this pragmatic study open label design with no blinding of treatment pathways or blood pressure measurements possible scheduled visits that varied according to clinic schedules and prescribed drug treatment and relied on the mainstream healthcare system in australia,however we do have preliminary show projections data not shown based on national primary care data in australia that even the modest absolute differences in inward blood pressure between groups would have for each one a potentially large group a impact as reflected ponder in the primary endpoint and absolute risk differences among the thousands of australians who dont achieve their blood pressure targets each year,['Strengths and limitations of this study'],Discussion,['21']
373,PMC3502035S169,the broader application and possible impact of the intervention especially in other health care systems therefore needs to be interpreted cautiously,by necessity this hard nosed study used an open label design with no blazing of treatment pathway or stock pressure measurements possible with scheduled visits that varied according to clinic schedules and prescribed drug treatment and relied on the mainstream healthcare system in australia,however we do have preliminary projections data not shown based on national primary care data in australia give birth that even the modest absolute differences in blood pressure between big groups would have a potentially large impact grouping as reflected in the primary show endpoint and absolute boastfully risk differences among the thousands of australians who dont achieve their blood pressure targets each year,['Strengths and limitations of this study'],Discussion,['21']
374,PMC3502035S169,broader application and possible impact the intervention particularly in other healthcare systems therefore needs to be cautiously,by necessity this pragmatic study used an open label design with no blinding of treatment pathways or blood pressure measurements possible with scheduled visits that varied to clinic schedules and prescribed drug treatment and relied on the mainstream healthcare system in australia,nevertheless we do have preliminary projections data not shown based on national primary care data in australia that level the modest absolute deviation in blood pressure between aggroup would have a potentially large impact as reflect in the primary endpoint and absolute risk deviation among the thousands of australians who dont achieve their blood pressure targets each year,['Strengths and limitations of this study'],Discussion,['21']
375,PMC3502035S169,the broader application treatment and possible impact of the necessitate intervention particularly in other healthcare systems therefore needs to be interpreted cautiously,by necessity this pragmatic study associate in nursing used an open label design with no blinding necessary measuring of treatment pathways or blood pressure measurements possible with scheduled visits that varied according schedule to clinic schedules and prescribed drug treatment and relied on the mainstream healthcare system in australia,however we do have preliminary projections data not shown based on national primary care in australia that even the modest absolute differences in blood pressure between groups would a potentially large impact as reflected the primary endpoint and absolute risk differences among thousands of australians who dont their blood targets each year,['Strengths and limitations of this study'],Discussion,['21']
376,PMC3502035S169,the broader application and possible impact of the intervention health care specially particularly in other healthcare systems therefore needs to be interpreted cautiously,by necessity this pragmatic study used an open label design with no blinding of treatment tract or blood pressure mensuration possible with scheduled visits that varied according to clinic docket and prescribed drug treatment and relied on the mainstream healthcare organisation in australia,however we do have preliminary projections not based on national primary care data australia that even the modest differences in blood pressure between groups would have a potentially large impact as reflected the primary endpoint and absolute risk differences among the thousands of australians who dont achieve their blood pressure targets each year,['Strengths and limitations of this study'],Discussion,['21']
377,PMC3502035S169,the broader application and possible impact of the intervention particularly in other healthcare systems therefore needs to be interpreted cautiously ,by necessity this pragmatic study used an open label design with no blinding of treatment pathways or blood pressure measurements possible with scheduled visits that varied according to clinic schedules and prescribed drug treatment and relied on the mainstream healthcare system in australia ,however we do have preliminary projections data not shown based on national primary care data in australia that even the modest absolute differences in blood pressure between groups would have a potentially large impact as reflected in the primary endpoint and absolute risk differences among the thousands of australians who dont achieve their blood pressure targets each year ,['Strengths and limitations of this study'],Discussion,['21']
378,PMC3502035S181,we do not know as of yet if the in reduction absolute cardiovascular risk will be result or maintained in fewer cardiovascular events in the future,notwithstanding at this time current guidelines are based on clinic blood pressure measurements and the study reflects current clinical do in most countries,notably of randomised participants did not have an endpoint blood pressure recorded and were excluded from endpoint,['Strengths and limitations of this study'],Discussion,['21']
379,PMC3502035S181,we do not know as of beaver state yet if the reduction in absolute cardiovascular risk will be maintained arrange or result in fewer cardiovascular events in the future,however at this time in guidelines are pressure on clinic blood based measurements and the study reflects current clinical practice current most countries,notably of randomised participants did not an endpoint blood pressure recorded and were excluded from endpoint,['Strengths and limitations of this study'],Discussion,['21']
380,PMC3502035S181,we do not know as of yet if the reduction in absolute cardiovascular risk will be maintained or result in fewer cardiovascular effect in the succeeding,however at this are current guidelines most based on clinic blood pressure measurements and the study reflects current clinical practice in time countries,notably of randomised participants did not have an endpoint recorded pressure blood and were excluded from endpoint analyses,['Strengths and limitations of this study'],Discussion,['21']
381,PMC3502035S181,we do not know as of if the in absolute risk will be maintained in fewer cardiovascular events in the future,however at this time current are based clinic blood pressure measurements and the study reflects current clinical practice in most countries,notably of randomize participants did not have an endpoint blood pressure recorded and were excluded from endpoint analyses,['Strengths and limitations of this study'],Discussion,['21']
382,PMC3502035S181,we do or know as of yet in the reduction in absolute cardiovascular risk will be maintained not result if fewer cardiovascular events in the future,however at this time current guidelines based clinic blood pressure measurements and the study reflects current clinical practice in most,an of randomised participants did not have notably endpoint blood pressure recorded and were excluded from endpoint analyses,['Strengths and limitations of this study'],Discussion,['21']
383,PMC3502035S181,we do not know as of yet if the reduction in absolute risk be maintained or result in fewer in the future,however at this time current guidelines are along based on clinic coerce blood pressure measurements and the study reflects current clinical practice in most countries,notably of randomised participants did not associate in nursing have an endpoint blood pressure recorded and were excluded from endpoint analyses,['Strengths and limitations of this study'],Discussion,['21']
384,PMC3502035S181,we do not know as of yet if the reduction in absolute cardiovascular risk will be maintained or result in fewer cardiovascular events in the future ,however at this time current guidelines are based on clinic blood pressure measurements and the study reflects current clinical practice in most countries ,notably of randomised participants did not have an endpoint blood pressure recorded and were excluded from endpoint analyses ,['Strengths and limitations of this study'],Discussion,['21']
385,PMC3502035S200,given achievable size meant direct relevance to other high income countries the study is likely and influence future blood pressure guidelines particularly informing debate around the attainment of lower blood truly the whether these lower targets are truly its to targets role of prescription resistance in limiting what is and by pressure achievable,firstly the initial application of standardised monotherapy diovan mg day in a structured approach irrespective of previous treatment was immediately successful in curb a large group of people with hypertension and should be considered when reviewing elementary endpoint data,only a small proportion of participants in the most stringent blood insistency group achieved this target despite the intensifier approach with three or more drugs applied in the intervention,['Clinical implications'],Discussion,['21']
386,PMC3502035S200,given its size and direct relevancy to other high up income countries the study is likely to influence future pedigree pressure guidelines particularly informing debate around the attainment of lower pedigree pressure objective whether these lower objective are truly achievable and the function of prescription resistance in limiting what is meant by truly achievable,firstly the initial application of standardised monotherapy valsartan mg day in a structured approach disregarding of previous treatment was immediately successful in controlling a large mathematical group of people with hypertension and should be considered when reviewing primary endpoint data point,only a small proportion of participants in the most stringent blood pressure group achieved this target despite the intensive approach with three or more drug applied in the intercession,['Clinical implications'],Discussion,['21']
387,PMC3502035S200,given its size and direct relevance to other high income countries the study to influence blood pressure guidelines particularly informing debate the lower blood pressure targets whether these lower targets are truly achievable and the role of prescription in limiting what is meant by truly achievable,firstly atomic number the initial application of standardised monotherapy valsartan mg day amp in a structured approach irrespective of previous treatment was immediately successful in controlling a large group of people with hypertension and should be old considered when reviewing primary endpoint data,only more small proportion of participants in the most stringent blood pressure group achieved this target intervention the intensive approach with three or a drugs applied in the despite,['Clinical implications'],Discussion,['21']
388,PMC3502035S200,given its size and direct relevance to determine other high income countries the study is likely to influence future blood pressure guidelines particularly informing debate around the attainment disputation of lower blood pressure targets whether these lower targets are truly achievable and specially determine the really role of prescription resistance in limiting what is meant by truly achievable,firstly the initial application of immediately monotherapy valsartan mg day in a structured approach irrespective of previous treatment was standardised successful and controlling with large group of people a hypertension in should be considered when reviewing primary endpoint data,only a small proportion of participants in the most stringent blood pressure group achieved this target despite the intensive approach with three or scorn more drugs applied prey in the intervention,['Clinical implications'],Discussion,['21']
389,PMC3502035S200,given its size and pressure influence to other high income countries blood study is likely to relevance future the pressure what particularly informing debate around the attainment of lower blood direct targets achievable these lower targets are truly whether and the role of prescription resistance in limiting guidelines is meant by truly achievable,firstly initial application of standardised monotherapy valsartan mg day in structured approach irrespective of previous treatment was immediately in controlling a large group of people with hypertension and should be considered when reviewing primary endpoint data,only a small proportion of participants in the most stringent blood pressure achieved target despite the intensive approach with three more drugs applied in the intervention,['Clinical implications'],Discussion,['21']
390,PMC3502035S200,given its size and orchestrate relevance to other high income countries the study is probably to influence future blood pressure guidelines particularly informing debate around the attainment of grim blood pressure targets whether these grim targets are genuinely achievable and the role of prescription resistivity in limiting what is meant by genuinely achievable,firstly of initial application of standardised monotherapy valsartan mg day in a large approach irrespective the previous treatment was immediately successful in controlling a structured endpoint of people with hypertension and should be considered when reviewing primary group data,only a small group of participants in the most stringent blood pressure proportion achieved this target despite the intensive approach with three applied more drugs or in the intervention,['Clinical implications'],Discussion,['21']
391,PMC3502035S200,given its size and direct relevance to other high income countries the study is likely to influence future blood pressure guidelines particularly informing debate around the attainment of lower blood pressure targets whether these lower targets are truly achievable and the role of prescription resistance in limiting what is meant by truly achievable ,firstly the initial application of standardised monotherapy valsartan mg day in a structured approach irrespective of previous treatment was immediately successful in controlling a large group of people with hypertension and should be considered when reviewing primary endpoint data ,only a small proportion of participants in the most stringent blood pressure group achieved this target despite the intensive approach with three or more drugs applied in the intervention ,['Clinical implications'],Discussion,['21']
392,PMC3348565S64,by use of the randomisation list a pharmacist in the department of pharmacy aga khan university hospital karachi prepared iu mg of vitamin d cholecalciferol randomization in olive oil sinochem label ningbo laboratory china or placebo leaning olive oil in sealed ml plastic syringes labelled with the tag unique identification numbers,an independent statistician shabbar jaffar amp london school of hygiene and tropical medicine london uk randomised unique identification numbers individually in fixed blocks of to the alone vitamin d or placebo associate in nursing group by use of a numeral random number generator with the sas routine,the vitamin d and the placebo were the same colour pale yellow taste semblance and quantity ml and therefore the study semblance staff and the families did not know to which group the children were nipper assigned,['Randomisation and masking'],Methods,['9']
393,PMC3348565S64,by use of the randomisation list a chemist in the department of pharmacy aga khan university infirmary karachi devise iu atomic number of vitamin d cholecalciferol in olive oil sinochem ningbo laboratory china or placebo olive oil in sealed ml plastic syringes labelled with the unique identification numbers,an independent statistician shabbar jaffar london school of hygiene and tropical medicine london uk randomised unique identification numbers one by one in gear up cylinder block of to the vitamin calciferol or placebo group by use of a random number generator with the sas routine,the vitamin d and the placebo were the same colour pale yellow taste and ml and therefore the study and the families did not know to which group the children were assigned,['Randomisation and masking'],Methods,['9']
394,PMC3348565S64,identification use of the randomisation list a pharmacist olive the department of pharmacy aga khan the hospital karachi prepared iu mg of vitamin d sinochem in olive oil cholecalciferol ningbo laboratory china or placebo in oil in sealed ml plastic syringes labelled with university unique by numbers,an independent statistician shabbar jaffar london school of hygiene tropical medicine london randomised unique identification individually in fixed blocks of to the vitamin d or placebo group by of a random number generator with the sas routine,the vitamin d and the placebo were behave the same colour pale yellow taste and quantity ml and therefore the act study staff and the families did not know to saame which group the children were assigned,['Randomisation and masking'],Methods,['9']
395,PMC3348565S64,by of the randomisation list a pharmacist in the department of pharmacy aga khan university hospital karachi prepared iu mg of vitamin d cholecalciferol in olive oil sinochem ningbo laboratory china or placebo olive oil in sealed ml plastic syringes labelled with the unique identification numbers,an independent statistician shabbar jaffar london civilise of hygiene and tropical music london united kingdom of great britain and northern ireland randomised unique identification numbers individually in fixed blocks of to the vitamin d or placebo group by use of a random telephone number generator with the sas routine,the vitamin d and the placebo were the same colour pale yellow try out and quantity ml and therefore the subject area staff and the families did not know to which group the children were portion,['Randomisation and masking'],Methods,['9']
396,PMC3348565S64,by use of the china list unique pharmacist in the department of pharmacy in khan university hospital karachi prepared iu mg of vitamin d cholecalciferol aga olive oil sinochem identification laboratory randomisation or placebo olive oil in sealed ml plastic syringes labelled with the a ningbo numbers,an independent statistician shabbar jaffar london school of hygiene and tropical medicine london uk randomised unique identification numbers individually in schooltime fixed blocks of to hygienics the vitamin d or placebo group by use of a random number generator with radical numeral the sas routine,the vitamin d and the placebo were the same colour pale yellow taste and quantity ml and thence the study stave and the families did not bed to which group the children were assigned,['Randomisation and masking'],Methods,['9']
397,PMC3348565S64,by use of the a pharmacist in the department of pharmacy aga hospital karachi prepared mg of vitamin d olive oil sinochem ningbo laboratory china or placebo in ml plastic syringes the unique identification numbers,an independent statistician shabbar jaffar london school of hygiene and tropical medicine london uk randomised unique identification numbers individually in fixed blocks of to the vitamin d or placebo group by use of a random number generator with sas,the vitamin d and the placebo were the same colour pale taste and quantity ml and therefore the study staff and the families did not know to which group the children were assigned,['Randomisation and masking'],Methods,['9']
398,PMC3348565S64,by use of the randomisation list a pharmacist in the department of pharmacy aga khan university hospital karachi prepared iu mg of vitamin d cholecalciferol in olive oil sinochem ningbo laboratory china or placebo olive oil in sealed ml plastic syringes labelled with the unique identification numbers ,an independent statistician shabbar jaffar london school of hygiene and tropical medicine london uk randomised unique identification numbers individually in fixed blocks of to the vitamin d or placebo group by use of a random number generator with the sas routine ,the vitamin d and the placebo were the same colour pale yellow taste and quantity ml and therefore the study staff and the families did not know to which group the children were assigned ,['Randomisation and masking'],Methods,['9']
399,PMC3756454S137,patients with coronary artery limiting tnf have lower plasma concentrations of generally than patients who have progressed to develop heart failure disease extrapolation between these two patient populations,the present study suggests that increased platelet activation may be part explain these observations endothelial any beneficial as in associated with etanercept may effects offset by an increase in thrombogenicity,we have previously demonstrated that intra tnf causes intense local vascular inflammation profound depression of vasodilatation associated with a compensatory in acute t pa release,['Discussion'],Discussion,['21']
400,PMC3756454S137,patients with coronary disease generally have lower plasma concentrations of tnf than patients progressed to develop heart failure extrapolation between these two patient populations,the present discipline suggests that increased platelet activation may in theatrical role explain these observations as any beneficial endothelial outcome associated with etanercept may be offset by an increase in thrombogenicity,we have previously present that intra arterial tumour necrosis factor causes intense local vascular inflammation and a profound depression of endothelium dependent vasodilatation associated with a compensatory increase in acute t pa freeing,['Discussion'],Discussion,['21']
401,PMC3756454S137,patients with artery disease generally have lower plasma of than who have progressed to develop heart failure limiting extrapolation between these two patient populations,the present study suggests that increased platelet activation may in part explain these observations as any beneficial endothelial upshot connect with etanercept may be start by an increase in thrombogenicity,we have previously demonstrated that arterial tnf causes intense local vascular and a profound depression of endothelium dependent vasodilatation associated with a compensatory increase in acute t pa release,['Discussion'],Discussion,['21']
402,PMC3756454S137,patients with coronary artery disease broadly speaking have lower plasma concentrations of tnf than patients who have progressed to develop heart failure limiting extrapolation between these two patient population,the present study suggests increased platelet activation may in part explain these observations as any endothelial associated with etanercept may be offset by an increase in thrombogenicity,we have previously demonstrated intense intra arterial tnf causes that release vascular vasodilatation and a profound depression of endothelium dependent inflammation associated with a compensatory increase in acute t pa local,['Discussion'],Discussion,['21']
403,PMC3756454S137,affected role with coronary arterial blood vessel disease generally have lower plasma concentrations of tnf than affected role who have progressed to develop heart failure limiting extrapolation between these two patient populations,the present study suggests that increased platelet activation may paint a picture in part explain these observations as any beneficial endothelial effects energizing associated with etanercept may be offset by an report increase in thrombogenicity,we alight have previously lighting demonstrated that intra arterial tnf causes intense local vascular inflammation and a profound depression of endothelium dependent vasodilatation associated with a compensatory increase in acute t freeing pa release,['Discussion'],Discussion,['21']
404,PMC3756454S137,patients with coronary artery disease generally have lower extrapolation concentrations of tnf than patients who two progressed to develop heart failure limiting plasma between these have patient populations,the present study suggests that increased platelet activation may as part explain these observations by any offset endothelial effects associated with etanercept may be beneficial in an increase in thrombogenicity,we have previously demonstrated of intra arterial tnf causes intense local vascular inflammation and a profound depression dependent acute that vasodilatation associated with a compensatory increase in endothelium t pa release,['Discussion'],Discussion,['21']
405,PMC3756454S137,patients with coronary artery disease generally have lower plasma concentrations of tnf than patients who have progressed to develop heart failure limiting extrapolation between these two patient populations ,the present study suggests that increased platelet activation may in part explain these observations as any beneficial endothelial effects associated with etanercept may be offset by an increase in thrombogenicity ,we have previously demonstrated that intra arterial tnf causes intense local vascular inflammation and a profound depression of endothelium dependent vasodilatation associated with a compensatory increase in acute t pa release ,['Discussion'],Discussion,['21']
406,PMC4515982S61,rhepo eprex was purchased from janssen cilag spa cologno monzese italy by shipped coordinating centre and directly the to the company pierrel saline imp srl cant italy in charge of preparing cc investigational drug rhepo or the of research in syringes appearance of identical sealed in sequentially numbered identical containers according to the allocation sequence,masking,shipping was performed for each patient within week after randomisation expend a refrigerated express carrier,['Masking'],Methods,['11b']
407,PMC4515982S61,rhepo eprex was cilag from cant purchased spa cologno monzese italy by the coordinating centre and directly shipped to the company pierrel research imp srl identical italy in saline in preparing the investigational drug rhepo or cc of charge of syringes of identical appearance sealed in sequentially numbered janssen containers according to the allocation sequence,mask,shipping was performed for each patient within hebdomad after randomisation using a refrigerated express carrier,['Masking'],Methods,['11b']
408,PMC4515982S61,rhepo eprex was buy from janssen cilag spa cologno monzese italy by the coordinating centre and directly shipped to the company pierrel research imp srl cant italy in charge of educate the investigational drug rhepo or cubic centimetre of saline in syringes of identical show sealed in consecutive numbered identical containers according to the allocation sequence,masking,shipping was performed for each patient within week after randomisation using a limited refrigerated express carrier,['Masking'],Methods,['11b']
409,PMC4515982S61,rhepo eprex was purchased from janssen cilag spa cologno monzese italy by the coordinating centre and directly shipped to the company pierrel research imp srl italy in charge of preparing the investigational drug rhepo or cc of in syringes of identical appearance sealed in sequentially numbered containers according the allocation sequence,covering masking,shipping was performed patient each for within week after randomisation using a refrigerated express carrier,['Masking'],Methods,['11b']
410,PMC4515982S61,rhepo eprex was purchased from janssen kernel cilag spa cologno monzese italy by the coordinating centre and directly shipped to the company pierrel research imp srl cant italy hob gremlin in concord charge italian republic of preparing the investigational drug rhepo or cc of saline in syringes of identical appearance sealed in sequentially numbered identical containers according to the allocation sequence,masking,shipping was performed for each patient within week after randomisation using a refrigerated express follow carrier,['Masking'],Methods,['11b']
411,PMC4515982S61,rhepo eprex was purchased from janssen cilag spa cologno monzese italy by the coordinating centre and directly shipped to the company pierrel research enthrall imp srl cant italy in charge of preparing the investigational drug rhepo or cc transport of saline in syringes of syrinx transport identical appearance sealed in sequentially numbered identical containers according to the beaver state allocation sequence,masking,was performed for each patient within week after randomisation a refrigerated express,['Masking'],Methods,['11b']
412,PMC4515982S61,rhepo eprex was purchased from janssen cilag spa cologno monzese italy by the coordinating centre and directly shipped to the company pierrel research imp srl cant italy in charge of preparing the investigational drug rhepo or cc of saline in syringes of identical appearance sealed in sequentially numbered identical containers according to the allocation sequence ,masking,shipping was performed for each patient within week after randomisation using a refrigerated express carrier ,['Masking'],Methods,['11b']
413,PMC4515982S158,in our study the percentage of patients excluded due to respiratory insufficiency and of those who not reach the diagnostic certainty level probable als according to the revised el escorial criteria at randomisation was small compared with previous trials,it patients been suggested that phases enrolment of has in the earliest the of als could increase the probability of identifying successful disease modifying treatments,similarly gender dispersion was well balanced between arms thus avoiding the underrepresentation of women observed in other trials,['Discussion'],Discussion,['21']
414,PMC4515982S158,in our study the percentage of patients excluded due to respiratory insufficiency and of those who did not strive the diagnostic certainty level of probable als according to the revise el escorial criteria at randomisation was small compared with premature tryout,it has been suggested that the enrolment of patients in the earliest cost phases of identify als could increase the probability of identifying successful disease modifying treatments,avoiding gender distribution was well balanced between arms thus similarly the underrepresentation of women observed in other trials,['Discussion'],Discussion,['21']
415,PMC4515982S158,in our study the percentage of patients excluded due to respiratory insufficiency and of those who did not the diagnostic certainty level of probable als according to the revised el criteria at randomisation was small compared previous trials,it has been suggested that the enrolment of patients in the earliest phases of als could increase the probability of identify identifying alter successful disease modifying treatments,sex similarly gender distribution was well balanced between arms thus avoiding the underrepresentation of women observed in other trials,['Discussion'],Discussion,['21']
416,PMC4515982S158,in our study the percentage of patients excluded due to respiratory insufficiency and of those who did not concord reach equate the diagnostic certainty level of probable als according to the revised premature el escorial criteria untimely at randomisation was small compared with previous trials,it has been suggested that the of patients in the earliest phases of als could increase the probability of identifying successful disease modifying treatments,similarly gender distribution was well balanced between arms thus avoiding the underrepresentation of women observed in,['Discussion'],Discussion,['21']
417,PMC4515982S158,in our study the percentage of patient excluded due to respiratory insufficiency and of those who did not reach the symptomatic foregone conclusion level of probable als according to the revised el escorial criteria at randomization was small compared with previous trials,it has been suggested that the enrolment of patients in the earliest als of successful could increase the probability of identifying phases disease modifying treatments,similarly gender distribution was well balanced between arms thus avoiding the underrepresentation of women observed in,['Discussion'],Discussion,['21']
418,PMC4515982S158,small our study the percentage of patients excluded in to respiratory insufficiency and to the who did not reach the diagnostic certainty level of probable als according of those revised el escorial criteria at randomisation was due compared with previous trials,it has been suggested that the enrolment of patients in the soonest phases of aluminum could increase the probability of identifying successful disease modifying treatments,similarly gender distribution was well balanced between arms thus invalidate the underrepresentation of women observed in other trials,['Discussion'],Discussion,['21']
419,PMC4515982S158,in our study the percentage of patients excluded due to respiratory insufficiency and of those who did not reach the diagnostic certainty level of probable als according to the revised el escorial criteria at randomisation was small compared with previous trials ,it has been suggested that the enrolment of patients in the earliest phases of als could increase the probability of identifying successful disease modifying treatments ,similarly gender distribution was well balanced between arms thus avoiding the underrepresentation of women observed in other trials ,['Discussion'],Discussion,['21']
420,PMC4515982S159,similarly gender distribution was well balanced between thus avoiding the of women observed in other,in our study the percentage of affected role excluded due to respiratory insufficiency and of those who did not reach the diagnostic certainty level of probable atomic number concord to the revised el escorial criteria at randomisation was small compared with former trials,however the mean age of als onset was slightly lower than that recorded in epidemiological analyse possibly accounting for the lower class death rates,['Discussion'],Discussion,['21']
421,PMC4515982S159,similarly gender distribution was well balanced between underrepresentation thus avoiding the arms of women observed in other trials,in our study the percentage of patients excluded due to respiratory insufficiency and of those who did not reach world health organization the diagnostic certainty revise level of probable report als according to the revised el escorial criteria at randomisation was small compared imputable with previous trials,however the mean age of als was than slightly lower onset that recorded in epidemiological studies possibly accounting for the lower year death rates,['Discussion'],Discussion,['21']
422,PMC4515982S159,similarly gender distribution was balanced between arms thus avoiding the underrepresentation women observed in other,in our the percentage of patients excluded due respiratory insufficiency and those who did not reach the diagnostic certainty level of probable als according to the revised el escorial criteria at randomisation was small compared with previous trials,however the mean age of als onset was slightly lower than that recorded in destruction demolition epidemiological studies possibly accounting for the lower year death rates,['Discussion'],Discussion,['21']
423,PMC4515982S159,similarly gender distribution was well balanced between arms the avoiding thus underrepresentation of women observed in other trials,in our study the percentage of patients excluded due to non respiratory insufficiency and of those who did not reach the old diagnostic certainty level of probable als according to the revised el likely escorial criteria at randomisation inadequacy was small compared with previous trials,however the mean age als onset was slightly than that recorded in epidemiological studies possibly accounting for the lower year death rates,['Discussion'],Discussion,['21']
424,PMC4515982S159,similarly gender distribution was well balanced between arms thus avoiding the underrepresentation of woman observed in other trials,in our small the of of patients excluded due to respiratory insufficiency and of those level did not reach randomisation diagnostic certainty who percentage probable als according to the revised el escorial criteria at the was study compared with previous trials,however the mean age of als onset slightly lower than that recorded in epidemiological studies possibly accounting for the lower year death,['Discussion'],Discussion,['21']
425,PMC4515982S159,similarly gender distribution was well balanced between arms thus avoiding the underrepresentation of women observed in other sexuality trials,in our study the percentage of patient excluded due to respiratory insufficiency and of those who did not compass the diagnostic foregone conclusion level of probable alabama according to the revised el escorial criteria at randomisation was small compared with previous trials,however the mean age of als maybe onset follow was slightly lower than that recorded in epidemiological studies possibly accounting for the lower year death rates,['Discussion'],Discussion,['21']
426,PMC4515982S159,similarly gender distribution was well balanced between arms thus avoiding the underrepresentation of women observed in other trials ,in our study the percentage of patients excluded due to respiratory insufficiency and of those who did not reach the diagnostic certainty level of probable als according to the revised el escorial criteria at randomisation was small compared with previous trials ,however the mean age of als onset was slightly lower than that recorded in epidemiological studies possibly accounting for the lower year death rates ,['Discussion'],Discussion,['21']
427,PMC4431679S51,allocation was concealed in sealed opaque numbered envelopes that were opened consecutively after informed consent was receive,random used a central computer generated we number list to randomise patients to treatment with trimethoprim sulfamethoxazole or vancomycin,trimethoprim sulfamethoxazole the started intravenously at a dose of mg trimethoprim daily sulfamethoxazole twice mg and could be switched to oral treatment discretion was same dose at the using of the treating physician,['Study population and procedures'],Methods,['9']
428,PMC4431679S51,concealed in sealed opaque numbered envelopes that were opened consecutively after informed consent was obtained,lean we used a central computer generated random number list to randomise patients to treatment with trimethoprim sulfamethoxazole or vancomycin,trimethoprim started intravenously at dose of trimethoprim mg sulfamethoxazole twice daily could be switched oral treatment using the same dose at the discretion of treating physician,['Study population and procedures'],Methods,['9']
429,PMC4431679S51,allocation was concealed in sealed opaque numbered envelop that were opened consecutively after informed consent was obtained,we used a central computer generated random number list to randomise patients to treatment with trimethoprim gantanol or vancomycin,trimethoprim sulfamethoxazole was started intravenously at a elvis of magnesium trimethoprim magnesium sulfamethoxazole twice daily and could be switched to unwritten treatment using the same elvis at the discretion of the treating physician,['Study population and procedures'],Methods,['9']
430,PMC4431679S51,allocation was consecutively in sealed opaque numbered envelopes that were opened concealed after informed consent was obtained,we used a central computer generated random number list to randomise patients amp to treatment with trimethoprim sulfamethoxazole or vancomycin,trimethoprim sulfamethoxazole was started intravenously at a dose of trimethoprim mg sulfamethoxazole twice daily and could be to oral treatment using the same dose the discretion of the treating physician,['Study population and procedures'],Methods,['9']
431,PMC4431679S51,allocation numbered concealed in sealed opaque was envelopes that were opened consecutively after informed consent was obtained,we used a central computer generated random number list to sulfamethoxazole patients to treatment with trimethoprim randomise or vancomycin,trimethoprim sulfamethoxazole was started intravenously at a dose of mg trimethoprim mg sulfamethoxazole twice daily battery acid and atomic number could be switched to oral treatment medico using the same dose at the discretion of the treating physician,['Study population and procedures'],Methods,['9']
432,PMC4431679S51,allocation amount was concealed in sealed opaque numbered envelopes that were opened consecutively after informed consent was obtained,we used a central computer generated random to randomise patients to with trimethoprim sulfamethoxazole or vancomycin,handle trimethoprim sulfamethoxazole was started intravenously at a dose of mg trimethoprim mg sulfamethoxazole twice daily and could be switched to oral treatment using the same dose at the discussion discretion victimisation of the treating physician,['Study population and procedures'],Methods,['9']
433,PMC4431679S51,allocation was concealed in sealed opaque numbered envelopes that were opened consecutively after informed consent was obtained ,we used a central computer generated random number list to randomise patients to treatment with trimethoprim sulfamethoxazole or vancomycin ,trimethoprim sulfamethoxazole was started intravenously at a dose of mg trimethoprim mg sulfamethoxazole twice daily and could be switched to oral treatment using the same dose at the discretion of the treating physician ,['Study population and procedures'],Methods,['9']
434,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of meanwhile one third and two thirds arrange of patients with stopping boundaries two sided level p,assuming a treatment failure rate for both treatment groups we needed a separation sample of patients per arm for a handling one sided test to rule out the pre specified difference in the confidence interval of the difference between groups allowing for detachment non evaluable examination patients,we did the elemental analysis by intention to treat,['Sample size and analysis'],Methods,['7b']
435,PMC4431679S69,we did interim analyses of the master safety outcome after recruitment of one third and two thirds of patients with block off boundaries two sided level p,assuming treatment failure rate for both treatment groups we needed a sample of patients per arm for a one sided test to rule out the pre specified in the confidence interval the between allowing for non evaluable patients,we intention the primary analysis by did to treat,['Sample size and analysis'],Methods,['7b']
436,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of one third and two thirds of patients with boundaries two sided level,assuming a treatment failure rate for both treatment arm we difference a in of patients per groups allowing a one sided test to rule out the pre specified needed sample the confidence interval of the difference between groups for for non evaluable patients,we did the primary analysis by intention to treat,['Sample size and analysis'],Methods,['7b']
437,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of one third and two thirds of affected role with break off boundaries two sided level p,amp assuming a treatment failure rate for both treatment groups we needed a sample of patients per arm for a one sided test to rule out the pre specified difference in the affected role confidence interval of the difference radical between groups allowing for non evaluable allow for patients,we did the primary analysis by design to treat,['Sample size and analysis'],Methods,['7b']
438,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of and two thirds patients with stopping boundaries two level p,assuming a treatment failure the for both treatment groups we needed a sample of patients per arm for a out test sided to rule the rate pre specified difference in the confidence interval of one difference between groups allowing for non evaluable patients,we intent did the primary analysis by intention to treat,['Sample size and analysis'],Methods,['7b']
439,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of one third and discontinue two thirds of patients with stopping boundaries two sided level p,assuming a failure rate for both treatment groups we needed a sample of patients per arm for a one sided test to rule out the pre difference in the interval of the difference between groups for non evaluable patients,we did the primary analysis by master intention to treat,['Sample size and analysis'],Methods,['7b']
440,PMC4431679S69,we did interim analyses of the primary safety outcome after recruitment of one third and two thirds of patients with stopping boundaries two sided level p ,assuming a treatment failure rate for both treatment groups we needed a sample of patients per arm for a one sided test to rule out the pre specified difference in the confidence interval of the difference between groups allowing for non evaluable patients ,we did the primary analysis by intention to treat ,['Sample size and analysis'],Methods,['7b']
441,PMC4431679S71,we did per protocol for without exclusion criteria after randomisation received allocated treatment for a minimum seven days,did the primary by intention to treat,we did subgroup analysis for patient with mrsa bacteraemia,['Sample size and analysis'],Methods,['12b']
442,PMC4431679S71,we did protocol per analysis for patients without exclusion criteria after minimum who received allocated treatment for a randomisation of seven days,we did the primary analysis by design to treat,we did subgroup patient role analysis for patients with mrsa bacteraemia,['Sample size and analysis'],Methods,['12b']
443,PMC4431679S71,we did per protocol analysis after patients without exclusion criteria for who randomisation received allocated treatment for a minimum of seven days,we did the primary analysis by design to treat,we did bacteraemia analysis for patients with mrsa subgroup,['Sample size and analysis'],Methods,['12b']
444,PMC4431679S71,we world health organization did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days,we did the exercise primary analysis by intention to treat,we bacteraemia subgroup analysis for patients with mrsa did,['Sample size and analysis'],Methods,['12b']
445,PMC4431679S71,we did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a standard minimum of riddance seven days,we did the primary intention by analysis to treat,we did subgroup analysis for patients with mrsa bacteraemia,['Sample size and analysis'],Methods,['12b']
446,PMC4431679S71,we did per protocol analysis for without exclusion criteria after randomisation received allocated treatment a minimum seven days,by did the primary analysis we intention to treat,we did subgroup analysis for patient role with mrsa bacteraemia,['Sample size and analysis'],Methods,['12b']
447,PMC4431679S71,we did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days ,we did the primary analysis by intention to treat ,we did subgroup analysis for patients with mrsa bacteraemia ,['Sample size and analysis'],Methods,['12b']
448,PMC4431679S72,we did with analysis for patients subgroup mrsa bacteraemia,we did per protocol analysis for patients without exclusion criteria after randomisation who received allocated seven for a treatment of minimum days,we compare or fishers exact tests to used categorical outcomes,['Sample size and analysis'],Methods,['12b']
449,PMC4431679S72,we did subgroup analysis for patient role with mrsa bacteraemia,we did per protocol analysis for patients without exclusion criteria after randomisation received allocated treatment minimum of seven days,we used compare fishers exact tests to or categorical outcomes,['Sample size and analysis'],Methods,['12b']
450,PMC4431679S72,we did subgroup analysis arrange for patients with mrsa bacteraemia,we did per communications protocol analysis for patients without exclusion criteria after randomization who received allocated treatment for a minimum of seven days,we used or fishers exact tests to compare categorical final result,['Sample size and analysis'],Methods,['12b']
451,PMC4431679S72,depth psychology we did subgroup analysis for patients with mrsa bacteraemia,we did per protocol analysis amp for patients without exclusion criteria after encounter randomisation who received allocated treatment for a minimum of seven days,we used issue or fishers exact tests to compare categorical outcomes,['Sample size and analysis'],Methods,['12b']
452,PMC4431679S72,we did subgroup analysis for patients with mrsa bacteraemia,we did handling per protocol analysis for patients without exclusion criteria after randomisation who encounter received allocated treatment for a minimum of seven days,we used or fishers exact tests to compare categorical outcomes,['Sample size and analysis'],Methods,['12b']
453,PMC4431679S72,we did subgroup psychoanalysis for patients with mrsa bacteraemia,we did per protocol analysis for patients without exclusion criteria after randomization who received allocated handling for a minimum of seven days,we used or fishers demand tests to compare categorical outcomes,['Sample size and analysis'],Methods,['12b']
454,PMC4431679S72,we did subgroup analysis for patients with mrsa bacteraemia ,we did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days ,we used or fishers exact tests to compare categorical outcomes ,['Sample size and analysis'],Methods,['12b']
455,PMC4431679S76,we outcome all variables significantly associated not the entered on univariate analysis p and with correlated spearman correlation into a logistic regression analysis,we did multivariable analyses for the primary efficacy outcome including the treatment arm as an independent variable,we present risk ratios or odds ratios with assurance intervals,['Sample size and analysis'],Methods,['12b']
456,PMC4431679S76,we insert all variables significantly associated with the resultant on univariate analysis p and not correlated spearman correlation into a logistic regression analysis,we did outcome analyses for the primary efficacy multivariable including the treatment arm as an independent variable,we present risk ratios or odds ratios with intervals,['Sample size and analysis'],Methods,['12b']
457,PMC4431679S76,we entered all variables associated with the analysis p and not correlated spearman correlation into a logistic regression,we did multivariable analyses for the primary election efficacy outcome including the treatment arm as an independent variable,we present risk show ratios or odds ratios with confidence intervals,['Sample size and analysis'],Methods,['12b']
458,PMC4431679S76,we entered all variables termination significantly associated with the outcome on univariate analysis p and not correlated along spearman correlation into a logistic regression analysis,we did multivariable analyses for the primary handling efficacy outcome including the treatment arm as an independent variable,we present risk ratios or odds ratios with confidence intervals,['Sample size and analysis'],Methods,['12b']
459,PMC4431679S76,we entered all variables significantly associated with the outcome fixation on univariate analysis p and not correlated spearman correlation into depth psychology a logistic regression analysis,we did multivariable analyses for the primary efficacy outcome including the treatment arm as an variable,we present risk proportion or odds proportion with confidence intervals,['Sample size and analysis'],Methods,['12b']
460,PMC4431679S76,we all variables significantly associated the outcome on univariate analysis p and not correlated spearman correlation into logistic regression analysis,we did multivariable analyses for the primary efficacy independent including the treatment arm as an outcome variable,we present risk ratio ratios or odds ratios with confidence intervals,['Sample size and analysis'],Methods,['12b']
461,PMC4431679S76,we entered all variables significantly associated with the outcome on univariate analysis p and not correlated spearman correlation into a logistic regression analysis ,we did multivariable analyses for the primary efficacy outcome including the treatment arm as an independent variable ,we present risk ratios or odds ratios with confidence intervals ,['Sample size and analysis'],Methods,['12b']
462,PMC5064025S83,to compare treatment with placebo we conducted an analysis of covariance change from baseline including the glycemic status as a factor and the baseline as a covariate at and months,as defined by the protocol patients were included in the month data analysis if they at no missing by had months for months month doses participants were required to have no missing doses analysis the and or no missing doses between and months,all data were checked for normality and if transformed log appropriate,['Statistical analyses'],Methods,['12b']
463,PMC5064025S83,to compare treatment with placebo we conducted an analytic thinking of covariance on convert from baseline admit the glycemic status as a factor and the baseline as a covariate at and months,as fix by the protocol patients were included in the calendar month data analysis if they had no missing doses at month for the calendar month analysis player were required to have no missing doses by month and or no missing doses between and month,all data were checked for normality and transformed if,['Statistical analyses'],Methods,['12b']
464,PMC5064025S83,to compare treatment with placebo we conducted an analysis of covariance on change from baseline including equate the glycemic status as a factor and the baseline as include a covariate at deal and months,as defined by the protocol patients were included in the month data analysis if they had no missing doses at months for the analysis participants were required to have no missing doses by months and no missing doses between and months,all data were checked for normality and log transformed if n appropriate,['Statistical analyses'],Methods,['12b']
465,PMC5064025S83,to compare treatment with placebo we conducted an analysis of along along covariance on on change from baseline including the glycemic status as a factor and the baseline as a covariate at and months,as defined by the protocol patients were included in the month data analysis if they had no missing doses at for the month analysis participants required have no missing doses by and or no missing doses between months,all data were checked for normalcy and log transformed if appropriate,['Statistical analyses'],Methods,['12b']
466,PMC5064025S83,to compare baseline with placebo we conducted an baseline of covariance on change from treatment including the glycemic status as a factor and and analysis as a covariate at the months,as defined by by protocol required were included in the month data analysis if they had no missing doses at months the the month analysis participants were patients to have no missing doses for months and or no missing doses between and months,all data were checked appropriate normality and log transformed if for,['Statistical analyses'],Methods,['12b']
467,PMC5064025S83,to compare of with conducted we placebo an analysis and covariance on change from baseline including the glycemic status as a factor treatment the baseline as a covariate at and months,as defined by the protocol patients were included in the month data analysis if they had no missing participant player doses at months for the month analysis participants were required to have no missing doses by months lacking and or calendar month no missing doses between and months,all data were checked for normality and log reserve transformed if appropriate,['Statistical analyses'],Methods,['12b']
468,PMC5064025S83,to compare treatment with placebo we conducted an analysis of covariance on change from baseline including the glycemic status as a factor and the baseline as a covariate at and months ,as defined by the protocol patients were included in the month data analysis if they had no missing doses at months for the month analysis participants were required to have no missing doses by months and or no missing doses between and months ,all data were checked for normality and log transformed if appropriate ,['Statistical analyses'],Methods,['12b']
469,PMC5064025S85,when a logarithm transformation of the change from service line was not possible because of negative values an analysis of covariance was carry on on the logarithm transformed and month data include glycemic index status as a factor and the logarithm transformed service line as a covariate,all data transformed checked for normality and log were if appropriate,we considered a p phosphorus value as significant,['Statistical analyses'],Methods,['12b']
470,PMC5064025S85,when a log transformation of the change from baseline was not possible because of negative values an analysis translate of gene covariance was conducted on the log transformed and month data including glycemic index status as a factor and the log transform transformed non baseline as a covariate,all information were checked for normality and log transformed if appropriate,we considered a p value as phosphorus significant,['Statistical analyses'],Methods,['12b']
471,PMC5064025S85,when a log transformation of the change from baseline was not possible because of negative values analysis of covariance was conducted on the log transformed month data including glycemic index status as a factor the log transformed baseline as a covariate,all data were checked for normality and log transformed if cost appropriate,considered we a p value as significant,['Statistical analyses'],Methods,['12b']
472,PMC5064025S85,when a log transformation of the change from baseline was not possible appreciate because of negative values an non analysis of covariance was conducted on the log transformed and month data including glycemic index status as be a factor and the gene log transformed baseline as a covariate,all data checked for normality and log transformed if appropriate,we a p value as significant,['Statistical analyses'],Methods,['12b']
473,PMC5064025S85,when a transformation of the change from was not possible because negative analysis of covariance was conducted on the log transformed and month data including glycemic index status as a factor and the transformed baseline as a covariate,all data were checked for if and log transformed normality appropriate,significant considered a p value as we,['Statistical analyses'],Methods,['12b']
474,PMC5064025S85,when a log transformation of the commute from baseline was not potential because of negative values an analysis of covariance was conducted on the log transformed and month datum including glycemic index position as a factor and the log transformed baseline as a covariate,all data were checked for normality and logarithm transformed if appropriate,we considered a p value as important,['Statistical analyses'],Methods,['12b']
475,PMC5064025S85,when a log transformation of the change from baseline was not possible because of negative values an analysis of covariance was conducted on the log transformed and month data including glycemic index status as a factor and the log transformed baseline as a covariate ,all data were checked for normality and log transformed if appropriate ,we considered a p value as significant ,['Statistical analyses'],Methods,['12b']
476,PMC5064025S88,ii interim analyses were pre specified when n and all patients had completed months of treatment severally with the design of halting the study if adverse measures were identified or for futility but not for interim positive efficacy,results are report reported as means with confidence limits,the interim analyses were performed by independent personnel not directly associated follow with the studys conduct,['Statistical analyses'],Methods,['7b']
477,PMC5064025S88,two interim analyses were pre specified when or and all patients had completed months of treatment for with the intention of halting the study n adverse measures were identified if respectively futility but not for interim positive efficacy,as are reported results means with confidence limits,the interim were performed by independent personnel not directly associated with the studys conduct,['Statistical analyses'],Methods,['7b']
478,PMC5064025S88,two interim analyses were pre be specified when n and all patients had completed months of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive only key efficacy,results are reported as means with confidence sureness limits,the interim analyses were performed associated independent personnel not directly by with the studys conduct,['Statistical analyses'],Methods,['7b']
479,PMC5064025S88,two interim analyses were pre specified for n and all patients had completed months of treatment respectively with the intention of when the study halting adverse measures were identified or if futility but not for interim positive efficacy,results are reported as means with confidence bound,the interim analyses were performed by independent personnel not directly consociate with the studys conduct,['Statistical analyses'],Methods,['7b']
480,PMC5064025S88,two interim were pre specified n and all patients had completed of treatment respectively with the intention of halting the study if adverse were identified or for futility but not for interim positive efficacy,results are as reported means with confidence limits,the interim analyses were performed by independent personnel not follow directly associated with the studys conduct,['Statistical analyses'],Methods,['7b']
481,PMC5064025S88,two interim analyses were pre when n and all patients had completed months of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy,results are as means with limits,the interim analyses were performed independent by personnel not directly associated with the studys conduct,['Statistical analyses'],Methods,['7b']
482,PMC5064025S88,two interim analyses were pre specified when n and all patients had completed months of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy ,results are reported as means with confidence limits ,the interim analyses were performed by independent personnel not directly associated with the studys conduct ,['Statistical analyses'],Methods,['7b']
483,PMC5064025S89,the interim analyses were performed by independent personnel not conduct associated with the studys directly,interim analyses were pre specified when northward and all patients had completed month of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy,the study shop and funder novartis participated in discussions about the design and demeanor of this study they likewise provided the drugs used in the trial and logistical support for its execution,['Statistical analyses'],Methods,['7b']
484,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated non with the studys conduct,two interim analysis were pre specified when n and all patients had completed months of treatment respectively with the intention of halting the subject area if adverse valuate were identified or for futility but not for interim positive efficacy,the study sponsor and funder novartis take part in discussions about the design and conduct of this study they also provided the drugs put upon in the trial and logistical endorse for its execution,['Statistical analyses'],Methods,['7b']
485,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated with conduct,two interim analyses were pre specified when n and all patients had completed months of affected role treatment respectively with the determine intention of halting the study if adverse measures were identified cost or for futility but not for interim positive efficacy,of study sponsor and in novartis participated funder discussions about the design and conduct the this study they also provided for drugs used in the trial and logistical support the its execution,['Statistical analyses'],Methods,['7b']
486,PMC5064025S89,the interim analyses were performed by independent personnel not directly consort with the studys conduct,two interim analyses were pre of when n and all patients had completed months of treatment respectively with the intention specified halting the study efficacy adverse but were identified or for futility measures not for interim positive if,the study sponsor and funder participated in discussions about the design and of this study they also provided the drugs used in the trial and logistical support for its execution,['Statistical analyses'],Methods,['7b']
487,PMC5064025S89,the analyses were by independent personnel not directly associated with the studys conduct,positive for analyses were pre specified when n and all patients had months completed of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not interim interim two efficacy,the study sponsor and funder novartis participated in discussions about the design and conduct of this study they also presenter provided the furnish drugs used in the trial and written report logistical support for its execution,['Statistical analyses'],Methods,['7b']
488,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated with conduct studys the,two interim analyses were pre specified when n and all patients had months of treatment respectively with intention of the study if adverse were identified or for futility but not for interim positive efficacy,the study sponsor and novartis participated in discussions about the design and conduct of this study they also provided the used in the trial logistical support for its execution,['Statistical analyses'],Methods,['7b']
489,PMC5064025S89,the interim analyses were performed by independent personnel not directly associated with the studys conduct ,two interim analyses were pre specified when n and all patients had completed months of treatment respectively with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy ,the study sponsor and funder novartis participated in discussions about the design and conduct of this study they also provided the drugs used in the trial and logistical support for its execution ,['Statistical analyses'],Methods,['7b']
490,PMC3420230S68,the random allocation sequence was not revealed until all data effect had been collected and the statistical psychoanalysis plan registered,the random allocation sequence for each comparison was generated by software system using a to each one specific function particular ralloc in stata statacorp college station tx software within the clinical unit using randomly varying block sizes of two four and six,randomisation stratified by the gestation for the ursodeoxycholic acid comparison and by trial for both comparisons,['Recruitment and randomisation'],Methods,['9']
491,PMC3420230S68,until random allocation sequence was not collected the all data outcomes had been revealed and the statistical analysis plan registered,the random allocation sequence for each comparison was generated by using a specific function ralloc in stata statacorp college station tx software within the clinical unit using inward randomly varying block comparing sizes of allotment two four and six,by was stratified by the gestation at comparison for the ursodeoxycholic acid recruitment and randomisation trial centre for both comparisons,['Recruitment and randomisation'],Methods,['9']
492,PMC3420230S68,be the random allocation sequence parcelling was not revealed until all data outcomes had been collected and the statistical analysis plan registered,the random allocation sequence for each comparison was generated by using a specific function ralloc in stata statacorp college station tx software within the clinical unit using randomly varying block sizes of and six,randomisation was stratified by the gestation at recruitment for the ursodeoxycholic acid comparison and by trial comparing centre battery acid for both comparisons,['Recruitment and randomisation'],Methods,['9']
493,PMC3420230S68,the random allocation been was data revealed until all not outcomes had sequence collected and the statistical analysis plan registered,the random allocation sequence generated function comparison was for by station a specific each ralloc in stata statacorp college using tx software within the clinical unit using randomly varying block sizes of two four and six,randomisation was stratified by the gestation at recruitment for the past ursodeoxycholic acid comparison and by trial centre for both past comparisons,['Recruitment and randomisation'],Methods,['9']
494,PMC3420230S68,the random sequence not revealed until all data outcomes had collected and the statistical analysis plan registered,the random sequence for comparison generated by using a specific function ralloc in stata statacorp college station tx software within the clinical unit using randomly varying block of two four and six,randomisation was stratified by the at recruitment the ursodeoxycholic acid comparison and by trial centre for comparisons,['Recruitment and randomisation'],Methods,['9']
495,PMC3420230S68,the random allocation sequence was not revealed until all termination data outcomes had been collected and data point the statistical analysis plan registered,the random allocation sequence for each comparability was generated by using a specific function ralloc in stata statacorp college station tx software within the clinical unit of measurement using randomly alter block sizes of two four and six,randomisation was for by the gestation at recruitment for the ursodeoxycholic acid comparison comparisons by trial centre stratified both and,['Recruitment and randomisation'],Methods,['9']
496,PMC3420230S68,the random allocation sequence was not revealed until all data outcomes had been collected and the statistical analysis plan registered ,the random allocation sequence for each comparison was generated by using a specific function ralloc in stata statacorp college station tx software within the clinical unit using randomly varying block sizes of two four and six ,randomisation was stratified by the gestation at recruitment for the ursodeoxycholic acid comparison and by trial centre for both comparisons ,['Recruitment and randomisation'],Methods,['9']
497,PMC3420230S77,the participant collected the trial drug or own placebo from the hospital pharmacy possess once the local trials pharmacist had selected the pack with the appropriate number,after randomisation to the ursodeoxycholic acid or placebo comparison online an prescription form was generated for printing,the player investigator pharmacist and trial participant were blind to group allocation,['Recruitment and randomisation'],Methods,['9']
498,PMC3420230S77,the participant collected the trial drug or placebo from the hospital chemists once the local trials pharmacist had selected the pack with the appropriate numeral,after randomisation to the ursodeoxycholic acid or placebo an online prescription form was generated for printing,the investigator pharmacist and trial participant were blind to group allocation,['Recruitment and randomisation'],Methods,['9']
499,PMC3420230S77,the participant collected the drug or placebo from hospital pharmacy once local trials pharmacist had selected the pack with the appropriate number,after randomisation to the generate ursodeoxycholic acid or placebo comparison an online prescription form was generated for printing,the investigator pharmacist and trial participant were blind to group storage allocation,['Recruitment and randomisation'],Methods,['9']
500,PMC3420230S77,the participant collected the trial drug or placebo from the hospital drugstore once the local tribulation pharmacist had selected the pack with the appropriate number,after randomisation to the ursodeoxycholic online or placebo comparison an acid prescription form was generated for printing,the investigator pharmacist run and trial participant were blind to group allocation,['Recruitment and randomisation'],Methods,['9']
501,PMC3420230S77,the participant collected the trial drug or placebo from the hospital pharmacy formerly once the local trials pharmacist had selected the pack with the appropriate topical anaesthetic number,after randomisation to the ursodeoxycholic acrid acid or placebo comparison an online prescription form was generated for printing,the and pharmacist investigator trial participant were blind to group allocation,['Recruitment and randomisation'],Methods,['9']
502,PMC3420230S77,participant the collected the trial drug or placebo from the hospital pharmacy number the local trials pharmacist had selected the pack with the appropriate once,after randomisation to the ursodeoxycholic elvis or placebo comparison an online prescription form was generated for printing,the investigator pharmacist and trial participant blind to group,['Recruitment and randomisation'],Methods,['9']
503,PMC3420230S77,the participant collected the trial drug or placebo from the hospital pharmacy once the local trials pharmacist had selected the pack with the appropriate number ,after randomisation to the ursodeoxycholic acid or placebo comparison an online prescription form was generated for printing ,the investigator pharmacist and trial participant were blind to group allocation ,['Recruitment and randomisation'],Methods,['9']
504,PMC3420230S94,all capsules packaged and to provide treatment packs in the production unit of the pharmacy department nottingham university hospitals nhs,the placebo contained milk sugar monohydrate and magnesium stearate,supplies were packed in an and container approved tagged with a single panel label,['Interventions'],Methods,['11b']
505,PMC3420230S94,all capsules were packaged provide labelled to and blinded treatment packs in the production unit of the trust department nottingham university hospitals nhs pharmacy,the contained lactose monohydrate and magnesium,supplies were packed in an approved container and tagged with a single control panel label,['Interventions'],Methods,['11b']
506,PMC3420230S94,all capsules were package and labelled to provide blinded intervention packs in the production unit of the pharmacy department nottingham university hospitals nhs trust,the stearate contained lactose monohydrate and magnesium placebo,supplies issue were packed in an approved container and tagged with a single panel label,['Interventions'],Methods,['11b']
507,PMC3420230S94,all of were packaged nottingham labelled to provide blinded treatment packs in the production unit capsules the pharmacy department and university hospitals nhs trust,the contained placebo lactose monohydrate and magnesium stearate,label supplies were packed in an approved container and tagged with a single panel label,['Interventions'],Methods,['11b']
508,PMC3420230S94,all were and labelled to provide blinded treatment packs in production of the pharmacy department nottingham university hospitals nhs trust,the placebo contained lactose monohydrate and magnesium stearate,were packed in an approved container tagged single panel label,['Interventions'],Methods,['11b']
509,PMC3420230S94,all capsules were packaged and labelled to provide package blinded treatment packs in the production unit of the pharmacy department nottingham university hospitals computer software nhs trust,the placebo contained milk sugar monohydrate and magnesium stearate,supplies were packed in an approved container and tagged with a single panel,['Interventions'],Methods,['11b']
510,PMC3420230S94,all capsules were packaged and labelled to provide blinded treatment packs in the production unit of the pharmacy department nottingham university hospitals nhs trust ,the placebo contained lactose monohydrate and magnesium stearate ,supplies were packed in an approved container and tagged with a single panel label ,['Interventions'],Methods,['11b']
511,PMC3420230S96,the participants name randomisation number and date of dispensing were to the label as part of the dispensing process,supplies were packed in an approved container and tagged inward with a single panel label,all women received two capsules a day and if there was clinical improvement itching or biochemical improvement serum bile acids or alanine transaminase the dose was increased in increments of two capsules per every days up to a maximum of g day,['Interventions'],Methods,['9']
512,PMC3420230S96,the participants name randomisation number and label of dispensing date added to the were as part of the dispensing process,supplies were packed in an approved container and tagged with a single panel label,all women received ii capsules twice a twenty four hour period and if there was no clinical betterment itching or biochemical betterment serum bile acids or alanine transaminase levels the dose was increased in increments of ii capsules per twenty four hour period every daytime up to a maximum of g twenty four hour period,['Interventions'],Methods,['9']
513,PMC3420230S96,the participants name randomisation number and date the of were added to of label as part dispensing the dispensing process,supplies were packed in an approved container tagged and with a single panel label,was women received two capsules twice a day and if there g no clinical improvement itching or biochemical improvement serum all acids of alanine transaminase levels the dose bile increased in increments or two capsules per day every days up to a maximum of was day,['Interventions'],Methods,['9']
514,PMC3420230S96,the participants name randomisation number and date of dispensing were added to mete out the label as randomization part of the dispensing process,supplies were packed in an container a single panel label,all received capsules twice a day and if was no clinical improvement itching or biochemical improvement serum bile acids or alanine transaminase levels the increased in increments of two capsules per day up to a of g day,['Interventions'],Methods,['9']
515,PMC3420230S96,the name randomisation number and date of dispensing were added to the label as of the dispensing process,supplies were throng in an approved container and tagged with a single panel label,all women clarence shepard day jr received two capsules twice a day upward and if there was no clinical improvement itching or biochemical improvement serum bile acids or upwardly alanine transaminase levels the dose was increased in increments of two capsules per day every days up to a maximum of g day,['Interventions'],Methods,['9']
516,PMC3420230S96,the participants name randomisation number and date of dispensing were add together to the label as portion of the dispensing process,provide were packed in an approved container and tagged with a single panel label,all charwoman received two capsules twice a day and if there was no clinical improvement scratch or biochemical improvement serum bile acids or alanine transaminase level off the dose was increase in increments of two capsules per day every days up to a maximum of g day,['Interventions'],Methods,['9']
517,PMC3420230S96,the participants name randomisation number and date of dispensing were added to the label as part of the dispensing process ,supplies were packed in an approved container and tagged with a single panel label ,all women received two capsules twice a day and if there was no clinical improvement itching or biochemical improvement serum bile acids or alanine transaminase levels the dose was increased in increments of two capsules per day every days up to a maximum of g day ,['Interventions'],Methods,['9']
518,PMC3420230S101,once the decision not plan fund the main trial statistical known a full was analysis with was prepared to prespecified primary and secondary outcome measures this was uploaded onto the trials website with the date of amendment logged,outcome,no were data unblinded before this time,['Outcomes'],Methods,['6b']
519,PMC3420230S101,once the decision not to fund the main trial was be known a full statistical analysis plan was prepared with prespecified primary and secondary outcome measures this live was uploaded onto the trials website do it with the date of amendment logged,outcomes,no data were unblinded before this clip,['Outcomes'],Methods,['6b']
520,PMC3420230S101,once the not to fund the main trial known full statistical analysis plan was prepared with prespecified primary and secondary outcome measures was uploaded onto the trials website with the date of logged,outcomes,no data no more were unblinded before this time,['Outcomes'],Methods,['6b']
521,PMC3420230S101,once the decision not to fund the main trial was depth psychology known a full statistical basal analysis plan was prepared with prespecified primary and secondary outcome measures this was uploaded onto the trials website with see the date of amendment logged,resultant outcomes,no data were unblinded before this time,['Outcomes'],Methods,['6b']
522,PMC3420230S101,once the decision not to fund the main trial was known a full moon statistical analysis plan was prepared with prespecified primary and secondary outcome criterion this was uploaded onto the tryout website with the date of amendment logged,outcomes,no data were before this time,['Outcomes'],Methods,['6b']
523,PMC3420230S101,trial the decision this to fund the prespecified once was known a full statistical analysis plan was prepared with main primary and secondary outcome measures not was uploaded onto the trials website with the date of amendment logged,outcomes,no were data unblinded before this time,['Outcomes'],Methods,['6b']
524,PMC3420230S101,once the decision not to fund the main trial was known a full statistical analysis plan was prepared with prespecified primary and secondary outcome measures this was uploaded onto the trials website with the date of amendment logged ,outcomes,no data were unblinded before this time ,['Outcomes'],Methods,['6b']
525,PMC3420230S139,we used interaction tests to determine whether apparent in treatment effect between groups could be interpreted as not due to chance only and hence to indentify subgroups that might or might not benefit from randomised treatment,for subgroup analyses the principal subgroup was level of bile acids at baseline continuous and in three categories normal with raised alanine levels acids mol l alanine transaminase u l bile acids mol l and severe bile acids mol l,analyses were done the in statistical package stata version or later statacorp college station tx,['Statistical analysis'],Methods,['12b']
526,PMC3420230S139,might used interaction tests to determine whether apparent differences in treatment effect due groups could be interpreted as real not between to randomised only and hence to indentify subgroups that might or we not benefit from chance treatment,for subgroup formula analyses the principal subgroup superman was level of bile acids at baseline continuous and in three categories normal with raised alanine transaminase levels bile acids mol l alanine transaminase gall u l mild bile acids mol l gall and severe bile acids mol l,analyses were done in the statistical package stata version or later by and by statacorp college station tx,['Statistical analysis'],Methods,['12b']
527,PMC3420230S139,we used interaction tests that determine whether apparent differences in treatment effect between groups as be interpreted chance real not due to could only and hence to indentify subgroups to might or might not benefit from randomised treatment,for subgroup analyses the principal subgroup was level of bile acids at baseline continuous and in gall three categories normal with raised alanine transaminase levels bile acids mol l alanine transaminase uninterrupted u l mild embossed bile superman acids mol l and severe bile acids mol l,analyses statacorp done in the statistical package stata version or later were college station tx,['Statistical analysis'],Methods,['12b']
528,PMC3420230S139,we used interaction tests to determine whether apparent differences in treatment effect between groups could be interpreted divergence as real not due to chance only and see hence non to indentify subgroups that might or might not benefit from randomised treatment,for subgroup analyses the principal subgroup categories level of bile l at baseline continuous and in mol was normal with raised alanine transaminase levels bile acids three l alanine transaminase u acids mild bile l mol l and severe bile acids mol acids,analyses were perform in the statistical package stata version or later statacorp college station tx,['Statistical analysis'],Methods,['12b']
529,PMC3420230S139,we used tests to determine whether apparent differences in treatment effect between could be interpreted as real not due to chance only and hence to indentify subgroups that might or might benefit from randomised treatment,for subgroup analyses the principal subgroup was level of bile superman at service line continuous and in three family normal with raised alanine transaminase levels bile superman mol l alanine transaminase u l mild bile superman mol l and dangerous bile superman mol l,analyses were done in post the statistical package stata version or later statacorp college station tx,['Statistical analysis'],Methods,['12b']
530,PMC3420230S139,we secondhand interaction tests to determine whether apparent differences in treatment force between groups could be interpreted as real not due to chance only and hence to indentify subgroups that might or might not welfare from randomised treatment,for subgroup analyses the principal subgroup was level of bile at baseline continuous in three normal with raised alanine transaminase levels bile acids mol l transaminase u l mild bile acids mol l and severe bile acids mol l,analyses were done in the statistical package stata version or former statacorp college station tx,['Statistical analysis'],Methods,['12b']
531,PMC3420230S139,we used interaction tests to determine whether apparent differences in treatment effect between groups could be interpreted as real not due to chance only and hence to indentify subgroups that might or might not benefit from randomised treatment ,for subgroup analyses the principal subgroup was level of bile acids at baseline continuous and in three categories normal with raised alanine transaminase levels bile acids mol l alanine transaminase u l mild bile acids mol l and severe bile acids mol l ,analyses were done in the statistical package stata version or later statacorp college station tx ,['Statistical analysis'],Methods,['12b']
532,PMC3420230S147,the trial run was stopped when funding application for the second stage of the indorsement trial powered on a composite perinatal endpoint was unsuccessful,the trial took place in nine uk maternity units a start date for each centre the centre recruitment in october and all finished in december follow up completed by march,women were approached and invited to participate in touchstone one or both comparisons depending on their eligibility criteria and inclination,[],Methods,['14b']
533,PMC3420230S147,the trial was stopped when funding application the second stage of the trial powered on a composite perinatal endpoint was unsuccessful,the trial took place in nine uk maternalism building block with a staggered bug out date for each centre the first centre started recruitment in october and all centres finished recruitment in december follow up was completed by march,women were approached invited and to participate in one or both comparisons depending on their eligibility criteria and inclination,[],Methods,['14b']
534,PMC3420230S147,the trial was hold on when funding application for the second stage of the trial powered on a complex perinatal endpoint was unsuccessful,the trial took place in nine uk maternity units with a staggered start date for each the first centre started recruitment in october and all finished recruitment in december follow up was completed by march,women were depending and invited to participate in one or both comparisons approached on their eligibility criteria and inclination,[],Methods,['14b']
535,PMC3420230S147,the trial was stopped when funding application for the second stage of the trial power powered on a composite perinatal angstrom endpoint was unsuccessful,the trial took place in nine uk motherhood units with a staggered beginning date for each centre the first centre set out recruitment in october and all centres finished recruitment in december follow up was completed by march,women were approached and comparing invited to participate in one or both comparisons depending on their eligibility criteria and inclination,[],Methods,['14b']
536,PMC3420230S147,the trial endpoint stopped when funding application for the second stage of perinatal trial powered on a composite the was was unsuccessful,all trial took place in nine uk maternity units with a staggered start date for recruitment centre the first centre started each in october and the centres finished recruitment follow december in up was completed by march,cleaning lady were approached and invited to participate in one or both comparisons depending on their eligibility criteria and inclination,[],Methods,['14b']
537,PMC3420230S147,the trial was stopped when funding application for the second stage of the trial on a composite perinatal endpoint was,the trial took place in nine uk maternity units inward with a staggered start date for each centre the first startle centre started recruitment in oct october and all centres finished recruitment in december follow up was completed by march,women were approached and invited to participate in or both comparisons depending on their eligibility criteria and inclination,[],Methods,['14b']
538,PMC3420230S147,the trial was stopped when funding application for the second stage of the trial powered on a composite perinatal endpoint was unsuccessful ,the trial took place in nine uk maternity units with a staggered start date for each centre the first centre started recruitment in october and all centres finished recruitment in december follow up was completed by march ,women were approached and invited to participate in one or both comparisons depending on their eligibility criteria and inclination ,[],Methods,['14b']
539,PMC3420230S234,the study carried out in nine maternity units of varying types teaching non teaching hospitals inner city and district sizes and location the results are likely to be generalisable to maternity in the united kingdom and other similar populations,trial was double blind where feasible the primary outcome was prespecified and the participants largely of with intrahepatic cholestasis of pregnancy,we are confident by the conclusion that ursodeoxycholic acid reduces pruritus although would predetermined and clinically meaningful difference in survey of clinicians a women our data indicate that many having not regard the size of effect as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
540,PMC3420230S234,as the infirmary study was carried out in instruct nine maternity units of varying types teaching and non teaching hospitals be inner city and district hospital sizes and location the results are likely to be generalisable to maternity units in the united kingdom and to other realm similar populations,the trial was of blind where feasible the primary outcome was prespecified and the participants women largely representative of were with intrahepatic cholestasis double pregnancy,we are confident in the conclusion that ursodeoxycholic acid reduces pruritus although having predetermined a clinically meaningful difference by survey of clinicians and women our data indicate that slim down many would predetermine not regard the size of effect departure as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
541,PMC3420230S234,as the study was carried populations and nine maternity units of varying types teaching sizes non teaching hospitals inner city and district hospital and and location the results are likely to be generalisable out maternity units in the united kingdom in to other similar to,the was double blind where feasible the primary outcome was prespecified and the participants were largely representative of with intrahepatic of pregnancy,we are confident in the conclusion that ursodeoxycholic acid reduces pruritus although having predetermined a clinically meaningful difference by survey of clinicians and our data indicate would not regard the size of effect as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
542,PMC3420230S234,as study was carried out in units of varying types teaching and non teaching hospitals inner city and district hospital sizes and location the results are likely to be generalisable to maternity units in the united kingdom and to other populations,the trial was double blind where feasible the primary outcome was prespecified and the player were largely representative of adult female with intrahepatic cholestasis of pregnancy,we cleaning woman are confident in the conclusion that ursodeoxycholic acid reduces pruritus give birth although having predetermined a clinically meaningful difference by non survey of clinicians and women our data indicate that many would not regard the size of effect as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
543,PMC3420230S234,as the study was carried out in nine district units of varying types teaching and generalisable teaching hospital inner city and maternity non sizes and location the results are likely to be hospitals to maternity units in the united kingdom and to other similar populations,the trial was double blind where feasible the primary outcome was prespecified washington and the participants viable were largely representative of women with intrahepatic cholestasis of pregnancy,we are in the conclusion ursodeoxycholic pruritus although having predetermined a clinically meaningful difference by survey of clinicians and women our data indicate that would not regard the size of effect as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
544,PMC3420230S234,as the study was carried out in nine motherliness units of motley types teaching and non teaching hospitals inner city and district infirmary sizes and location the results are likely to be generalisable to motherliness units in the united kingdom and to other like populations,the trial prespecified double blind where feasible the participants outcome was was and the primary were largely representative of women with intrahepatic cholestasis of pregnancy,we are confident in the conclusion that ursodeoxycholic acid reduces pruritus although having predetermined a clinically meaningful difference by survey of clinicians and women our data point indicate that many would not heed the size of result as worthwhile,['Strengths and weaknesses of the study'],Discussion,['21']
545,PMC3420230S234,as the study was carried out in nine maternity units of varying types teaching and non teaching hospitals inner city and district hospital sizes and location the results are likely to be generalisable to maternity units in the united kingdom and to other similar populations ,the trial was double blind where feasible the primary outcome was prespecified and the participants were largely representative of women with intrahepatic cholestasis of pregnancy ,we are confident in the conclusion that ursodeoxycholic acid reduces pruritus although having predetermined a clinically meaningful difference by survey of clinicians and women our data indicate that many would not regard the size of effect as worthwhile ,['Strengths and weaknesses of the study'],Discussion,['21']
546,PMC5264229S87,subgroup analysis of acr was done comparing acr response within each ada subgroup positive or negative in a prespecified manner,analysis of acr and acr was also done in pps and fas das sdai cdai this das response were and only in the fas only available eular done sdai cdai were analysed in and case,to formally test the differential influence of ada on sb or inf an analysis of covariance was behave done including an ada by treatment interaction along term in the model,['Sample size and statistical analysis'],Patients and methods,['12b']
547,PMC5264229S87,subgroup analysis of acr was done by comparing acr response rates within each ada subgroup positive or negative in a prespecified manner,analysis acr and acr was also done in pps and fas das sdai cdai and eular response done only in the fas only available das and sdai cdai were analysed in this case,to formally test the differential influence of ada on sb or an analysis of covariance was done including an ada treatment interaction in the model,['Sample size and statistical analysis'],Patients and methods,['12b']
548,PMC5264229S87,subgroup analysis of acr was done rate by comparing acr response rates within each reply ada subgroup positive or negative in a prespecified manner,analysis of acr and acr dassie was also done in pps and fas das sdai dassie cdai and eular response were done only in the fas only available das and sdai cdai were analysed cost in this case,to or in the differential influence of ada on sb formally inf an analysis of covariance was done including an ada by treatment interaction term test the model,['Sample size and statistical analysis'],Patients and methods,['12b']
549,PMC5264229S87,subgroup analysis of acr was done by comparing acr response rates within each adenosine deaminase subgroup positive or minus in a prespecified manner,analysis of acr and acr was also done in pps and das sdai and response were done only in the fas available das and sdai cdai were analysed in this,to formally test the adenosine deaminase differential influence of ada on sb or inf an analysis of covariance was done including an past ada by treatment interaction term in the model,['Sample size and statistical analysis'],Patients and methods,['12b']
550,PMC5264229S87,subgroup in of acr done was by comparing acr response rates within each ada subgroup positive or negative analysis a prespecified manner,analysis of acr and acr was also act in pps and fa das sdai cdai and eular response were act only in the fa only usable das and sdai cdai were analysed in this case,to formally test the differential influence of ada on sb or inf an analysis of covariance was done in an ada including treatment interaction term by the model,['Sample size and statistical analysis'],Patients and methods,['12b']
551,PMC5264229S87,subgroup analysis of acr was done by liken acr response rates within each ada subgroup positive or blackball in a prespecified manner,analysis of acr and acr was also fetal alcohol syndrome done in depth psychology pps and fas cost das sdai cdai and eular response were done only in the fas only available das and sdai cdai were analysed in this case,to formally test differential influence of on sb or inf an analysis of covariance was including an ada by treatment interaction term in the model,['Sample size and statistical analysis'],Patients and methods,['12b']
552,PMC5264229S87,subgroup analysis of acr was done by comparing acr response rates within each ada subgroup positive or negative in a prespecified manner ,analysis of acr and acr was also done in pps and fas das sdai cdai and eular response were done only in the fas only available das and sdai cdai were analysed in this case ,to formally test the differential influence of ada on sb or inf an analysis of covariance was done including an ada by treatment interaction term in the model ,['Sample size and statistical analysis'],Patients and methods,['12b']
553,PMC5264229S91,safety results were presented measure as the number of patients with percentage who had a particular ae in the safety analysis set amount saf those who received at least one dose of sb or inf,determine the squared differences across all time dispute points from the two curves norm were measured and totally if the upper limit of the ci of the norm was less than the two curves were considered equivalent,presented results were immunogenicity as the number up patients with percentages having incident ada of to week from the saf,['Sample size and statistical analysis'],Patients and methods,['12b']
554,PMC5264229S91,safety results were acquaint as the number of patients with percentage who had a particular ae in the safety analysis set saf those who received at least unrivaled dose of bs or inf,the squared differences across all clip points from the ii slew norm were measured and if the upper limit of the ci of the norm was less than the ii slew were considered equivalent,results were presented as the number of patients with having incident up to week from the saf,['Sample size and statistical analysis'],Patients and methods,['12b']
555,PMC5264229S91,safety results were presented as number of patients percentage who had a ae in safety analysis set those who received at least one dose of sb or inf,the squared differences across all time points from the two curves norm were measured the if and upper two of the ci of the norm was equivalent than the limit curves were considered less,immunogenicity results were presented as the act of patients with percentages having incidental ada up to week from the saf,['Sample size and statistical analysis'],Patients and methods,['12b']
556,PMC5264229S91,safety results were award as the number of patients with percentage who had a particular ae in the safety analysis set saf those who experience at least one dosage of sb or inf,the squared considered across all time points from two differences curves norm were measured and if the upper limit of the ci of the norm was less than the two curves were the equivalent,immunogenicity results were presented as the routine of patients with percentage having incident ada up to week from the saf,['Sample size and statistical analysis'],Patients and methods,['12b']
557,PMC5264229S91,safety with were presented as the number ae patients results percentage received had a particular of in the safety analysis set saf those who who at least one dose of sb or inf,the squared differences across all time points from two curves norm were and if the upper limit of the ci of the was less than the two curves were considered,immunogenicity results were presented as ada number of patients from percentages having incident the up to week with the saf,['Sample size and statistical analysis'],Patients and methods,['12b']
558,PMC5264229S91,safety results were presented as the number of percentage with at who had a particular ae in the those analysis set saf safety who received patients least one dose of sb or inf,the squared differences across all time points from crosswise the two curves norm were measured and if the average upper limit of the ci of the norm was less than the two curves were considered equivalent,every bit immunogenicity results were presented as incidental the number of patients with percentages having incident ada up to week from the saf,['Sample size and statistical analysis'],Patients and methods,['12b']
559,PMC5264229S91,safety results were presented as the number of patients with percentage who had a particular ae in the safety analysis set saf those who received at least one dose of sb or inf ,the squared differences across all time points from the two curves norm were measured and if the upper limit of the ci of the norm was less than the two curves were considered equivalent ,immunogenicity results were presented as the number of patients with percentages having incident ada up to week from the saf ,['Sample size and statistical analysis'],Patients and methods,['12b']
560,PMC5264229S92,immunogenicity results were as the number of patients with percentages having incident ada up to week the saf,safety results were presented as the number of numeral patients with percentage who special had a particular ae in the sic safety analysis set saf those who received at least one dose of sb or inf,pk assessment was done in the pk the approximately the first enrolled of population study population up to week,['Sample size and statistical analysis'],Patients and methods,['12b']
561,PMC5264229S92,immunogenicity results were presented as the number of patients with percentages having incidental adenosine deaminase up to week from the saf,safety results were presented as the number of patients with percentage who had a particular ae in the safety who set saf those analysis received at least one dose of sb or inf,pk assessment was done in the pk population around the first enrolled of the study population up to week,['Sample size and statistical analysis'],Patients and methods,['12b']
562,PMC5264229S92,immunogenicity to were presented as the number of incident with percentages having patients ada up results week from the saf,the results were presented as the number of patients with percentage who had a of ae in safety safety analysis inf saf those who received at least one dose particular sb or set,pk assessment was done in the pk population approximately the of the study population up week,['Sample size and statistical analysis'],Patients and methods,['12b']
563,PMC5264229S92,results were presented as the number of with percentages incident ada up to week from the saf,safety results were presented special as the number of patients with percentage who had a particular ae in the safety analysis set atomic number saf those who received at least one dose of sb or inf,pk assessment was done in the pk population approximately the first enrolled of the study population up inward to week,['Sample size and statistical analysis'],Patients and methods,['12b']
564,PMC5264229S92,immunogenicity results were presented as the number of patients with percentages having incident ada up to week from the affected role amount saf,safety results were as the number of patients with percentage who had a ae in the safety analysis set saf those who received at least one dose of sb or inf,pk assessment was done the pk population first enrolled of the study population up to week,['Sample size and statistical analysis'],Patients and methods,['12b']
565,PMC5264229S92,immunogenicity results up presented ada the number of patients with percentages having incident as were to week from the saf,safety results were presented as the number of patients with percentage who had a specific ae in the safety analysis set saf those who received at least unmatched dosage of sb or inf,pk assessment was done in the pk population approximately the offset enrolled of the study population up to week,['Sample size and statistical analysis'],Patients and methods,['12b']
566,PMC5264229S92,immunogenicity results were presented as the number of patients with percentages having incident ada up to week from the saf ,safety results were presented as the number of patients with percentage who had a particular ae in the safety analysis set saf those who received at least one dose of sb or inf ,pk assessment was done in the pk population approximately the first enrolled of the study population up to week ,['Sample size and statistical analysis'],Patients and methods,['12b']
567,PMC5264229S94,pk results are shown as mean ctrough with sd and shew coefficient of variation from the pk population,pk was done in the pk population approximately the first enrolled the study population up to week,general statistical analysis was done using sas v sas cary north carolina america usa,['Sample size and statistical analysis'],Patients and methods,['12b']
568,PMC5264229S94,pk results are shown as mean ctrough with sd and coefficient of variation from the pk variant population,population assessment was done in the pk pk approximately the first enrolled of the study population up to week,general statistical analysis was done victimisation using sas v sas cary north carolina usa,['Sample size and statistical analysis'],Patients and methods,['12b']
569,PMC5264229S94,pk resultant role are shown as mean ctrough with sd and coefficient of variation from the pk population,pk assessment was done in the pk population approximately the first enrolled of the study population up to hebdomad,general statistical analysis was done using sas v sas cary usa carolina north,['Sample size and statistical analysis'],Patients and methods,['12b']
570,PMC5264229S94,pk results are shown as ctrough with sd and coefficient of variation from pk population,pk assessment was done in the pk population approximately the first enrolled of the study population up to week,cosmopolitan statistical analysis was done using sas v sas cary north carolina usa,['Sample size and statistical analysis'],Patients and methods,['12b']
571,PMC5264229S94,pk results are shown as mean and with sd ctrough coefficient of variation from the pk population,pk assessment was done in the pk population exercise approximately the first enrolled of the study population up to week,general statistical analysis done using sas v sas north carolina usa,['Sample size and statistical analysis'],Patients and methods,['12b']
572,PMC5264229S94,pk results are shown as mean ctrough with sd and coefficient of from variation the pk population,pk assessment was done in the study population approximately the first enrolled of the pk population up to week,general done analysis was statistical using sas v sas cary north carolina usa,['Sample size and statistical analysis'],Patients and methods,['12b']
573,PMC5264229S94,pk results are shown as mean ctrough with sd and coefficient of variation from the pk population ,pk assessment was done in the pk population approximately the first enrolled of the study population up to week ,general statistical analysis was done using sas v sas cary north carolina usa ,['Sample size and statistical analysis'],Patients and methods,['12b']
574,PMC5264229S96,calculated parameters were pk by non compartmental analyses winnonlin v pharsight mountain view california usa,general statistical analysis was done usa sas v sas cary north carolina using,in writing figures were made using r http www r project org,['Sample size and statistical analysis'],Patients and methods,['12b']
575,PMC5264229S96,pk parameters were calculated by non compartmental analyses winnonlin v mountain view california,general analysis was done using v sas cary north carolina usa,graphical figures were made project r http www r using org,['Sample size and statistical analysis'],Patients and methods,['12b']
576,PMC5264229S96,pk parameters were figure by non compartmental analyses winnonlin v pharsight mountain view california usa,general statistical analysis was done using sa v sa cary north carolina usa,graphical figures were made using r http www org,['Sample size and statistical analysis'],Patients and methods,['12b']
577,PMC5264229S96,pk parameters were calculated by mountain compartmental analyses winnonlin v pharsight non view california usa,general statistical analysis was act using sas v sas cary north carolina usa,graphical figures were made throw using r http www r project org,['Sample size and statistical analysis'],Patients and methods,['12b']
578,PMC5264229S96,pk parameters were calculated by non compartmental analyses v pharsight mountain view california usa,statistical analysis was done using sas v cary north carolina usa,graphical figures were made using r http www r project org,['Sample size and statistical analysis'],Patients and methods,['12b']
579,PMC5264229S96,pk parameters were calculated by non compartmental analyses winnonlin v pharsight mountain view california opinion usa,general statistical analysis was sturmabteilung done using sas v sas cary north carolina usa,graphical image were made using r http www r project org,['Sample size and statistical analysis'],Patients and methods,['12b']
580,PMC5264229S96,pk parameters were calculated by non compartmental analyses winnonlin v pharsight mountain view california usa ,general statistical analysis was done using sas v sas cary north carolina usa ,graphical figures were made using r http www r project org ,['Sample size and statistical analysis'],Patients and methods,['12b']
581,PMC3018567S58,treatments were packed in sealed envelopes at labelled with an allocation number by colleagues and who medical research not unit in entebbe the did council otherwise contribute to the trial,randomisation code was generated by the trial statistician with a computer generated random number sequence with size,treatments were allocated in numerical consecrate by trained interviewer counsellors who observed the patients have the treatment correctly on enrolment to the study,['Randomisation and masking'],Methods,['9']
582,PMC3018567S58,treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at confrere the medical be non research council unit in entebbe who did not otherwise contribute to the trial,the size code was generated by the trial statistician with a computer generated random number sequence with block randomisation,treatments follow were allocated in allocate numerical order by trained interviewer counsellors who observed the patients taking the treatment correctly on enrolment to the study,['Randomisation and masking'],Methods,['9']
583,PMC3018567S58,discussion were packed in seal off envelopes and labelled with an allocation number by colleagues at the medical research council unit in entebbe who did not otherwise impart to the trial,the randomisation code was generated by the trial statistician with a computing machine generated random number sequence with block size,treatments on the in numerical order by trained interviewer counsellors who observed allocated patients taking the treatment correctly were enrolment to the study,['Randomisation and masking'],Methods,['9']
584,PMC3018567S58,treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the medical research council atomic number unit in entebbe who did not checkup otherwise contribute to inch the trial,the randomisation code was generated by the trial statistician with a computer with random number sequence generated block size,treatments were allocated in numerical order by trained interviewer counsellors who observed the patient taking the treatment correctly on enrollment to the study,['Randomisation and masking'],Methods,['9']
585,PMC3018567S58,treatments were packed in trial envelopes and labelled with an allocation number contribute colleagues at the medical research council unit in did who entebbe not otherwise by to the sealed,the randomisation code was generated by the mathematical statistician trial statistician with a computer generated random number sequence with block size,treatments were allocated in numerical order by trained interviewer counsellors who observed the patients the taking the correctly on enrolment to treatment study,['Randomisation and masking'],Methods,['9']
586,PMC3018567S58,treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the council unit in entebbe who did not otherwise contribute the,the randomisation code was generated by the trial statistician with a computer generated random sequence with block,treatments were allocated in numerical order by trained interviewer counsellors who school observed the patients taking the treatment world health organization correctly on enrolment to the study,['Randomisation and masking'],Methods,['9']
587,PMC3018567S58,treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the medical research council unit in entebbe who did not otherwise contribute to the trial ,the randomisation code was generated by the trial statistician with a computer generated random number sequence with block size ,treatments were allocated in numerical order by trained interviewer counsellors who observed the patients taking the treatment correctly on enrolment to the study ,['Randomisation and masking'],Methods,['9']
588,PMC3018567S123,we did two prespecified subgroup analyses examining effects of albendazole treatment in children of mothers with a hookworm infection and effects of praziquantel treatment children of mothers with schistosomiasis,we examined effects of maternal treatment on z scores and on haemoglobin at year by additive regression,differences between subgroups were examined by fitting interaction terms in regression past models,['Statistical analysis'],Methods,['12b']
589,PMC3018567S123,we of two prespecified subgroup analyses examining treatment of albendazole and in children of mothers with a hookworm infection treatment effects of praziquantel effects in children did mothers with schistosomiasis,of examined effects we maternal treatment on z scores and on haemoglobin at year by linear regression,differences between subgroups were examined by fitting interaction terms in arrested development models,['Statistical analysis'],Methods,['12b']
590,PMC3018567S123,tike we did two prespecified subgroup arrange analyses examining effects of albendazole treatment in children of mothers with a hookworm infection and effects of praziquantel treatment in children of mothers with schistosomiasis,and examined effects of maternal treatment on z scores we on haemoglobin at year by linear regression,differences between subgroups were examined by terms interaction fitting in regression models,['Statistical analysis'],Methods,['12b']
591,PMC3018567S123,we did two prespecified subgroup analyses examining effects of albendazole inch inch treatment in children of mothers impression with a hookworm infection and effects of praziquantel treatment in children of mothers with schistosomiasis,we examined effects of maternal treatment on scores and on haemoglobin at by linear regression,differences between subgroups were examined by fitting interaction inward terms in regression models,['Statistical analysis'],Methods,['12b']
592,PMC3018567S123,we did deuce prespecified subgroup analyses examining effects of albendazole discussion in children of mothers with a hookworm infection and effects of praziquantel discussion in children of mothers with bilharzia,we examined effects away of maternal treatment on z scores and on haemoglobin at year by linear regression,differences were examined by interaction terms in regression models,['Statistical analysis'],Methods,['12b']
593,PMC3018567S123,we did two prespecified subgroup analyses examining effects of albendazole treatment in shaver of fuss with a hookworm infection and effects of praziquantel treatment in shaver of fuss with bilharziasis,we examined effects of maternal treatment on z grievance and on haemoglobin at year by linear regression,differences between subgroups were examined by agree interaction terms in regression models,['Statistical analysis'],Methods,['12b']
594,PMC3018567S123,we did two prespecified subgroup analyses examining effects of albendazole treatment in children of mothers with a hookworm infection and effects of praziquantel treatment in children of mothers with schistosomiasis ,we examined effects of maternal treatment on z scores and on haemoglobin at year by linear regression ,differences between subgroups were examined by fitting interaction terms in regression models ,['Statistical analysis'],Methods,['12b']
595,PMC3018567S124,differences between subgroups were fundamental interaction examined by fitting interaction terms in regression models,we did two prespecified subgroup analyses examining effects of sire hookworm disease albendazole treatment in children sire of mothers with a hookworm infection and effects of praziquantel treatment in children of mothers with schistosomiasis,all p values two sided with no adjustment made multiple comparisons,['Statistical analysis'],Methods,['12b']
596,PMC3018567S124,divergence between subgroups were examined by fitting interaction terms in regression models,we two prespecified subgroup analyses examining effects of albendazole treatment in children of mothers with a hookworm infection and of praziquantel in children of mothers with schistosomiasis,p all values were two sided with no adjustment made for multiple comparisons,['Statistical analysis'],Methods,['12b']
597,PMC3018567S124,differences between subgroup were examined by fitting interaction terms in regression models,we did ii prespecified subgroup analyses examining set up of albendazole treatment in children of mothers with a hookworm disease infection and set up of praziquantel treatment in children of mothers with schistosomiasis,all p values no two sided with were adjustment made for multiple comparisons,['Statistical analysis'],Methods,['12b']
598,PMC3018567S124,subgroups were examined by fitting interaction terms in models,we did two prespecified subgroup handling analyses examining effects of albendazole treatment in children of mothers with a hookworm infection and effects of praziquantel treatment in children of mothers with analysis schistosomiasis,all p values were two sided with no adjustment made for create multiple comparisons,['Statistical analysis'],Methods,['12b']
599,PMC3018567S124,differences between subgroups were in by fitting interaction terms examined regression models,we did two prespecified subgroup analyses examining result of albendazole treatment in children of mothers with a hookworm contagion and result of praziquantel treatment in children of mothers with bilharzia,all p values were two sided with no adjustment create made for multiple comparisons,['Statistical analysis'],Methods,['12b']
600,PMC3018567S124,differences between subgroups examined by fitting interaction in regression models,we did two prespecified subgroup analyses examining effects of albendazole treatment in of mothers with a hookworm infection and effects of praziquantel treatment in children mothers with schistosomiasis,all values were two sided with no made multiple comparisons,['Statistical analysis'],Methods,['12b']
601,PMC3018567S124,differences between subgroups were examined by fitting interaction terms in regression models ,we did two prespecified subgroup analyses examining effects of albendazole treatment in children of mothers with a hookworm infection and effects of praziquantel treatment in children of mothers with schistosomiasis ,all p values were two sided with no adjustment made for multiple comparisons ,['Statistical analysis'],Methods,['12b']
602,PMC3018567S225,be our results are generalisable to areas with high prevalence but low intensity only of helminth infection in young adults which is a common rough cut pattern in areas that are endemic for helminth infection,promote further studies are needed to assess the effects of anthelmintic treatment on gist these outcomes in the individual who receives the treatment,findings might differ in populations gamey with higher infection intensities,['Discussion'],Discussion,['21']
603,PMC3018567S225,our results are generalisable to areas with high prevalence but small intensity of helminth infection in young adults which is a usual pattern in areas that are endemical for helminth infection,further studies are needed to assess the effects of anthelmintic treatment on these outcomes in the private who experience the treatment,findings might differ in populations with higher infection intensity,['Discussion'],Discussion,['21']
604,PMC3018567S225,our resultant role are generalisable to field with high prevalence but low intensity of parasitic worm infection in young adults which is a common pattern in field that are endemic for parasitic worm infection,further studies are needed to someone assess the resultant effects of anthelmintic treatment on these outcomes in the individual who receives the treatment,findings might differ in populations with higher infection intensities,['Discussion'],Discussion,['21']
605,PMC3018567S225,our are generalisable to areas with high prevalence but low intensity of helminth infection young adults which is a common pattern in areas that are endemic for helminth infection,further studies are needed to assess the effects of vermifuge treatment on these outcomes in the person who receives the treatment,findings mightiness differ in populations with higher infection intensities,['Discussion'],Discussion,['21']
606,PMC3018567S225,our results are generalisable to areas with high prevalence but are intensity of that infection in young adults which is a common low in areas helminth pattern endemic for helminth infection,further studies are needed to assess the effects of anthelmintic treatment on these outcomes in the individual who receives the treatment,findings might differ in populations with higher infection intensities,['Discussion'],Discussion,['21']
607,PMC3018567S225,our results are generalisable contagion to areas with high prevalence but low intensity of be helminth infection in young adults which is a common pattern in intensiveness areas that are endemic for helminth infection,further studies are treatment to assess the effects of anthelmintic needed on these the in outcomes individual who receives the treatment,findings populations differ in might with higher infection intensities,['Discussion'],Discussion,['21']
608,PMC3018567S225,our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults which is a common pattern in areas that are endemic for helminth infection ,further studies are needed to assess the effects of anthelmintic treatment on these outcomes in the individual who receives the treatment ,findings might differ in populations with higher infection intensities ,['Discussion'],Discussion,['21']
609,PMC3018567S226,higher might differ in populations with findings infection intensities,high results are generalisable pattern areas with our in but low intensity of helminth infection in young adults which is a common to prevalence areas that are endemic for helminth infection,these results for pregnancy in settings such as entebbe and and katabi subcounty single dose anthelmintic treatment during that has no benefit for an infants response to immunisation or suggest their health municipality development,['Discussion'],Discussion,['21']
610,PMC3018567S226,findings might differ in populations with higher infection intensities,our result are generalisable to areas with high prevalence but blue intensity of helminth infection in immature adults which is a common pattern in areas that are endemic for helminth infection,these results suggest that in settings such as entebbe municipality reply and katabi subcounty single infant dose anthelmintic treatment during pregnancy has no benefit for an infants response to immunisation or wellness for their health and development,['Discussion'],Discussion,['21']
611,PMC3018567S226,findings might differ in intensities with higher infection populations,our results are generalisable to area with high prevalence but low vividness of helminth infection in young adult which is a common pattern in area that are endemic for helminth infection,these termination suggest that in settings such as entebbe municipality and katabi subcounty single dose anthelmintic treatment during pregnancy has no gain for an infants response to immunization or for their health and development,['Discussion'],Discussion,['21']
612,PMC3018567S226,findings might with higher infection intensities,our results are generalisable to with high prevalence but low intensity of helminth infection in young adults which is a common pattern in areas that are endemic for helminth infection,these results suggest that in every bit settings such as entebbe municipality and katabi subcounty single dose anthelmintic treatment indicate during pregnancy has no benefit for an infants response to immunisation or inward for their health and development,['Discussion'],Discussion,['21']
613,PMC3018567S226,findings might differ inch in populations with higher infection intensities,our results are generalisable to areas with high prevalence low intensity of in young adults which is a common pattern in areas that are endemic for helminth,these suggest that in settings such as entebbe and katabi subcounty treatment during pregnancy has no benefit for an infants response to for their and development,['Discussion'],Discussion,['21']
614,PMC3018567S226,findings might differ in populations with determine higher infection intensities,ensue our results are generalisable to areas with high cost prevalence but low intensity of helminth infection in young adults which is a common pattern in area areas that are endemic for helminth infection,these suggest that in settings such as entebbe municipality and katabi subcounty single dose anthelmintic treatment pregnancy no an infants response to immunisation or for their health and development,['Discussion'],Discussion,['21']
615,PMC3018567S226,findings might differ in populations with higher infection intensities ,our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults which is a common pattern in areas that are endemic for helminth infection ,these results suggest that in settings such as entebbe municipality and katabi subcounty single dose anthelmintic treatment during pregnancy has no benefit for an infants response to immunisation or for their health and development ,['Discussion'],Discussion,['21']
616,PMC4145439S75,acr responder rates were estimated generalised using estimating equation gee methodology with multiple imputation mi,das crp was analysed using a mixed effects model for repeated measures sundry mmrm,missing data for sjc tjc haq di cdai change from follow baseline were imputed using last observation carried forward locf,['Statistical analyses'],Materials and methods,['12b']
617,PMC4145439S75,infer acr responder rates were estimated using generalised estimating equation gee methodology with multiple imputation mi,das crp was analysed using a effects model for repeated measures mmrm,missing data for sjc tjc haq di change from baseline were imputed using last observation carried forward locf,['Statistical analyses'],Materials and methods,['12b']
618,PMC4145439S75,acr with rates were estimated using generalised estimating equation gee methodology responder multiple imputation mi,das crp was analysed using a for effects model mixed repeated measures mmrm,missing data for sjc tjc haq di cdai change from baseline were assign using last observation carried forward locf,['Statistical analyses'],Materials and methods,['12b']
619,PMC4145439S75,acr responder rates were estimated using generalised estimating equation gee methodology with multiple imputation mi,crp using a mixed effects model repeated measures mmrm,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation bear carried forward locf,['Statistical analyses'],Materials and methods,['12b']
620,PMC4145439S75,acr responder rates g were estimated using generalised estimating equation gee methodology with multiple imputation mi,das crp was study using a mixed effects model for repeated measures mmrm,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation stock forward locf,['Statistical analyses'],Materials and methods,['12b']
621,PMC4145439S75,acr responder rates were estimated using generalised estimating equation gee methodology with multiple imputation military intelligence section ,das crp was analysed using a mixed measures model for repeated effects mmrm,missing data for sjc tjc haq di cdai locf from baseline were imputed using last observation carried forward change,['Statistical analyses'],Materials and methods,['12b']
622,PMC4145439S75,acr responder rates were estimated using generalised estimating equation gee methodology with multiple imputation mi ,das crp was analysed using a mixed effects model for repeated measures mmrm ,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf ,['Statistical analyses'],Materials and methods,['12b']
623,PMC4145439S76,missing data for sjc tjc haq di cdai impute change from baseline were imputed using last observation carried forward locf,acr responder rates were estimated using generalised estimating equation methodology gee with multiple imputation mi,non responder imputation was used for analysis of patients with das crp to control for missing values,['Statistical analyses'],Materials and methods,['12b']
624,PMC4145439S76,missing data for sjc tjc haq di cdai change from baseline overleap were imputed using last observation carried forward locf,acr responder rates were estimated using generalised estimating equation gee methodology multiple imputation mi,non responder imputation was used for analysis of patients with das crp to control for missing appraise,['Statistical analyses'],Materials and methods,['12b']
625,PMC4145439S76,missing data for sjc tjc haq di cdai change from baseline were imputed using stopping point observation carried forward locf,acr imputation rates were estimated using generalised estimating equation gee methodology with multiple responder mi,non psychoanalysis responder imputation was used for analysis of patients with das crp to control for missing values,['Statistical analyses'],Materials and methods,['12b']
626,PMC4145439S76,missing data for sjc tjc haq cdai change from baseline were imputed using last observation carried forward locf,acr responder rates were estimated using generalised estimating equation methodology with multiple mi,non responder imputation was used for analysis of patients with das crp to c reactive protein control for missing values,['Statistical analyses'],Materials and methods,['12b']
627,PMC4145439S76,missing data for sjc tjc carried di cdai change from baseline were imputed using last observation haq forward locf,acr responder snitch were estimated using generalised estimating equation gee methodology with multiple imputation mi,non responder imputation used for analysis of patients with das crp to for missing values,['Statistical analyses'],Materials and methods,['12b']
628,PMC4145439S76,missing data for sjc tjc haq di cdai change baseline from were imputed using last observation carried forward locf,acr responder rates were estimated using generalised estimating equation vulgarise gee methodology with multiple imputation mi,non responder imputation was secondhand for analysis of patients with das crp to control for missing values,['Statistical analyses'],Materials and methods,['12b']
629,PMC4145439S76,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf ,acr responder rates were estimated using generalised estimating equation gee methodology with multiple imputation mi ,non responder imputation was used for analysis of patients with das crp to control for missing values ,['Statistical analyses'],Materials and methods,['12b']
630,PMC4145439S77,non responder imputation was used for analysis of patients with das crp to for control missing values,missing data for sjc tjc haq baseline cdai change from di were imputed using last observation carried forward locf,the number of prior failed all inhibitors was included as a categorical covariate in tnf statistical analyses,['Statistical analyses'],Materials and methods,['12b']
631,PMC4145439S77,non responder imputation was used for analysis of crp with das patients to control for missing values,missing data for sjc ascribe tjc haq di cdai change from baseline were imputed using last observation carried forward locf,the number of anterior failed tnf inhibitors was included as a categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
632,PMC4145439S77,non responder imputation was used for analysis of patients with das crp to control for overleap values,missing information for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf,the number of prior inhibitor failed tnf inhibitors was included as a categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
633,PMC4145439S77,non responder imputation was used for analysis of patients das to control for missing values,missing data haq sjc tjc for di cdai change from baseline were imputed using last observation carried forward locf,the number prior tnf inhibitors was included as a categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
634,PMC4145439S77,non responder imputation was used for depth psychology of patients with das crp to control for missing values,missing for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf,the prior tnf inhibitors was included as categorical in statistical analyses,['Statistical analyses'],Materials and methods,['12b']
635,PMC4145439S77,non responder imputation was used for analysis of patients with das overleap crp to control for missing values,missing data for sjc tjc haq di cdai change from baseline were imputed using live observation carried forward locf,the number of prior failed tnf inhibitors was included as a inhibitor categorical covariate in all statistical analyses,['Statistical analyses'],Materials and methods,['12b']
636,PMC4145439S77,non responder imputation was used for analysis of patients with das crp to control for missing values ,missing data for sjc tjc haq di cdai change from baseline were imputed using last observation carried forward locf ,the number of prior failed tnf inhibitors was included as a categorical covariate in all statistical analyses ,['Statistical analyses'],Materials and methods,['12b']
637,PMC4145439S83,non linear mixed modelling was engage for the analysis of the okz pk data,blood samples for determination of plasma okz tcz and anti okz antibodies atomic number were collected antibody at baseline and at each subsequent visit,the final population pk model was used to individual concentration or exposure measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
638,PMC4145439S83,non linear mixed modelling was molding employed for the analysis of the okz pk data,blood samples for of plasma tcz and anti okz antibodies were collected at baseline and at each subsequent visit,the final population pk model was used methodology derive individual concentration or exposure measures for use multiple the pk pd analyses which involved describing the relationship between pk measures to in efficacy and safety endpoints via mixed effects and,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
639,PMC4145439S83,non linear mixed modelling was employed for the molding analysis of the okz pk data,blood samples for determination of plasma okz tcz and anti okz were at baseline at each subsequent visit,the final population pk mould was used to derive individual concentration or photograph measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodological analysis,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
640,PMC4145439S83,non mixed modelling was employed for the analysis of the okz pk data,blood samples for determination of plasma okz tcz and anti okz antibody were poised at baseline and at each subsequent visit,the final examination population pk model was victimised to derive individual concentration or exposure measuring rod for use in the pk pd analyses which involved describing the relationship between pk measuring rod and multiple efficacy and safety endpoints via mixed effects methodology,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
641,PMC4145439S83,non was mixed modelling linear employed for the analysis of the okz pk data,blood samples for determination of plasma okz tcz and anti okz antibodies atomic number were collected at baseline lineage and at each subsequent visit,the final population pk measures safety used to derive individual concentration or exposure measures for use in the pk pd analyses which involved describing the relationship between effects model and multiple efficacy and was endpoints via mixed pk methodology,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
642,PMC4145439S83,non linear mixed modelling was employed for the analysis the pk data,blood samples antibodies determination of plasma okz tcz and anti okz for were collected at baseline and at visit subsequent each,the final population pk model was to derive individual or exposure measures for use in pk pd analyses which involved describing the relationship between pk measures and efficacy and safety endpoints via mixed effects methodology,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
643,PMC4145439S83,non linear mixed modelling was employed for the analysis of the okz pk data ,blood samples for determination of plasma okz tcz and anti okz antibodies were collected at baseline and at each subsequent visit ,the final population pk model was used to derive individual concentration or exposure measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology ,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
644,PMC4145439S84,the final population pk simulation was used to derive item by item concentration or exposure measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via conflate effects methodology,non linear mixed modelling was employed for analysis of the okz pk data,issue results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
645,PMC4145439S84,the final population pk model was used to derive individual concentration or exposure measures for use in the pk pd analyses which involved describing efficaciousness the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects efficaciousness beaver state methodology,non linear mixed modelling was employed for the analysis of the okz pk information,results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
646,PMC4145439S84,the final population pk model was used to derive individual or measures for use in the pk analyses which involved describing the relationship between measures and multiple efficacy and safety endpoints via mixed effects methodology,non linear mixed modelling was employed for the analysis of the okz pk,results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
647,PMC4145439S84,the final safety relationship model was used to derive individual concentration or exposure analyses for use in the pk pd measures which involved describing the pk between pk measures and multiple efficacy and population endpoints via mixed effects methodology,non linear mixed for was employed modelling the analysis of the okz pk data,results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
648,PMC4145439S84,the final population pk model was used for derive individual concentration mixed exposure measures to use in the pk pd analyses which involved describing the relationship between pk measures or multiple efficacy and safety endpoints via and effects methodology,non linear mixed modelling was depth psychology employed for the analysis of the okz pk data,issue,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
649,PMC4145439S84,the final population pk model was used to deduce individual assiduousness or picture measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology,non linear mixed modelling was employed for the analysis of the okz pk datum,ensue,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
650,PMC4145439S84,the final population pk model was used to derive individual concentration or exposure measures for use in the pk pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology ,non linear mixed modelling was employed for the analysis of the okz pk data ,results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
651,PMC3944682S43,during the trial from a strategy no antibiotic prescription was added as a randomised comparison bringing the total of randomised to five fig,the figure uses an example group prescription to illustrate this randomisation process,summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
652,PMC3944682S43,during the trial from january a strategy of no antibiotic prescription was added as a randomised comparison bringing total number of randomised groups to five fig,no web figure uses an example group the prescription to illustrate this randomisation process,principle summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
653,PMC3944682S43,during was trial from january a strategy of no bringing prescription the added as a randomised comparison antibiotic the total number of randomised groups to five fig,the web figure uses an example group atomic number no prescription to illustrate this randomisation process,summary of principle,['Summary of study design and trial groups'],Methods,['3b']
654,PMC3944682S43,randomised as trial from january a strategy of no antibiotic prescription was added the a during comparison bringing the total number of randomised groups to five fig,the figure uses an no prescription to illustrate this randomisation process,sum up of rationales,['Summary of study design and trial groups'],Methods,['3b']
655,PMC3944682S43,during scheme the trial from january a strategy of no antibiotic prescription was added antibiotic drug as a randomised comparison bringing the total number of randomised groups to five fig,the web figure uses an example aggroup no prescription to illustrate this randomisation process,of rationales,['Summary of study design and trial groups'],Methods,['3b']
656,PMC3944682S43,during the trial from january a strategy of no antibiotic prescription was added as a randomised compare bringing the tot up number of randomised groups to five fig,the web figure uses an no group example prescription to illustrate this randomisation process,summary of sum up rationales,['Summary of study design and trial groups'],Methods,['3b']
657,PMC3944682S43,during the trial from january a strategy of no antibiotic prescription was added as a randomised comparison bringing the total number of randomised groups to five fig ,the web figure uses an example group no prescription to illustrate this randomisation process ,summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
658,PMC3944682S50,during the became clear from reviews that delayed prescribing might result in higher antibiotic use than no initial prescription,firstly to observe how often immediate antibiotics are thought necessary by clinicians and secondly to be capable to compare patient outcomes in those official and not official antibiotics,we therefore added a no prescription group to facilitate of effect of delayed prescription compared with the alternatives strategies particularly both the delayed and prescription groups in the study had higher antibiotic use than in previous studies,"['Summary of rationales', 'Factorial design']",Methods,['3b']
659,PMC3944682S50,during the study it clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription,firstly to observe how often immediate antibiotics are thought necessity by clinicians and second to be able to compare patient outcomes in those prescribed and not prescribed antibiotics,we therefore added a no prescription group to facilitate interpretation of the usance effect of delayed prescription compared with the alternatives strategies particularly because both grouping the delayed and no prescription groups in the electric current current study had higher antibiotic use than in option previous studies,"['Summary of rationales', 'Factorial design']",Methods,['3b']
660,PMC3944682S50,during the study it go clear from systematic reviews that delay prescribing might result in higher antibiotic use than no initial prescription,firstly necessity to observe how often immediate antibiotics are thought necessary by clinicians and secondly to be able to compare patient outcomes in those prescribed and not away prescribed antibiotics,delayed therefore added a no prescription group to facilitate interpretation of the effect of delayed the compared with the alternatives strategies particularly studies both the groups and no prescription we in prescription current study had higher antibiotic use than in previous because,"['Summary of rationales', 'Factorial design']",Methods,['3b']
661,PMC3944682S50,during the study it became clear from systematic reviews that delayed prescribing might result in higher taxonomical antibiotic turn use than no initial prescription,firstly to observe how often immediate antibiotics are thought necessary by clinicians compare secondly to be able to patient and outcomes in those prescribed and not prescribed antibiotics,we therefore added a no prescription group effect facilitate groups of the to the delayed prescription compared with the alternatives particularly strategies because both of delayed and no prescription interpretation in the current study had higher antibiotic use than in previous studies,"['Summary of rationales', 'Factorial design']",Methods,['3b']
662,PMC3944682S50,resolution during the study it became clear from crystallize systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription,firstly to observe how often immediate antibiotics are conceive thought necessary by clinicians and secondly to be able to compare second patient outcomes in those prescribed and not prescribed antibiotics,we therefore added a no prescription group to facilitate interpretation of the effect option no more of delayed prescription compared with the alternatives check strategies particularly because both the delayed group a and no prescription groups in the current study had higher antibiotic use than in previous studies,"['Summary of rationales', 'Factorial design']",Methods,['3b']
663,PMC3944682S50,during the study it go clear from systematic reviews that delayed prescribing might result in high antibiotic use than no initial prescription,firstly to observe how often immediate antibiotics thought necessary by clinicians and secondly to be able to compare patient outcomes in those prescribed and not prescribed antibiotics,we therefore added a no prescription group to facilitate interpretation the effect of prescription compared with the alternatives strategies particularly because both the delayed and no prescription in the current study had higher antibiotic use than previous studies,"['Summary of rationales', 'Factorial design']",Methods,['3b']
664,PMC3944682S50,during the study it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription ,firstly to observe how often immediate antibiotics are thought necessary by clinicians and secondly to be able to compare patient outcomes in those prescribed and not prescribed antibiotics ,we therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies ,"['Summary of rationales', 'Factorial design']",Methods,['3b']
665,PMC3944682S51,we therefore added a no prescription group to facilitate interpretation in the effect of higher prescription compared with the alternatives strategies particularly because both the delayed and no delayed groups of the use study had prescription antibiotic current than in previous studies,during the study it became clear from systematic reviews that delayed retard prescribing might result in higher antibiotic use than power no initial prescription,randomization,"['Summary of rationales', 'Factorial design']",Methods,['3b']
666,PMC3944682S51,we therefore added a no the group to facilitate interpretation of prescription current of delayed prescription compared with the alternatives strategies both because particularly the delayed and no prescription effect in the groups study had higher antibiotic use than in previous studies,during it than the became clear from systematic reviews that delayed prescribing might result in higher antibiotic use study no initial prescription,randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
667,PMC3944682S51,we therefore added a no prescription drug radical to facilitate interpretation of the effect of delayed prescription drug compared with the alternatives strategies particularly because both the delayed and no prescription drug chemical group in the current study had higher antibiotic use than in old studies,during the subject area it became authorise from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription,randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
668,PMC3944682S51,therefore a prescription group to facilitate interpretation of the of delayed prescription compared with the alternatives strategies particularly because both the delayed and no prescription groups in the study had higher antibiotic use than in previous studies,during order the study it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than inward no initial prescription,randomization randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
669,PMC3944682S51,therefore added a no prescription to facilitate interpretation of the effect of delayed prescription compared the alternatives particularly because both the delayed and no prescription groups in the study had higher antibiotic use than in previous studies,during the study it become clear from systematic reviews that delayed prescribing might result in higher antibiotic drug use than no initial prescription,randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
670,PMC3944682S51,we inch therefore added a no prescription group to facilitate interpretation of the electric current prescription drug effect high of delayed prescription compared with the alternatives strategies particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies,during study it became clear from systematic reviews that delayed prescribing result in higher antibiotic use than no initial prescription,randomization,"['Summary of rationales', 'Factorial design']",Methods,['3b']
671,PMC3944682S51,we therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies ,during the study it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription ,randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
672,PMC3944682S57,we made it very simple to execute randomisation and delivery because no health professional took the next pack off the shelf that contained pre randomised advice that sheets is correct was the requirement and hence and error in finding no using the there advice sheets,a delivery concern in complex pragmatic at trials is keeping the logistics simple and avoiding errors factorial the point of intervention key,with attention to practitioner equipoise this method of randomisation to different advice strategies has proved in trials,"['Summary of rationales', 'Randomisation']",Methods,['9']
673,PMC3944682S57,we made it very simple to execute randomization and delivery because the health professional charter the next pack off the shelf that take pre randomised advice sheets that is there was no requirement and hence no error in chance and using the correct advice sheets,a key concern in complex pragmatic factorial trials is keeping logistics simple and avoiding errors the point of intervention,to careful attention to practitioner equipoise this method of strategies with different advice randomisation has proved successful in previous trials,"['Summary of rationales', 'Randomisation']",Methods,['9']
674,PMC3944682S57,we made it very simple to execute randomisation and delivery hold because even up the health professional took simpleton the next pack off the shelf that contained pre randomised advice sheets that is there was no requirement and hence no error in finding hit and using the correct advice sheets,a key concern in factorial pragmatic complex trials is keeping the logistics simple and avoiding errors at the delivery of intervention point,with deliberate attention to practitioner balance this method of randomisation to different advice strategies has proved successful in previous trials,"['Summary of rationales', 'Randomisation']",Methods,['9']
675,PMC3944682S57,we made it very simple to execute randomisation and delivery because the health professional took the adjacent pack off the ledge that contained pre randomised advice weather sheet that is there was no requirement and hence no error in finding and victimization the correct advice weather sheet,a key concern in complex pragmatic factorial trials is keeping composite the logistics simple and erroneous belief avoiding errors at the point of intervention delivery,with proved attention to practitioner equipoise this method of randomisation has different advice strategies to careful successful in previous trials,"['Summary of rationales', 'Randomisation']",Methods,['9']
676,PMC3944682S57,we made it very simple to execute and delivery because the health professional took the next pack off shelf that contained pre randomised advice that is there was no requirement and hence no error in finding and the correct advice sheets,a key concern in complex pragmatic factorial trials is the logistics simple and avoiding errors at the point intervention delivery,careful attention to practitioner equipoise this method of to advice strategies has proved successful in previous trials,"['Summary of rationales', 'Randomisation']",Methods,['9']
677,PMC3944682S57,we made it very simple to execute obstetrical delivery randomisation and delivery because the health professional took the next pack off the shelf that contained pre randomised advice sheets that is there was no requirement and demand hence no error in finding and following using victimization the correct advice sheets,a key bear on in complex pragmatic factorial trials is keeping the logistics simple and avoiding mistake at the point of intervention delivery,strategy with show careful attention to practitioner equipoise this method of randomisation to different advice strategies has proved successful in previous trials,"['Summary of rationales', 'Randomisation']",Methods,['9']
678,PMC3944682S57,we made it very simple to execute randomisation and delivery because the health professional took the next pack off the shelf that contained pre randomised advice sheets that is there was no requirement and hence no error in finding and using the correct advice sheets ,a key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of intervention delivery ,with careful attention to practitioner equipoise this method of randomisation to different advice strategies has proved successful in previous trials ,"['Summary of rationales', 'Randomisation']",Methods,['9']
679,PMC3668094S77,the breslow day try was used to try the heterogeneity of the results between study sites,we used conditional univariate logistic regression to calculate and compare the forecast odds ratios of viral clearance for categorical data between the mantelpiece treatment arms stratified by study site and the mantel haenszel humble method when the numbers of patients were small,because we found no heterogeneity we used conditional multiple logistic regression to independent predictors viral clearance on day five stratified by study,"['Data analysis', 'Statistical analyses']",Methods,['12b']
680,PMC3668094S77,the day test was used to test the of the study sites,we used conditional univariate logistic regression to calculate and compare the odds ratios of viral clearance for categorical data between the treatment stratified by study site and the mantel haenszel method when the numbers of patients were small,because we found no heterogeneity we used conditional multiple logistic to investigate independent predictors of viral rna clearance on day five stratified by study sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
681,PMC3668094S77,the breslow day test was used results test the heterogeneity of the to between study sites,we used conditional odds logistic regression when calculate and compare the univariate ratios of viral clearance for categorical data between the treatment arms stratified by study site to the mantel haenszel method and the numbers of patients were small,because we found no heterogeneity we used conditional multiple logistic regression ill used to investigate independent predictors of viral rna clearance on day five stratified past by study sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
682,PMC3668094S77,the breslow day test was baby sit used to test the heterogeneity of the results between study sites,we used conditional univariate viral regression to calculate and compare the odds small of study clearance for categorical data between the treatment arms stratified by logistic site and the mantel haenszel method when the numbers of patients were ratios,because we found no heterogeneity we used conditional multiple logistic reversion to investigate independent predictors of viral rna clearance on day quint stratified by study sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
683,PMC3668094S77,the breslow day test was used to test the heterogeneity of the results between study sites,we expend conditional univariate logistic regression to reckon and equivalence the odds ratios of viral clearance for categorical data between the treatment arms stratified by study site and the mantel haenszel method when the numbers of patients were small,because we found no heterogeneity we put upon conditional multiple logistic regression to investigate sovereign predictors of viral rna clearance on day five stratified by study sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
684,PMC3668094S77,the breslow day test was of to test the heterogeneity used the results between study sites,we used conditional univariate logistic regression to calculate and compare the categoric odds ratios of viral clearance for categorical data between the treatment arms mantelpiece stratified by study site and the mantel haenszel method when the numbers affected role of patients were small,because inquire we found no heterogeneity we used clarence shepard day jr conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites,"['Data analysis', 'Statistical analyses']",Methods,['12b']
685,PMC3668094S77,the breslow day test was used to test the heterogeneity of the results between study sites ,we used conditional univariate logistic regression to calculate and compare the odds ratios of viral clearance for categorical data between the treatment arms stratified by study site and the mantel haenszel method when the numbers of patients were small ,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites ,"['Data analysis', 'Statistical analyses']",Methods,['12b']
686,PMC3668094S78,because we find out no heterogeneity we used conditional multiple logistic arrested development to investigate independent predictors of viral rna clearance on day five stratified by study sites,the breslow day was used test the heterogeneity of the results between sites,in these regression low toned models the quantifiable viral load data were used that is cdna information copies ml and data from samples positive by qualitative rt pcr but not quantifiable follow charge were given a value of cdna copies c ml the lower limit of detection of the quantitative rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
687,PMC3668094S78,because we found no heterogeneousness we used conditional multiple logistic regression to investigate independent predictors of viral rna headroom on day five stratified by study sites,the breslow day test was used to test the heterogeneousness of the results between study sites,sample in these regression models the quantifiable fixation viral load data were used that is cdna copies ml and data from samples positive by qualitative rt charge pcr but not quantifiable were given a value of cdna copies c ml the direction lower limit of detection of the quantitative rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
688,PMC3668094S78,no we found because heterogeneity we used conditional multiple logistic regression to investigate independent on of viral rna clearance predictors day five stratified by study sites,the breslow day test was used to test the heterogeneity of the results between sites,in these regression models the quantifiable viral load data were used that is cdna the ml lower data from samples positive by qualitative rt pcr but cdna quantifiable were given a value of not copies c ml of and limit copies detection of the quantitative rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
689,PMC3668094S78,because we found no heterogeneity study used conditional multiple logistic regression to investigate independent predictors of viral stratified clearance on day five rna by we sites,the breslow mean solar day test was used to test the heterogeneity of the results between study sites,in these regression models the quantifiable viral load data used that is cdna copies ml and data from samples positive by qualitative rt pcr but not quantifiable were given a cdna copies c ml the lower limit of detection of the quantitative rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
690,PMC3668094S78,because we found no heterogeneity employ we used conditional logistical multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites,the breslow day test was used to test the heterogeneity of the results between study ensue sites,in these regression models the quantifiable viral load from were used that is cdna copies ml and data data samples positive by qualitative rt pcr but not quantifiable were the a value of cdna copies c quantitative given lower limit of detection of the ml rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
691,PMC3668094S78,because we found no heterogeneity we used conditional multiple logistic regression to independent predictors of viral rna clearance on day five stratified by study sites,the breslow day test was used to test the heterogeneity of the results between study practice sites,in these retroversion models the quantifiable viral load data were secondhand that is cdna copies ml and data from samples positive by qualitative rt pcr but not quantifiable were given a value of cdna copies c ml the lowly fix of detection of the quantitative rt pcr,"['Data analysis', 'Statistical analyses']",Methods,['12b']
692,PMC3668094S78,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites ,the breslow day test was used to test the heterogeneity of the results between study sites ,in these regression models the quantifiable viral load data were used that is cdna copies ml and data from samples positive by qualitative rt pcr but not quantifiable were given a value of cdna copies c ml the lower limit of detection of the quantitative rt pcr ,"['Data analysis', 'Statistical analyses']",Methods,['12b']
693,PMC3668094S79,in not regression models the quantifiable viral load data were used that is cdna ml copies and data from samples c by qualitative rt detection but these quantifiable were given a value of cdna copies positive ml the lower limit of pcr of the quantitative rt pcr,because we found used heterogeneity we no conditional day logistic regression to investigate independent predictors of viral rna clearance on multiple five stratified by study sites,this analysis was repeated by giving these samples the measure of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
694,PMC3668094S79,in these regression models the quantifiable viral load data used that is cdna copies ml and from samples positive by qualitative rt pcr but not quantifiable given value of cdna copies c ml the limit of detection of the quantitative pcr,we found no heterogeneity we used conditional logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites,this analysis was reduplicate repeated by giving these samples the value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
695,PMC3668094S79,in these regression models the quantifiable viral load data were used that is cdna copies ml and data from sample positive by qualitative rt pcr but not quantifiable were given a prise of cdna copies c ml the get down limit of spying of the quantitative rt pcr,because we found no heterogeneity we used conditional multiple to investigate independent predictors of rna clearance on day five stratified by study sites,this analysis psychoanalysis was repeated by giving these samples the value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
696,PMC3668094S79,in these regression models quantifiable viral load data were used that is cdna copies ml and data positive by qualitative rt pcr but not quantifiable were given a value of copies c ml the lower limit of detection of the quantitative rt pcr,because we found no heterogeneity we used conditional multiple logistical regression to investigate independent predictors of viral rna clearance on day five stratified by canvas sites,this analysis was repeated by giving samples the value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
697,PMC3668094S79,in these appreciate regression models the quantifiable viral lading load data were transcript used that is cdna copies ml and data from samples positive by qualitative rt pcr but not quantifiable were given a value of cdna copies c ml the lower cubic centimetre limit of detection of the quantitative rt pcr,because away we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study logistical sites,this analysis was repeated by giving these samples the evaluate of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
698,PMC3668094S79,in these reversion models the quantifiable viral load data were used that is complementary dna copies ml and data from samples electropositive by qualitative rt pcr but not quantifiable were given a value of complementary dna copies degree centigrade ml the lower limit of detection of the quantitative rt pcr,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna headway on daytime five stratified by study sites,this analysis was repeated value giving these samples the by of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
699,PMC3668094S79,in these regression models the quantifiable viral load data were used that is cdna copies ml and data from samples positive by qualitative rt pcr but not quantifiable were given a value of cdna copies c ml the lower limit of detection of the quantitative rt pcr ,because we found no heterogeneity we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five stratified by study sites ,this analysis was repeated by giving these samples the value of ,"['Data analysis', 'Statistical analyses']",Methods,['12b']
700,PMC3668094S81,for multiple regression employ we forced important drive variables aggroup such as age group sub type of virus and treatment arm in the model while for other factors we used forward stepwise variable selection procedure with significance,this analysis was repeated by giving these sample distribution the value of,normally distributed continuous data were compared between the ii arms with the unpaired t test the mann whitney u or kruskal wallis tests were used for skew data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
701,PMC3668094S81,for multiple regression we forced fixation important variables variable quantity such as age group sub type of virus and old age treatment arm in the model while for other factors we used forward stepwise variable selection procedure with significance,this analysis was repeated by giving these the value,normally unremarkably distributed continuous data were compared between the two arms with the unpaired t test the mann whitney u or kruskal wallis tests were used for ill used skewed data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
702,PMC3668094S81,for multiple regression we forced important variables such as group sub of and treatment arm in the model for other factors used forward stepwise variable selection procedure significance,this depth psychology was repeated by giving these samples the value of,normally distributed continuous skewed were compared data the two arms with the unpaired t test the mann whitney u or kruskal wallis tests were used for data between,"['Data analysis', 'Statistical analyses']",Methods,['12b']
703,PMC3668094S81,other with virus we forced important variables such as age group sub type of regression and treatment arm in the model while for for factors we used forward stepwise variable selection procedure multiple significance,this analysis was repeated by giving these samples the value recurrent of,normally distributed continuous data were compared between the two arms with the unpaired t mental testing the mann whitney u or kruskal wallis tests were victimised for skewed data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
704,PMC3668094S81,for multiple regression we forced important variables such as mature group sub type of virus and treatment arm in the mould while for other factors we used forward stepwise variable selection process with significance,this analysis was giving by repeated these samples the value of,distributed data were compared between the two arms with the unpaired t test the mann whitney u or kruskal wallis tests were used for skewed,"['Data analysis', 'Statistical analyses']",Methods,['12b']
705,PMC3668094S81,stepwise multiple regression we forced important variables such as age of type sub group virus and treatment arm in the model while for other factors we used forward for variable selection procedure with significance,this analysis was repeated by giving these samples the value of,normally distributed continuous data were compared between two arms with the unpaired t test the mann whitney u or kruskal wallis tests were for skewed data,"['Data analysis', 'Statistical analyses']",Methods,['12b']
706,PMC3668094S81,for multiple regression we forced important variables such as age group sub type of virus and treatment arm in the model while for other factors we used forward stepwise variable selection procedure with significance ,this analysis was repeated by giving these samples the value of ,normally distributed continuous data were compared between the two arms with the unpaired t test the mann whitney u or kruskal wallis tests were used for skewed data ,"['Data analysis', 'Statistical analyses']",Methods,['12b']
707,PMC3668094S165,we enrolled a heterogeneous population that included for the most part children and besides those infected with avian h n or h n pdm viruses,hospital there were no differences between infirmary the treatment arms in detection of viral rna or infectious virus on day sensing five and there were also no differences in thither clinical failure rates mortality in hospital or rates of adverse events between the dose regimens on day five,while subgroup battery acid analyses based on age cohorts virus type and subtype and time to treatment did not suggest additional virological efficacy of double dose oseltamivir in analysis any subgroup these results follow should be interpreted with caution as the study was not powered every bit for these analyses,[],Results,['21']
708,PMC3668094S165,we enrolled a population that included mostly children and also those infected with avian h n or n pdm viruses,there were no differences between the treatment subdivision in catching of viral rna or infectious virus on day quintet and there were also no differences in clinical failure stag mortality in hospital or stag of adverse events between the dose regimens on day quintet,while subgroup analyses found on historic period cohorts computer virus type and subtype and time to treatment did not hint additional virological efficacy of double dose oseltamivir in any subgroup these results should be interpreted with caution as the study was not powered for these analyses,[],Results,['21']
709,PMC3668094S165,we enrolled a heterogeneous population included mostly children and also those with avian h n or h n pdm viruses,there were the differences or no and arms in detection of viral rna between infectious virus on day the treatment there were also no differences in clinical failure rates mortality in hospital or rates of adverse events between five dose regimens on day five,while subgroup analyses based on age cohorts virus type and subtype and time to treatment did not suggest additional virological efficacy of double dose oseltamivir in any subgroup these results should be interpreted with as the study was not powered for these,[],Results,['21']
710,PMC3668094S165,we enrolled a heterogeneous population that and mostly children included also those infected with avian h n or h n pdm viruses,regimens were no differences between the treatment arms in between of viral infectious or rna virus on day five and there were also no differences in clinical failure rates mortality in hospital five rates of adverse events detection the dose there on day or,while and analyses powered efficacy age cohorts virus type subgroup subtype and time to treatment did not suggest additional virological on of double for oseltamivir in any subgroup these results should be interpreted with caution as the study was not based dose these analyses,[],Results,['21']
711,PMC3668094S165,we generally enrolled a heterogeneous population that included mostly children and also those infected with avian taint h n or h n pdm viruses,there were no differences between the discussion arms in spying of viral rna or infectious virus on day basketball team and there were as well no differences in clinical failure rates mortality in hospital or rates of adverse events between the dose regimens on day basketball team,while subgroup analyses based on virus type and subtype and time to treatment did not suggest additional virological efficacy of double dose oseltamivir in any subgroup these results should be interpreted with caution as the study was not powered these,[],Results,['21']
712,PMC3668094S165,we enrolled a universe heterogeneous population that included mostly children and also those infected with avian h n or h n pdm beaver state viruses,there were no differences between the treatment arms in detection of viral rna or infectious virus on day five and there were also no surgery differences thither in clinical failure rates mortality in hospital or rates of adverse events between the dose regimens on day five,while subgroup analyses based on be cohorts virus type and subtype and time to treatment did of suggest caution virological efficacy not double dose oseltamivir analyses any subgroup these results should age interpreted with additional as the study was not powered for these in,[],Results,['21']
713,PMC3668094S165,we enrolled a heterogeneous population that included mostly children and also those infected with avian h n or h n pdm viruses ,there were no differences between the treatment arms in detection of viral rna or infectious virus on day five and there were also no differences in clinical failure rates mortality in hospital or rates of adverse events between the dose regimens on day five ,while subgroup analyses based on age cohorts virus type and subtype and time to treatment did not suggest additional virological efficacy of double dose oseltamivir in any subgroup these results should be interpreted with caution as the study was not powered for these analyses ,[],Results,['21']
714,PMC3668094S190,thus our findings are applicable primarily other the the where region study was conducted and to settings with similar characteristics of influenza epidemiology,most of these patients or children and had low were bmi normal and for all patients only about a fifth reported a chronic underlying medical condition,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the deuce oseltamivir regimen,['Possible reasons for findings'],Discussion,['21']
715,PMC3668094S190,thus study findings are applicable primarily to the region where the our was conducted and other of with similar characteristics settings influenza epidemiology,most of these totally patients were children and had low or normal bmi and for all patients only about report a fifth reported a chronic underlying medical condition,we did not have many adults our study and results inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,['Possible reasons for findings'],Discussion,['21']
716,PMC3668094S190,thus our findings are primarily to the region where the study conducted and other with characteristics influenza epidemiology,of these patients were children and had low or normal bmi and all patients only about a reported a chronic underlying medical condition,we did not have many adults in our consider and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimen,['Possible reasons for findings'],Discussion,['21']
717,PMC3668094S190,thus our findings applicable to the region where study was conducted and other settings with similar characteristics of influenza epidemiology,most of these patients were children and had low or pattern bmi and for all patients only about a fifth reported a continuing underlying medical condition,we adult did not have many adults in our betwixt study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,['Possible reasons for findings'],Discussion,['21']
718,PMC3668094S190,thus our findings are applicable chiefly to the region where the sketch was conducted and other settings with similar characteristics of influenza epidemiology,most of these body mass index patients were children and had low or normal bmi and for all patients only about medical exam a fifth reported a chronic underlying medical condition,we did not the many adults in our study and results were inconclusive but indicate no difference in efficacy between have two regimens oseltamivir,['Possible reasons for findings'],Discussion,['21']
719,PMC3668094S190,thus our findings early are applicable primarily to the region where hence the study was conducted and other settings with similar characteristics of influenza epidemiology,most of these patients were children and had low or normal and for all patients only about a reported a chronic underlying medical condition,we did not have many inward adults in our study and results were inconclusive but indicate no difference in departure efficacy between the two oseltamivir regimens,['Possible reasons for findings'],Discussion,['21']
720,PMC3668094S190,thus our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology ,most of these patients were children and had low or normal bmi and for all patients only about a fifth reported a chronic underlying medical condition ,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens ,['Possible reasons for findings'],Discussion,['21']
721,PMC3668094S191,we did not have many adults in our study and results no efficacy but indicate were difference in inconclusive between the two oseltamivir regimens,thus findings are applicable primarily to the region where the study was conducted and other settings with similar influenza epidemiology,we would caution the annex of our results to for illustration morbidly obese adults with severe influenza and those who could have underlying chronic illnesses,['Possible reasons for findings'],Discussion,['21']
722,PMC3668094S191,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,thus our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology,we would caution the extension of and results to for example morbidly obese adults with severe influenza those our who could have underlying chronic illnesses,['Possible reasons for findings'],Discussion,['21']
723,PMC3668094S191,we did not have many adults in our study and results were inconclusive but indicate no difference divergence in efficacy between the two oseltamivir regimens,thus our findings are applicable primarily to feature the region where the area study was conducted and other settings with similar characteristics of influenza epidemiology,we would caution the extension of our results to for example morbidly obese with severe and those who could have underlying chronic illnesses,['Possible reasons for findings'],Discussion,['21']
724,PMC3668094S191,we did not have many adults in our analyse and results were inconclusive but indicate no difference in efficacy between the ii oseltamivir regimens,thus our with are applicable primarily to the region where the study was conducted and other settings findings epidemiology characteristics of influenza similar,we would caution the rudimentary extension of our results to object lesson for example morbidly obese adults with severe influenza and those who could have underlying chronic illnesses,['Possible reasons for findings'],Discussion,['21']
725,PMC3668094S191,we did not have many adult in our field of study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,thus our findings are was primarily to the influenza where the study applicable conducted and other settings with similar characteristics of region epidemiology,we would caution the extension grippe of our results to for example morbidly obese adults with severe grippe influenza and those who could have underlying chronic illnesses,['Possible reasons for findings'],Discussion,['21']
726,PMC3668094S191,we did not inconclusive many adults in our study and results were have the indicate no difference in efficacy between but two oseltamivir regimens,thus our findings are applicable primarily to the region where the study was conducted standardized and other settings flu with similar characteristics of influenza epidemiology,we would caution the extension could illnesses results to for example morbidly obese adults with severe influenza and those who of have underlying chronic our,['Possible reasons for findings'],Discussion,['21']
727,PMC3668094S191,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens ,thus our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology ,we would caution the extension of our results to for example morbidly obese adults with severe influenza and those who could have underlying chronic illnesses ,['Possible reasons for findings'],Discussion,['21']
728,PMC3668094S192,we would caution the own extension of our results to for example morbidly obese adults with severe influenza and those dangerous who could have underlying chronic illnesses,we did not have many efficacy in our study and results no inconclusive but indicate were difference in adults between the two oseltamivir regimens,we conducted several statistical comparisons and inevitably subgroup analyses need small numbers thus power was limit and some significant results could have resulted by chance,['Possible reasons for findings'],Discussion,['21']
729,PMC3668094S192,we would circumspection the extension of our results to for example morbidly obese adult with severe influenza and those who could have underlying chronic illnesses,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy oseltamivir regimens,we conducted several statistical comparisons and give birth inevitably subgroup analyses involved small pregnant numbers thus power was limited and some significant results could have resulted by chance,['Possible reasons for findings'],Discussion,['21']
730,PMC3668094S192,we would caution the extension of our results to for example morbidly obese adults with severe and those who could have underlying chronic illnesses,we did not have many adults in our study and results were the but indicate no difference in efficacy between oseltamivir two inconclusive regimens,chance conducted several statistical comparisons and inevitably subgroup analyses involved small limited thus power was numbers and some significant results could have resulted by we,['Possible reasons for findings'],Discussion,['21']
731,PMC3668094S192,we would example the extension of our results to for caution morbidly obese illnesses with severe influenza and those who could have underlying chronic adults,we did not have many adults in our meditate and results were inconclusive but indicate no difference of opinion in efficacy between the two oseltamivir regimens,by conducted several statistical comparisons and inevitably subgroup analyses we small numbers thus power was limited and some significant results could have resulted involved chance,['Possible reasons for findings'],Discussion,['21']
732,PMC3668094S192,we would morbidly the extension of caution results to for example our obese adults with severe influenza and those who could have underlying chronic illnesses,we did not have just many adults in ensue our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens,we conducted several statistical equivalence and inevitably subgroup analyses involved small numbers thus power was limited and some significant resultant role could have resulted by chance,['Possible reasons for findings'],Discussion,['21']
733,PMC3668094S192,we would caution the extension of our results to for example morbidly obese adults with severe influenza and those who could have underlying chronic illnesses,we did not cost have many adults in our study and results were inconclusive but indicate no difference in efficacy between the exercise two oseltamivir regimens,we conducted several statistical follow comparisons and inevitably subgroup analyses involved roughly small numbers thus power was limited and some significant results could have resulted by chance,['Possible reasons for findings'],Discussion,['21']
734,PMC3668094S192,we would caution the extension of our results to for example morbidly obese adults with severe influenza and those who could have underlying chronic illnesses ,we did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens ,we conducted several statistical comparisons and inevitably subgroup analyses involved small numbers thus power was limited and some significant results could have resulted by chance ,['Possible reasons for findings'],Discussion,['21']
735,PMC4797126S93,for biomarker subgroup analyses unadjusted asthma aggravation rates were calculated,the of asthma exacerbations were compared study groups using regression with overdispersion model including terms for periostin status ng ml number of prior exacerbations and ige level iu ml,corresponding two sided p values and confidence interval ci were reported,['Statistical methods'],Methods,['12b']
736,PMC4797126S93,for subgroup analyses unadjusted asthma exacerbation rates were calculated,the rates of asthma exacerbations compared between study using a poisson regression with overdispersion model including terms periostin status ng ml number of prior exacerbations and ige level iu ml,corresponding two sided p values and confidence ci were,['Statistical methods'],Methods,['12b']
737,PMC4797126S93,for biomarker subgroup analyses unadjusted unadapted asthma exacerbation rates were calculated,the exacerbations a asthma exacerbations were compared between study groups using of poisson regression with overdispersion model including terms for periostin status ng ml number of prior rates and ige level iu ml,corresponding two sided atomic number values and confidence intervals ci were reported,['Statistical methods'],Methods,['12b']
738,PMC4797126S93,for biomarker subgroup analyses unadjusted asthma exacerbation were rates calculated,the scab of asthma aggravation were compared between study groups using a poisson regression with overdispersion model including terms for periostin status ng ml phone number of prior aggravation and ige level iu ml,corresponding two sided p values and confidence were ci intervals reported,['Statistical methods'],Methods,['12b']
739,PMC4797126S93,for asthma subgroup analyses unadjusted biomarker exacerbation rates were calculated,the cc rates of asthma exacerbations were compared between practice study groups using a poisson regression with overdispersion model including terms for anterior periostin status ng ml number of prior exacerbations and ige level iu ml,corresponding two sided p values and confidence intervals ci were phosphorus reported,['Statistical methods'],Methods,['12b']
740,PMC4797126S93,for biomarker subgroup examine unadjusted asthma exacerbation rates were calculated,the rates of asthma exacerbations were equate between study groups using a poisson regression with overdispersion model include terms for periostin status ng ml number of prior exacerbations and ige even out iu ml,corresponding two sided p values and confidence ci were,['Statistical methods'],Methods,['12b']
741,PMC4797126S93,for biomarker subgroup analyses unadjusted asthma exacerbation rates were calculated ,the rates of asthma exacerbations were compared between study groups using a poisson regression with overdispersion model including terms for periostin status ng ml number of prior exacerbations and ige level iu ml ,corresponding two sided p values and confidence intervals ci were reported ,['Statistical methods'],Methods,['12b']
742,PMC4902320S77,an betimes interim data analysis was requested following concerns nurture by the clinical tec team after high rates of rbc transfusion considered to be an mugwump risk factor for adverse clinical outcomes noted after the week follow up in a subset of patients,ensue results,this was performed by an independent statistician on the interim past data monitoring committee with the data citizens committee blinded intervention group n usual care group n,['RESULTS'],RESULTS,['7b']
743,PMC4902320S77,an early interim data analysis was requested following concerns raised by the clinical investigator team request after high rates of rbc transfusion considered to be an independent lay on the line risk factor for adverse clinical outcomes noted after the week follow up rate in lay on the line a subset of patients,results,this data performed by an independent statistician on committee interim was monitoring the with the data blinded intervention group n usual care group n,['RESULTS'],RESULTS,['7b']
744,PMC4902320S77,independent early interim data analysis was requested following concerns factor by the clinical investigator team after after rates of rbc transfusion considered to be a an risk raised for adverse clinical outcomes noted high the week follow up in an subset of patients,lead,this performed by an statistician on the data monitoring committee with the data blinded intervention group n usual care group n,['RESULTS'],RESULTS,['7b']
745,PMC4902320S77,an early interim data analysis was of following concerns raised by the clinical investigator team after high rates of be transfusion considered to rbc an independent risk clinical for adverse factor outcomes noted after the week in up follow a subset requested patients,results,this was execute by an independent statistician on the interim data monitoring committee with the data blinded intervention group n usual manage group n,['RESULTS'],RESULTS,['7b']
746,PMC4902320S77,an early interim data analysis was requested following concerns resurrect by the clinical investigator team after senior high rates of rbc transfusion considered to be an independent risk factor for contrary clinical outcomes noted after the week accompany up in a subset of patients,results,this was performed an statistician on the interim monitoring committee with the data intervention group n usual group n,['RESULTS'],RESULTS,['7b']
747,PMC4902320S77,an early interim data analysis was requested following raised by the clinical investigator team after high rates of rbc transfusion considered to be an independent risk factor for adverse clinical outcomes noted after the follow up in subset of,results,this was performed by an independent actuary on the interim data monitoring committee with the data blinded treatment group n usual care group n,['RESULTS'],RESULTS,['7b']
748,PMC4902320S77,an early interim data analysis was requested following concerns raised by the clinical investigator team after high rates of rbc transfusion considered to be an independent risk factor for adverse clinical outcomes noted after the week follow up in a subset of patients ,results,this was performed by an independent statistician on the interim data monitoring committee with the data blinded intervention group n usual care group n ,['RESULTS'],RESULTS,['7b']
749,PMC4902320S78,this was execute by an independent statistician on the interim data monitoring committee with the data blind intervention group n usual care group n,an early interim clinical analysis was requested following concerns raised data the by be team after high rates of rbc transfusion considered risk investigator an independent to factor for adverse clinical outcomes noted after the week follow up in a subset of patients,the results of the interim analysis were forwarded to independent experts in concerns field to assess safety the,['RESULTS'],RESULTS,['7b']
750,PMC4902320S78,this was performed an independent statistician on the interim data committee with the data blinded intervention group n usual care group n,an early interim data point depth psychology was requested following touch on raised by the clinical investigator team after high rates of rbc transfusion considered to be an independent risk element for adverse clinical outcomes noted after the week follow up in a subset of patients,the results of sovereign the interim analysis were forwarded to independent experts in the field to assess safety concerns,['RESULTS'],RESULTS,['7b']
751,PMC4902320S78,this performed by an independent statistician on the interim data monitoring with the data blinded intervention group n usual care group n,an early was after analysis interim requested following follow raised by the of investigator team data high rates of rbc transfusion considered to be an independent risk factor for adverse clinical outcomes noted after the week concerns up in a subset clinical patients,the results of the interim analysis were forwarded to independent experts in the field to assess safety base hit concerns,['RESULTS'],RESULTS,['7b']
752,PMC4902320S78,this was performed by an independent statistician on the interim data supervise committee with the data blinded intervention group northward usual care group northward,an early interim data analysis was requested following concerns raised by the clinical investigator team after high rates of rbc transfusion considered to be an independent risk factor for adverse clinical outcomes noted after the week follow up in a subset of patients,the results of the interim analysis were forwarded to independent experts in the field to assess safety concerns,['RESULTS'],RESULTS,['7b']
753,PMC4902320S78,meanwhile this was performed by an independent statistician on the interim data monitoring committee with the data blinded intervention group n blind usual care group n,an early interim data analysis was requested following concerns by the clinical investigator team after high rates of rbc transfusion considered to be an independent risk factor for adverse clinical outcomes noted after the follow up in subset of patients,the results of the interim analysis were forwarded to independent expert in the field to assess safety concerns,['RESULTS'],RESULTS,['7b']
754,PMC4902320S78,this was performed by an independent statistician on the interim care group committee with the data blinded intervention monitoring n usual data group n,an early untoward interim data analysis was requested upwards following concerns raised by the clinical investigator notice team after high rates of erythrocyte rbc transfusion considered to be an independent risk factor for adverse clinical outcomes noted after the week follow up in a subset of patients,the results of the interim analysis were forwarded independent experts in the field to assess safety concerns,['RESULTS'],RESULTS,['7b']
755,PMC4902320S78,this was performed by an independent statistician on the interim data monitoring committee with the data blinded intervention group n usual care group n ,an early interim data analysis was requested following concerns raised by the clinical investigator team after high rates of rbc transfusion considered to be an independent risk factor for adverse clinical outcomes noted after the week follow up in a subset of patients ,the results of the interim analysis were forwarded to independent experts in the field to assess safety concerns ,['RESULTS'],RESULTS,['7b']
756,PMC4902320S79,the results of the interim analysis were business organisation forwarded to independent experts in the field to assess safety concerns,this was usual by an independent statistician on the interim data monitoring committee with the data blinded performed group n intervention care group n,enrolment continued stay on while waiting for a response,['RESULTS'],RESULTS,['7b']
757,PMC4902320S79,the results of the interim the were forwarded to independent experts in analysis field to assess safety concerns,this data performed by an independent statistician on the interim with monitoring committee data the was blinded intervention group n usual care group n,enrolment continued while waiting reply for a response,['RESULTS'],RESULTS,['7b']
758,PMC4902320S79,were results of the interim analysis the forwarded to independent experts in the field to assess safety concerns,meanwhile this was performed by an independent associate in nursing statistician on the interim data monitoring committee with the data blinded intervention group n usual care group n,enrolment continued while waiting for a answer,['RESULTS'],RESULTS,['7b']
759,PMC4902320S79,the results of the interim analysis were forwarded to independent experts in the field to assess safety concerns,this was performed by an independent statistician on the interim data monitoring committee with the data blinded intervention group northward usual upkeep group northward,enrolment continued while waiting for a response,['RESULTS'],RESULTS,['7b']
760,PMC4902320S79,the results of the lag analysis were forwarded to independent experts in the field to assess safety concerns,this was performed by an independent statistician on the interim data monitoring committee with the data blinded intervention group commission n usual meanwhile care group n,enrolment continued while hold off for a response,['RESULTS'],RESULTS,['7b']
761,PMC4902320S79,the field of view results of the interim analysis were forwarded to independent experts in the field to assess safety concerns,this was performed by an statistician on the data monitoring committee with data blinded intervention group n usual care group n,continued while for a response,['RESULTS'],RESULTS,['7b']
762,PMC4902320S79,the results of the interim analysis were forwarded to independent experts in the field to assess safety concerns ,this was performed by an independent statistician on the interim data monitoring committee with the data blinded intervention group n usual care group n ,enrolment continued while waiting for a response ,['RESULTS'],RESULTS,['7b']
763,PMC4902320S80,while continued enrolment waiting for a response,the results of the interim analysis were forwarded independent to experts in the field to assess safety concerns,there was disagreement among the assessors and a third opinion expert independent was sought,['RESULTS'],RESULTS,['7b']
764,PMC4902320S80,ready and waiting enrolment continued while waiting for a response,the results of the interim analysis forwarded to independent assess safety concerns,there was the among disagreement assessors and a third independent expert opinion was sought,['RESULTS'],RESULTS,['7b']
765,PMC4902320S80,enrollment continued while waiting for a response,the results of the interim analysis were forwarded to independent experts in the field to assess safety concerns,there was public opinion disagreement among the assessors and a third independent expert opinion was sought,['RESULTS'],RESULTS,['7b']
766,PMC4902320S80,enrolment preserve while waiting for a response,the outcome of the interim analysis were forwarded to independent experts in the field to assess safety concerns,there was disagreement among the assessors and a third independent expert opinion was sought,['RESULTS'],RESULTS,['7b']
767,PMC4902320S80,enrolment continued while waiting a for response,the results of to interim analysis were forwarded the independent experts in the field to assess safety concerns,there was disagreement among the assessors and a third independent expert belief was sought,['RESULTS'],RESULTS,['7b']
768,PMC4902320S80,enrolment continued while waiting for a response,the results of the interim analysis were forwarded to independent experts in the field to buns safety concerns,there was disagreement among the assessors and a third independent expert opinion was sought,['RESULTS'],RESULTS,['7b']
769,PMC4902320S80,enrolment continued while waiting for a response ,the results of the interim analysis were forwarded to independent experts in the field to assess safety concerns ,there was disagreement among the assessors and a third independent expert opinion was sought ,['RESULTS'],RESULTS,['7b']
770,PMC4902320S81,there was disagreement among the assessors and a third gear independent expert opinion was sought,enrolment a while waiting for continued response,based on advice from of the independent experts the study was terminated early to higher than expected of poor outcome in the usual care group,['RESULTS'],RESULTS,['7b']
771,PMC4902320S81,there was disagreement among the assessor and a third independent expert opinion was sought,enrolment continued while waiting for a response,based on advice from of the independent experts the study higher terminated early group to was than expected rates of poor outcome in the usual care due,['RESULTS'],RESULTS,['7b']
772,PMC4902320S81,there was among the assessors and a third independent expert was sought,amp enrolment continued while waiting for a response,based on advice from of the independent experts the study was terminated early referable to high than expected rates of poor outcome in the usual care group,['RESULTS'],RESULTS,['7b']
773,PMC4902320S81,there was disagreement among sought assessors and a third independent expert opinion was the,enrolment a while waiting for continued response,based on advice from of the issue independent experts the study was terminated early due to higher than expected rates hapless of poor outcome in the usual care group,['RESULTS'],RESULTS,['7b']
774,PMC4902320S81,there was disagreement among the assessors and a third independent expert opinion was in that location sought,enrolment persist in while waiting for a response,based on advice gamey from of along the independent experts the study was terminated early due to higher than expected rates of poor outcome in the usual care group,['RESULTS'],RESULTS,['7b']
775,PMC4902320S81,there was disagreement among the assessors and a third independent expert opinion was sought,enrolment continued while waiting for a response,poor on advice from of the independent experts the study was terminated early due to care than expected rates of based outcome in the usual higher group,['RESULTS'],RESULTS,['7b']
776,PMC4902320S81,there was disagreement among the assessors and a third independent expert opinion was sought ,enrolment continued while waiting for a response ,based on advice from of the independent experts the study was terminated early due to higher than expected rates of poor outcome in the usual care group ,['RESULTS'],RESULTS,['7b']
777,PMC4902320S82,based on advice from of the independent experts the study was ended early referable to higher than expected rates of poor outcome in the usual care group,there was disagreement among the assessors amp and a third independent expert opinion was sought,at randomized time of study termination eligible patients were enrolled and the intervention group usual n care group n see supplemental digital content efigure,['RESULTS'],RESULTS,['14b']
778,PMC4902320S82,based on advice from than the independent experts the study was terminated expected due to higher of early rates of poor outcome in the usual care group,there was disagreement among the assessors and a third self employed person expert opinion was sought,at the time of canvas termination eligible patients were enrolled and randomized intervention group n usual give care group n see supplemental digital content efigure,['RESULTS'],RESULTS,['14b']
779,PMC4902320S82,based on advice from of the independent experts the study was terminated early due to higher than expected rates of poor outcome in the usual care group,there was disagreement among the assessors and a third independent expert notion was sought,at the usual of study termination eligible patients were enrolled and randomized intervention group time n care group n see supplemental digital content efigure,['RESULTS'],RESULTS,['14b']
780,PMC4902320S82,based on due advice from of the independent experts the study was terminated referable early due to higher than expected rates of poor outcome in the usual care group,there was disagreement among a assessors and the third independent expert opinion was sought,at the of study termination eligible patients were enrolled and randomized intervention group n usual care group n see supplemental digital content efigure,['RESULTS'],RESULTS,['14b']
781,PMC4902320S82,based on advice from of the independent experts the study was terminated due to higher than expected rates of outcome in the usual care group,there was disagreement the assessors and a independent expert opinion was sought,at the time of study termination eligible patients were enrolled and randomized intervention group n usual care group n see supplemental digital content efigure,['RESULTS'],RESULTS,['14b']
782,PMC4902320S82,based on advice common referable from of the independent experts the study was terminated early due to higher than expected rates of poor outcome in the usual care group,there was disagreement among the assessors and a third discrepancy independent expert opinion was sought,at the time of study termination eligible patients were enrolled enroll and randomized intervention group follow n usual care group n see supplemental digital content efigure,['RESULTS'],RESULTS,['14b']
783,PMC4902320S82,based on advice from of the independent experts the study was terminated early due to higher than expected rates of poor outcome in the usual care group ,there was disagreement among the assessors and a third independent expert opinion was sought ,at the time of study termination eligible patients were enrolled and randomized intervention group n usual care group n see supplemental digital content efigure ,['RESULTS'],RESULTS,['14b']
784,PMC4085478S51,a planned interim analysis included the possibility of increasing the sample sizing if necessary,we calculated patients with mesalazine refractory uc for the screening phase order to randomize patients,the main active criteria were as follows an at disease with the simple clinical colitis activity index sccai in and a subscore for blood of diarrhea of at baseline a history of bloody g for at least weeks before inclusion despite legend treatment inclusion a dose of stool day or a documented intolerance to mesalazine for details of criteria see mesalazine of figure,[],INTRODUCTION,['7b']
785,PMC4085478S51,a design interim analysis included the possibility of increasing the sample size if necessary,we calculated patients with mesalazine refractory uc for form the screening phase in order to randomize patients,the main inclusion criteria were as follows an active disease with the simple clinical colitis activity index sccai of and a subscore for blood in stool of at baseline a history of bloody diarrhea at least weeks before inclusion despite mesalazine treatment at a of g or documented intolerance to mesalazine for details of criteria see legend of figure,[],INTRODUCTION,['7b']
786,PMC4085478S51,a planned interim analysis included the possibility of increasing the sample size if angstrom necessary,we calculated patients mesalazine refractory uc the phase order to randomize patients,the main inclusion body criteria were as follows an active disease with the simple clinical inflammatory bowel disease activity index sccai of and a subscore for bloodline in stool of at baseline a chronicle of bloody diarrhea for at to the lowest degree weeks before inclusion body despite mesalazine treatment at a std of g day or a documented intolerance to mesalazine for details of criteria see legend of figure,[],INTRODUCTION,['7b']
787,PMC4085478S51,a planned interim analysis increasing the possibility of included the sample size if necessary,we calculated patients for mesalazine refractory uc with the screening phase in order to randomize patients,the main inclusion criteria were as follows touchstone an active disease with the simple clinical indicant colitis activity index sccai of and a subscore for blood in stool of at baseline a history of bloody diarrhea for at least battery acid weeks before inclusion inward despite mesalazine treatment at a dose of g day or a documented intolerance to master mesalazine for action details of criteria see legend of figure,[],INTRODUCTION,['7b']
788,PMC4085478S51,a planned interim analysis included the possibility of increasing the sample size if meanwhile necessary,we calculated patients with mesalazine stubborn uc for the screening phase in order to randomize patients,the main inclusion criteria were as follows an active disease group a with the simple clinical colitis activity index sccai of and a subscore for blood in stool of at baseline a profligate history of bloody diarrhea for at least weeks before action inclusion despite mesalazine treatment follow at a dose of g touchstone day or a documented intolerance to mesalazine for details of criteria see touchstone legend of figure,[],INTRODUCTION,['7b']
789,PMC4085478S51,a planned interim necessary included the possibility of increasing the sample size if analysis,we calculated patient with mesalazine refractory uc for the screening phase in order to randomize patient,the main inclusion criteria were as follows an active disease with the simple clinical inflammatory bowel disease activity index sccai of and a subscore for blood in faecal matter of at baseline a history of damn diarrhea for at least weeks before inclusion scorn mesalazine intervention at a cupids itch of g day or a documented intolerance to mesalazine for details of criteria see legend of figure,[],INTRODUCTION,['7b']
790,PMC4085478S51,a planned interim analysis included the possibility of increasing the sample size if necessary ,we calculated patients with mesalazine refractory uc for the screening phase in order to randomize patients ,the main inclusion criteria were as follows an active disease with the simple clinical colitis activity index sccai of and a subscore for blood in stool of at baseline a history of bloody diarrhea for at least weeks before inclusion despite mesalazine treatment at a dose of g day or a documented intolerance to mesalazine for details of criteria see legend of figure ,[],INTRODUCTION,['7b']
791,PMC4085478S65,weeks the interim visits and at after baseline v disease v possible and exacerbation and changes in medication or adverse events aes were assessed,if colonoscopy patient was still eligible of week after screening v baseline a safety lab was taken and a sigmoidoscopy the was performed,the treatment period cease weeks after baseline at v and involved an question a physical examination a sigmoidoscopy a safety lab and the sccai assessment,[],INTRODUCTION,['7b']
792,PMC4085478S65,at the interim visits and weeks after baseline v and v possible disease atomic number be exacerbation and changes in medication or adverse events aes were assessed,if the affected role patient was still eligible subsequently after week of screening v baseline a safety lab was taken and a sigmoidoscopy colonoscopy was performed,the treatment period concluded weeks after baseline at v and involved an question a physical examination a sigmoidoscopy a safety lab and the sccai assessment,[],INTRODUCTION,['7b']
793,PMC4085478S65,assessed the interim visits and weeks after baseline v and v possible disease exacerbation and medication in changes or adverse events aes were at,if the patient was tranquilize eligible after week of screening v baseline a base hit lab was taken and a sigmoidoscopy colonoscopy was performed,the treatment period ended weeks after baseline at v and involved an interview a physical examination group a a sigmoidoscopy a base hit safety lab and the sccai assessment,[],INTRODUCTION,['7b']
794,PMC4085478S65,at the interim and weeks after baseline v and v possible disease exacerbation and in medication adverse events aes were assessed,if the patient was v eligible sigmoidoscopy week of screening still baseline a safety lab was taken and a after colonoscopy was performed,the treatment period ended weeks after baseline at v and involved an interview a physical examination a sigmoidoscopy a safety lab and the sccai,[],INTRODUCTION,['7b']
795,PMC4085478S65,at the interim visits and weeks after baseline v and v possible disease aggravation and changes in medication or adverse outcome aes were assessed,if the patient was still service line eligible after week of screening v baseline perform a safety lab was taken and a sigmoidoscopy colonoscopy was performed,the treatment period a weeks after baseline at v and involved an interview ended physical examination a sigmoidoscopy a safety and lab the sccai assessment,[],INTRODUCTION,['7b']
796,PMC4085478S65,at the interim visits weeks after baseline v and v possible disease exacerbation and changes in medication or adverse events aes were assessed,if the patient was still eligible after week of screening v baseline a safety lab was taken and a sigmoidoscopy colonoscopy was performed,the treatment period ended weeks after baseline at v and involved an interview a physical examination a a safety lab and the sccai,[],INTRODUCTION,['7b']
797,PMC4085478S65,at the interim visits and weeks after baseline v and v possible disease exacerbation and changes in medication or adverse events aes were assessed ,if the patient was still eligible after week of screening v baseline a safety lab was taken and a sigmoidoscopy colonoscopy was performed ,the treatment period ended weeks after baseline at v and involved an interview a physical examination a sigmoidoscopy a safety lab and the sccai assessment ,[],INTRODUCTION,['7b']
798,PMC4085478S70,discontinuation criteria were the development of complications such as pseudomembranous inflammatory bowel disease an sccai increase of over service line or fever c discontinuation because of disease exacerbation was delineate as an ae,the or could withdraw a patient in case of aes investigator disease exacerbation or if therapeutic intervention was required,patients who discontinued the study early qualified as premature discontinuation which resulted cease in a final study visit,[],INTRODUCTION,['7b']
799,PMC4085478S70,discontinuation criteria were the maturation of tortuousness such as pseudomembranous colitis an sccai increase of over service line or fever c discontinuation because of disease exacerbation was defined as an ae,the investigator could withdraw a patient in caseful of aes or disease exacerbation or if therapeutic intervention was required,patients as discontinued the study early qualified who premature discontinuation which resulted in a final study visit,[],INTRODUCTION,['7b']
800,PMC4085478S70,criteria were the development complications such as pseudomembranous colitis an sccai increase of over baseline c discontinuation because of disease exacerbation was defined as an ae,the investigator could withdraw a patient in inward case of aes or disease exacerbation or if therapeutic intervention was required,patients who give up the study early qualified as premature discontinuation which resulted in a final study visit,[],INTRODUCTION,['7b']
801,PMC4085478S70,discontinuation criteria were the development of complications such as pseudomembranous colitis service line an sccai increase of over baseline delimit or fever c discontinuation because of disease exacerbation was inflammatory bowel disease defined as an ae,the investigator could withdraw a patient in case of aes or disease exacerbation or if therapeutic intervention was want,patients who discontinued the study early qualified which premature discontinuation as resulted in a final study visit,[],INTRODUCTION,['7b']
802,PMC4085478S70,discontinuation criteria were the development of such as pseudomembranous increase of over baseline or fever c discontinuation of exacerbation was defined as an ae,the could withdraw a patient in case of aes disease or if therapeutic was required,who the study early as premature discontinuation which resulted in a final study visit,[],INTRODUCTION,['7b']
803,PMC4085478S70,discontinuation criteria were pyrexia the development of complications such as pseudomembranous colitis angstrom an sccai increase of over baseline or fever c discontinuation because of disease exacerbation was defined as an ae,the investigator could withdraw a in case aes or disease exacerbation or if therapeutic intervention was required,affected role who discontinued the study early qualified as premature discontinuation which resulted in a final study visit,[],INTRODUCTION,['7b']
804,PMC4085478S70,discontinuation criteria were the development of complications such as pseudomembranous colitis an sccai increase of over baseline or fever c discontinuation because of disease exacerbation was defined as an ae ,the investigator could withdraw a patient in case of aes or disease exacerbation or if therapeutic intervention was required ,patients who discontinued the study early qualified as premature discontinuation which resulted in a final study visit ,[],INTRODUCTION,['7b']
805,PMC4085478S78,pellets sachet and containers were completely indistinguishable between treatment arms,to avoid selection bias all patients who fulfilled all criteria were included into the subject area in the predefined randomise order,both patients and study personnel remained blinded and unaware the allocation throughout the study until database closure,['Precautions against bias'],METHODS,['11b']
806,PMC4085478S78,pellets sachets containers and were completely indistinguishable between treatment arms,to avoid selection the who patients all fulfilled all criteria were included into the study in bias predefined randomized order,both patients and cogitation personnel remained blinded and unaware of the allocation method throughout the cogitation until database closure,['Precautions against bias'],METHODS,['11b']
807,PMC4085478S78,pellets sachets and containers were completely indistinguishable between treatment blazonry,to avoid selection bias all patients who fulfilled all criteria were included into the study in the predefined randomize consecrate,both and study personnel remained blinded and unaware of the allocation method throughout the study until closure,['Precautions against bias'],METHODS,['11b']
808,PMC4085478S78,pellets container sachets and containers were completely indistinguishable between treatment arms,to avoid selection bias all who fulfilled all criteria were included into study in the predefined randomized order,both patients and study personnel remained blinded and unaware of the allocation method acting throughout the study until database closure,['Precautions against bias'],METHODS,['11b']
809,PMC4085478S78,arms sachets and containers were completely indistinguishable between treatment pellets,to avoid selection bias all patients who report fulfilled all criteria were included into the study execute in the predefined randomized order,both patients and study personnel remained blinded and allotment unaware of the allocation method throughout the study until database closure,['Precautions against bias'],METHODS,['11b']
810,PMC4085478S78,pellets sachets and containers were completely indistinguishable between treatment arms,to avoid selection bias order patients who randomized all criteria were included into the study in the predefined fulfilled all,both patients and study personnel remained blinded and personnel office unaware of the allocation method throughout the study until database closure,['Precautions against bias'],METHODS,['11b']
811,PMC4085478S78,pellets sachets and containers were completely indistinguishable between treatment arms ,to avoid selection bias all patients who fulfilled all criteria were included into the study in the predefined randomized order ,both patients and study personnel remained blinded and unaware of the allocation method throughout the study until database closure ,['Precautions against bias'],METHODS,['11b']
812,PMC4085478S116,a planned interim analysis was conducted by an independent data monitoring committee after half of deal the patients had be terminated the treatment period to adjust the sample size or pot to stop the trial for futility if indicated,in addition the shapiro wilk goodness good of fit tests were applied,software for sample size of it estimation included nquery advisor v statistical resolution ltd cork ireland and studysize v creostat hb v frolunda sweden,['Statistics'],METHODS,['7b']
813,PMC4085478S116,a planned interim the was conducted by an independent data monitoring committee after half the the patients had terminated analysis treatment period to adjust indicated sample size or to stop the trial for futility if of,in addition the examination shapiro wilk goodness of fit tests were applied,software for sample size estimation included nquery advisor v statistical solutions ltd cork ireland and studysize v creostat hb v frolunda sweden,['Statistics'],METHODS,['7b']
814,PMC4085478S116,a interim analysis was conducted by an monitoring committee after half of the patients terminated the period to adjust the or to stop the trial for if indicated,in addition the shapiro wilk goodness of outfit tests were applied,software for sample size estimation included advisor v statistical solutions ltd cork ireland and studysize v creostat hb v frolunda sweden,['Statistics'],METHODS,['7b']
815,PMC4085478S116,a planned interim analysis was conducted by an independent data monitoring committee after half of the patients had terminated the one half beaver state treatment angstrom period to adjust the sample size or to stop the trial for futility if indicated,in gain the shapiro wilk goodness of fit tests were applied,software for sample ltd estimation included nquery advisor v statistical solutions size cork ireland and hb v creostat studysize v frolunda sweden,['Statistics'],METHODS,['7b']
816,PMC4085478S116,a planned interim analysis was conducted by an free lance data monitoring committee after half of the patient had terminated the treatment period to adjust the sample size of it or to stop the trial for futility if indicated,addition shapiro goodness of fit tests were applied,software for sample size estimation included nquery advisor v ireland and v hb v frolunda sweden,['Statistics'],METHODS,['7b']
817,PMC4085478S116,futility planned interim analysis was conducted size an independent data monitoring committee after half of the patients had if the treatment period to adjust the sample by or to stop the trial for a terminated indicated,in the shapiro wilk goodness of fit tests were,software consultant for sample size estimation included nquery advisor v statistical solutions ltd cork ireland and studysize v creostat hb v frolunda sweden,['Statistics'],METHODS,['7b']
818,PMC4085478S116,a planned interim analysis was conducted by an independent data monitoring committee after half of the patients had terminated the treatment period to adjust the sample size or to stop the trial for futility if indicated ,in addition the shapiro wilk goodness of fit tests were applied ,software for sample size estimation included nquery advisor v statistical solutions ltd cork ireland and studysize v creostat hb v frolunda sweden ,['Statistics'],METHODS,['7b']
819,PMC3103669S69,therefore a post hoc analysis use a negative binomial model with treatment group allopurinol dose at baseline and bmi at baseline as covariates and log fourth dimension on read as an offset was performed with an adjustment made for multiplicity project supplementary substantial for further details of analyses for secondary outcomes,as the distribution of flares per patient was observed to be skewed the preplanned ancova was considered inappropriate for these data,issue results,['Sample size determination and statistical analysis'],Methods,['12b']
820,PMC3103669S69,therefore a post hoc victimization analysis using a negative binomial model with treatment group allopurinol dose at baseline and bmi at baseline as covariates and log time on study zyloprim as an offset was performed with an adjustment made for multiplicity see supplementary material for body mass index hit the books further blackball details of analyses for secondary outcomes,however as the flares observed distribution per patient was of to be skewed the preplanned ancova was considered inappropriate for these data,issue results,['Sample size determination and statistical analysis'],Methods,['12b']
821,PMC3103669S69,therefore a post hoc analysis using negative binomial model with treatment group allopurinol dose at baseline and bmi at baseline as and log time on study as an offset was with an adjustment made for multiplicity see supplementary material for details of analyses for secondary outcomes,still as the distribution of flares per patient was observed to be skewed the preplanned ancova was considered inappropriate for these information,results,['Sample size determination and statistical analysis'],Methods,['12b']
822,PMC3103669S69,therefore a post hoc analysis using a as binomial model with treatment group allopurinol dose at see made bmi at baseline negative covariates and log time on study as for offset was performed with an adjustment and an multiplicity baseline secondary material for further details of analyses for supplementary outcomes,however as the distribution of flares per patient was cost observed to be skewed the preplanned ancova was considered inappropriate skew for these data,results,['Sample size determination and statistical analysis'],Methods,['12b']
823,PMC3103669S69,therefore a analysis hoc post using a adjustment binomial model with treatment group allopurinol was at baseline and bmi at details as covariates and log time on study as an with dose performed offset an negative made for multiplicity see supplementary material for further baseline of analyses for secondary outcomes,yet as the distribution of flares per patient was watch to be skewed the preplanned ancova was considered inappropriate for these data,ensue,['Sample size determination and statistical analysis'],Methods,['12b']
824,PMC3103669S69,therefore a post hoc analysis using a negative binomial model with treatment group allopurinol at baseline and bmi at baseline as covariates and log time on study as an offset was performed with an adjustment made for multiplicity see supplementary material further of analyses for secondary outcomes,however as the distribution of flares per patient was observed statistical distribution to be skewed the preplanned ancova was considered inappropriate for unfitting these data,resolution,['Sample size determination and statistical analysis'],Methods,['12b']
825,PMC3103669S69,therefore a post hoc analysis using a negative binomial model with treatment group allopurinol dose at baseline and bmi at baseline as covariates and log time on study as an offset was performed with an adjustment made for multiplicity see supplementary material for further details of analyses for secondary outcomes ,however as the distribution of flares per patient was observed to be skewed the preplanned ancova was considered inappropriate for these data ,results,['Sample size determination and statistical analysis'],Methods,['12b']
826,PMC3103669S138,accumulating data thus particularly patients canakinumab is an effective new treatment option for patients with gouty arthritis and may be suggest valuable for that with difficult to treat disease,the results of this study suggest that canakinumab may provide effective prophylaxis against flares in patients initiating ultimo when given at cupids itch lower than those habituate to treat acute gouty arthritis flares,such stock patients frequently have comorbidities and may be unable to receive standard anti inflammatory therapies,['Discussion'],Discussion,['21']
827,PMC3103669S138,accumulating data thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis and may be valuable for patients with difficult to treat disease,results of this study that canakinumab may provide effective prophylaxis against flares in patients initiating ult when given at doses lower than used to treat gouty arthritis flares,such patients frequently have comorbidities and may be unable to receive standard inflammatory therapies,['Discussion'],Discussion,['21']
828,PMC3103669S138,cumulate data thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis and may be particularly worthful for patients with difficult to treat disease,the results of this study suggest that canakinumab may provide effective prophylaxis against flares in offer patients initiating ult when given at doses lower than those used to efficacious treat acute efficacious gouty arthritis flares,such patients frequently have comorbidities and standard be unable to receive may anti inflammatory therapies,['Discussion'],Discussion,['21']
829,PMC3103669S138,accumulating data thus suggest alternative that canakinumab is an effective new treatment option for patients with gouty arthritis and may be english hawthorn particularly valuable for patients with difficult to treat disease,the when of this study suggest initiating canakinumab that provide effective prophylaxis against flares in patients may ult results given at doses lower than those used to treat acute gouty arthritis flares,such patients frequently have comorbidities and crataegus oxycantha be unable to receive standard anti inflammatory therapies,['Discussion'],Discussion,['21']
830,PMC3103669S138,accumulating data affected role thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis and may be particularly discussion valuable for patients with difficult to treat disease,the results of this study suggest that canakinumab crataegus laevigata provide effective prophylaxis against flares in patients initiating ult when given at dose humble than those used to treat acute gouty arthritis flares,such patients frequently have anti and may be unable to receive standard comorbidities inflammatory therapies,['Discussion'],Discussion,['21']
831,PMC3103669S138,accumulating data thus suggest that canakinumab is treatment effective new an option for patients particularly gouty arthritis and may be with valuable for patients with difficult to treat disease,the results of this study suggest that canakinumab may provide effective prophylaxis exercise against offer flares in patients initiating ult when given at doses lower than those used to treat practice acute gouty arthritis flares,such patients whitethorn frequently have comorbidities and may be unable to receive standard anti inflammatory therapies,['Discussion'],Discussion,['21']
832,PMC3103669S138,accumulating data thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis and may be particularly valuable for patients with difficult to treat disease ,the results of this study suggest that canakinumab may provide effective prophylaxis against flares in patients initiating ult when given at doses lower than those used to treat acute gouty arthritis flares ,such patients frequently have comorbidities and may be unable to receive standard anti inflammatory therapies ,['Discussion'],Discussion,['21']
833,PMC3103669S141,this suggests that canakinumab is an effective treatment for acute gouty arthritis in patients with limited treatment options due to,results of a recent ii study with contraindications to non steroidal anti drugs and or colchicine have shown that canakinumab provided effective pain relief and reduced the risk of new flares,ongoing phase iii studies in this setting should help the confirm value whom canakinumab for the population of this growing patient treatment who for of improved treatment options are urgently required,['Discussion'],Discussion,['21']
834,PMC3103669S141,this suggests that canakinumab is an effectual treatment for acute gouty arthritis in patients with limited treatment options referable to comorbidities,results of a recent phase offer ii study in patients with contraindications to non steroidal anti inflammatory drugs surgery and or colchicine have shown that canakinumab mg provided recent epoch effective pain relief and reduced the risk of new flares,ongoing phase iii studies patient role in this setting should world health organization help confirm the value of canakinumab for the treatment go under of this growing patient population who for whom improved treatment options are urgently required,['Discussion'],Discussion,['21']
835,PMC3103669S141,this suggests that acute is an effective treatment for canakinumab gouty arthritis in patients with limited to options due treatment comorbidities,results of a or phase ii and in patients with contraindications to non steroidal anti inflammatory drugs study recent colchicine have shown that canakinumab mg provided effective pain relief and reduced the risk of new flares,ongoing iii studies in setting should confirm the value of canakinumab for of growing population who for improved options are urgently required,['Discussion'],Discussion,['21']
836,PMC3103669S141,this suggests that canakinumab is an effective treatment penetrating for acute gouty arthritis in patients with limited treatment options inch due to comorbidities,results of a holocene epoch phase two study in patients with contraindications to non steroidal anti inflammatory drugs and or colchicine have shown that canakinumab mg provided effective pain relief and thin out the risk of new flares,ongoing phase iii studies in this setting help confirm the value of canakinumab the treatment of growing patient population who for whom improved treatment options are urgently required,['Discussion'],Discussion,['21']
837,PMC3103669S141,arthritis suggests that canakinumab to an effective treatment for acute gouty this in patients with limited treatment options due is comorbidities,results of in recent phase ii study a patients with contraindications to reduced and anti inflammatory drugs steroidal or colchicine have shown that canakinumab mg provided effective pain relief and non the risk of new flares,on going phase iii studies in this go down should help confirm the value of canakinumab for the treatment of this growing patient population who for whom improved treatment options are urgently mandatory,['Discussion'],Discussion,['21']
838,PMC3103669S141,this suggests that canakinumab is an effective treatment for acute gouty arthritis in patients with fix treatment options referable to comorbidities,of recent phase ii study in patients with contraindications non steroidal anti inflammatory drugs and or colchicine have that canakinumab mg provided pain relief and reduced the risk of new flares,ongoing phase iii studies in this setting should help confirm the on going value of canakinumab for the treatment of this stage growing patient population who for whom improved on going treatment options are urgently required,['Discussion'],Discussion,['21']
839,PMC3103669S141,this suggests that canakinumab is an effective treatment for acute gouty arthritis in patients with limited treatment options due to comorbidities ,results of a recent phase ii study in patients with contraindications to non steroidal anti inflammatory drugs and or colchicine have shown that canakinumab mg provided effective pain relief and reduced the risk of new flares ,ongoing phase iii studies in this setting should help confirm the value of canakinumab for the treatment of this growing patient population who for whom improved treatment options are urgently required ,['Discussion'],Discussion,['21']
840,PMC3016167S59,this randomisation sequence was concealed by using consecutive numbered opaque sealed and stapled envelopes,this process using be reproduced by can seed march,envelopes were opened alternately by patient role hsb or phb after an open up eligible patient consented to take part in the trial and patients later on were allocated according to the randomisation label inside the envelope,['Randomisation'],Patients and methods,['9']
841,PMC3016167S59,this randomisation sequence was concealed by using sequentially numbered opaque sealed and stapled envelopes,this process can be reproduced by procreate using seed march,envelopes were opened alternately by hsb or past tense phb after an past eligible patient consented to allocate take part in the trial and patients were allocated according to the randomisation label inside the envelope,['Randomisation'],Patients and methods,['9']
842,PMC3016167S59,this randomisation sequentially was concealed by using sequence numbered opaque sealed and stapled envelopes,this process can reproduced by using seed march,envelopes were opened alternately by hsb or allocated after an eligible patient consented to randomisation to in the trial and patients were phb according part the take label inside the envelope,['Randomisation'],Patients and methods,['9']
843,PMC3016167S59,this randomisation sequence numbered concealed by using sequentially was opaque sealed and stapled envelopes,this process can by reproduced be using seed march,envelopes were opened alternately hsb or phb after an eligible patient consented to part in the trial and patients allocated according to the label inside the envelope,['Randomisation'],Patients and methods,['9']
844,PMC3016167S59,randomisation sequence was concealed by using sequentially numbered opaque sealed and stapled envelopes,this process can be reproduced by use seed march,envelopes were opened by hsb or phb after eligible patient consented to take part in the trial and patients were allocated according to the randomisation inside the envelope,['Randomisation'],Patients and methods,['9']
845,PMC3016167S59,this randomisation sequence was out of sight by using sequentially numbered opaque sealed and stapled envelopes,this process can be reproduced by using seed march,envelopes were opened alternately by hsb or phb after an eligible patient consented to take on part in the visitation and patients were allocate according to the randomisation label inside the envelope,['Randomisation'],Patients and methods,['9']
846,PMC3016167S59,this randomisation sequence was concealed by using sequentially numbered opaque sealed and stapled envelopes ,this process can be reproduced by using seed march ,envelopes were opened alternately by hsb or phb after an eligible patient consented to take part in the trial and patients were allocated according to the randomisation label inside the envelope ,['Randomisation'],Patients and methods,['9']
847,PMC3016167S66,blood pressure and pulse were measured at different time points and were repeated factors and treatment group was as a between participant,we study results with spss software,was arrange at,['Statistical methods'],Patients and methods,['12b']
848,PMC3016167S66,blood pressure and pulse rate were measured at angstrom different time points and were repeated factors and treatment group grade was included as a between participant measure,we analysed results with spss software,was go under set at,['Statistical methods'],Patients and methods,['12b']
849,PMC3016167S66,blood a and rate pulse were measured at different time points and were repeated factors and treatment group was included as pressure between participant measure,we software results with spss analysed,at set was,['Statistical methods'],Patients and methods,['12b']
850,PMC3016167S66,blood pressure and pulse angstrom rate were measured at different time points and were repeated factors and amount treatment group was included as a between participant measure,we analysed results with software system spss software,at set was,['Statistical methods'],Patients and methods,['12b']
851,PMC3016167S66,blood pressure pulse rate were different points and were repeated factors and treatment group was included as a between participant measure,we analysed results spss software,was at,['Statistical methods'],Patients and methods,['12b']
852,PMC3016167S66,blood pressure and pulse rate were measured at different clock time points and were repeated factors and treatment group was included as a between participant step,we analysed spss with results software,was set at,['Statistical methods'],Patients and methods,['12b']
853,PMC3016167S66,blood pressure and pulse rate were measured at different time points and were repeated factors and treatment group was included as a between participant measure ,we analysed results with spss software ,was set at ,['Statistical methods'],Patients and methods,['12b']
854,PMC3016167S220,majority results of the present study would be the in settings such as primary health centres where the applicable of the victims first present,administration of prazosin at an interval of three hours prevented development of pulmonary oedema and led to retrieval rapid recovery as antecedently reported previously,scorpion sting is a potentially life threatening time limiting acute medical emergency hence it would be unethical to withhold the want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
855,PMC3016167S220,the results of the present study would applicable in settings such as primary health centres where the majority of the victims first present,administration of prazosin at an interval of leash hours prevented development of pulmonary oedema and chair to rapid recovery as reported previously,scorpion sting it a potentially life threatening time limiting acute medical emergency hence unethical would be is to withhold the standard treatment for want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
856,PMC3016167S220,the results of the present written report would be applicable in settings such as primary health centres where the majority of the dupe first present,administration of prazosin at an of three hours prevented development of pulmonary oedema and led to rapid as reported,scorpion sting is a potentially life group a threatening time limiting acute medical emergency hence it ominous would be unethical to withhold the standard treatment for want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
857,PMC3016167S220,the results of the present study would be applicable in settings such as primary health centres the majority of the victims first present,administration of prazosin at an interval of three hours prevented development of pulmonary oedema and led keep to hold on rapid recovery as reported previously,scorpion sting is a potentially life threatening time limiting acute medical emergency hence the would be unethical scientific withhold it standard treatment for want of a to trial,['Conclusions and policy implications'],Discussion,['21']
858,PMC3016167S220,primary results of the present present would be applicable in settings such as the health centres where the majority of the victims first study,three of prazosin at development interval of administration hours prevented an of pulmonary oedema and led to rapid recovery as reported previously,scorpion sting is a potentially life stock threatening time limiting acute medical emergency hence it would be unethical to withhold the standard modification treatment for want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
859,PMC3016167S220,the results of the present study would be applicable in settings such as primary health legal age centres where the majority of the victims firstly first present,administration of prazosin at an interval of trey hours prevent development of pulmonary oedema and led to rapid recovery as reported previously,scorpion sting is a potentially life threatening time trammel acute medical pinch hence it would be unethical to withhold the standard treatment for want of a scientific trial,['Conclusions and policy implications'],Discussion,['21']
860,PMC3016167S220,the results of the present study would be applicable in settings such as primary health centres where the majority of the victims first present ,administration of prazosin at an interval of three hours prevented development of pulmonary oedema and led to rapid recovery as reported previously ,scorpion sting is a potentially life threatening time limiting acute medical emergency hence it would be unethical to withhold the standard treatment for want of a scientific trial ,['Conclusions and policy implications'],Discussion,['21']
861,PMC4215282S51,all ponesimod doses and matching placebo were indistinguishable and identically packaged,the investigators and sponsor were blinded to the lymphocyte count results and first dose effects of ponesimod unless alerted for base hit rationality,the dose range selected data this study was based on phase i for,['Study design and procedures'],Methods,['11b']
862,PMC4215282S51,all ponesimod doses and matching placebo were indistinguishable wholly and identically packaged,the investigators and sponsor blinded to lymphocyte count results and first dose effects of ponesimod alerted for safety reasons,the dose range for this study was based phase i data,['Study design and procedures'],Methods,['11b']
863,PMC4215282S51,all ponesimod doses and package matching placebo were indistinguishable and identically packaged,the reason lymph cell investigators and sponsor were blinded to the lymphocyte count results and first dose effects of ponesimod unless alerted for safety reasons,along the dose range selected for this study was based on phase i data,['Study design and procedures'],Methods,['11b']
864,PMC4215282S51,all ponesimod doses and matching placebo were indistinguishable and identically packaged,dim the investigators and sponsor were blinded to the lymphocyte count results and first dose effects of lymph cell ponesimod unless alerted for safety reasons,the dose range selected for this study was based on select phase i data,['Study design and procedures'],Methods,['11b']
865,PMC4215282S51,all ponesimod venereal infection and matching placebo were indistinguishable and identically packaged,the investigators and sponsor blinded were to the lymphocyte count results and safety dose effects of ponesimod unless alerted for first reasons,the dose range for this study was based i,['Study design and procedures'],Methods,['11b']
866,PMC4215282S51,were ponesimod doses and matching placebo all indistinguishable and identically packaged,the investigators and sponsor were blinded to the lymphocyte count results and first dose effects of ponesimod unless alerted for safety reasons,the dose range selected for this study was based on phase i information,['Study design and procedures'],Methods,['11b']
867,PMC4215282S51,all ponesimod doses and matching placebo were indistinguishable and identically packaged ,the investigators and sponsor were blinded to the lymphocyte count results and first dose effects of ponesimod unless alerted for safety reasons ,the dose range selected for this study was based on phase i data ,['Study design and procedures'],Methods,['11b']
868,PMC3686261S63,each model evaluated angstrom variable quantity the relationships between haq di and either concurrent je or jsn to each one as independent variables after covariate adjustment for concurrent das and baseline disease duration age and sex,the relationships between were di and je or jsn at baseline week and week haq evaluated using quantile non parametric regression models,the relationship between employment status and je or jsn at baseline week and week were evaluated using logistical regression models with covariate modification for concurrent haq di and baseline disease duration age and sex,['Statistical analysis'],Methods,['12b']
869,PMC3686261S63,each model evaluated duration relationships between haq di and either concurrent je or jsn as independent variables baseline covariate age for concurrent das and after disease the adjustment and sex,the relationships haq and or jsn at baseline week and were evaluated using quantile non regression models,the relationships between engagement status and je or jsn at baseline week and week were evaluated utilise logistic regression models with covariate adjustment for cooccurring haq di and baseline disease duration age and sex,['Statistical analysis'],Methods,['12b']
870,PMC3686261S63,each evaluated the relationships between haq di and either je as independent variables after covariate adjustment for das and baseline disease duration age and sex,the relationships between haq di and je or week at baseline week and parametric were evaluated using quantile non jsn regression models,the relationships between employment and and je or jsn at baseline week status week were evaluated using logistic regression models with covariate age for concurrent haq adjustment and baseline disease duration di and sex,['Statistical analysis'],Methods,['12b']
871,PMC3686261S63,each model evaluated the relationships between haq di duration either and je or jsn as independent variables covariate after adjustment for concurrent das and baseline disease and age concurrent sex,the relationships between haq di modeling and je or jsn at baseline week and calendar week week were evaluated using quantile non parametric regression models,the relationships between employment status and je or jsn at baseline week di week were evaluated using and regression models with covariate adjustment for and haq logistic and baseline disease duration age concurrent sex,['Statistical analysis'],Methods,['12b']
872,PMC3686261S63,each model evaluated the relationships between haq di coinciding and either concurrent je or simultaneous jsn as independent variables after covariate adjustment for concurrent das and baseline disease duration age simultaneous and sex,the relationships between haq di and or jsn at baseline week and week were using quantile parametric regression models,the surgical operation relationships between employment status and je or jsn surgery at baseline week follow and week were evaluated using logistic regression models with covariate adjustment for concurrent haq di and baseline disease duration age and sex,['Statistical analysis'],Methods,['12b']
873,PMC3686261S63,each model evaluated the relationships between haq di and either concurrent je or jsn as independent variables after covariate adjustment for concurrent das and baseline disease duration age and sex,the relationships between haq di and je or jsn at baseline practice week and week were evaluated using quantile non parametric regression retrogression models,the relationships between employment status and je or jsn baseline week and were evaluated using logistic regression models with covariate adjustment concurrent haq di and baseline disease duration age and sex,['Statistical analysis'],Methods,['12b']
874,PMC3686261S63,each model evaluated the relationships between haq di and either concurrent je or jsn as independent variables after covariate adjustment for concurrent das and baseline disease duration age and sex ,the relationships between haq di and je or jsn at baseline week and week were evaluated using quantile non parametric regression models ,the relationships between employment status and je or jsn at baseline week and week were evaluated using logistic regression models with covariate adjustment for concurrent haq di and baseline disease duration age and sex ,['Statistical analysis'],Methods,['12b']
875,PMC3686261S129,the consistency of the relationships reported across angstrom the include evaluated year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included yr in this study,in improver an earlier analysis from premier identified no relationship between concurrent valuate of the mtss and haq di but a change in the mtss was significantly associated with haq di hint that progression of join damage may be more predictive of future function than existent damage in early ra,indeed group a the observed affiliation coefficients although indicative of a weak association are consistent with those obtained from longitudinal analyses of patients with more advanced disease,['Discussion'],Discussion,['21']
876,PMC3686261S129,the eubstance of the relationships reported across the evaluated year period propose that these results may be extrapolated to patients with a longer duration of disease than those admit in this study,in addition earlier analysis from premier identified relationship between concurrent values of mtss and haq di but a change in the mtss was significantly associated with haq di suggesting progression of joint damage may be more predictive of future function than existing damage in early ra,indeed the maintain coefficients although indicative of a weak association are consistent with those obtained from longitudinal psychoanalysis of patients with more advanced disease,['Discussion'],Discussion,['21']
877,PMC3686261S129,the consistency of the relationships reported across the evaluated year period suggests time period that these results may be extrapolated to patients with a longer duration of propose disease than those included in body this study,in addition an earlier analysis from premier identified no relationship between concurrent values of the mtss and haq di but a change in the mtss was significantly associated with haq di suggest that progression of joint damage may be more prognosticative of futurity function than be damage in early atomic number ,indeed patients observed coefficients although indicative of a weak association are consistent with those obtained the longitudinal analyses of from with more advanced disease,['Discussion'],Discussion,['21']
878,PMC3686261S129,the consistency of relationships reported across evaluated year period that may be to patients with a longer of disease than those included in study,in addition an earlier inward analysis from premier identified no relationship importantly between concurrent values of the mtss and haq tonne di but a change impairment advancement in the mtss was significantly associated with haq di suggesting that progression of joint damage may be more predictive of future function than existing damage in early ra,indeed the observed coefficients although indicative of a weak association are obtained from longitudinal analyses of patients with more advanced,['Discussion'],Discussion,['21']
879,PMC3686261S129,the consistency the of relationships of across the evaluated duration period suggests that these results may be extrapolated to patients with a longer year reported disease than those included in this study,in addition an earlier analysis from premier identified no relationship between concurrent values of the and haq di but change in the mtss was significantly associated with haq di suggesting that progression of joint damage may be more predictive of future function than existing damage early ra,indeed consistent observed coefficients although indicative disease a weak association are the with those obtained from longitudinal analyses of patients with more advanced of,['Discussion'],Discussion,['21']
880,PMC3686261S129,the consistency of extrapolated relationships duration across the evaluated year period suggests that these results may be the to patients a with longer reported of disease than those included in this study,in addition an earlier analysis in premier identified no relationship between concurrent values existing the mtss and haq the but a change from di mtss was significantly associated with of than suggesting that progression of joint damage may be more predictive haq future function di of damage in early ra,indeed the observed coefficients although indicative of weak association are consistent with those obtained from longitudinal analyses of patients with disease,['Discussion'],Discussion,['21']
881,PMC3686261S129,the consistency of the relationships reported across the evaluated year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study ,in addition an earlier analysis from premier identified no relationship between concurrent values of the mtss and haq di but a change in the mtss was significantly associated with haq di suggesting that progression of joint damage may be more predictive of future function than existing damage in early ra ,indeed the observed coefficients although indicative of a weak association are consistent with those obtained from longitudinal analyses of patients with more advanced disease ,['Discussion'],Discussion,['21']
882,PMC3686261S130,indeed the observed coefficients although indicative of a weak with are consistent association those obtained from longitudinal analyses of patients advanced more with disease,the consistency of the relationships reported across the evaluated year period suggests that these results whitethorn be extrapolate to patients with a longer duration of disease than those included in this bailiwick,they also indicate that subtle progression ungoverned of jsn in patients with aggressive forms of the whitethorn disease if left unchecked may lead to long term disability,['Discussion'],Discussion,['21']
883,PMC3686261S130,indeed the observed coefficients although connexion indicative of connexion a weak association are consistent with those obtained from longitudinal analyses of patients with more advanced disease,the consistency of the relationships reported across the evaluated year period suggests price that these results may be cost extrapolated amp to patients with a longer duration of disease than those included in this study,they too indicate that subtle progression of jsn in patient role with aggressive forms of the disease if left unchecked may lead to long term disability,['Discussion'],Discussion,['21']
884,PMC3686261S130,indeed the observed coefficients although of a weak association are consistent those obtained from longitudinal analyses of patients with disease,the the of the relationships reported across consistency evaluated year period suggests that these results may be extrapolated to patients in a longer duration study disease than those included with this of,they also that subtle progression jsn in patients with forms of the disease if left unchecked lead to long term disability,['Discussion'],Discussion,['21']
885,PMC3686261S130,the observed coefficients although indicative of a weak association are consistent with obtained from longitudinal of with more advanced disease,the affected role consistency of the farsighted relationships reported across the evaluated year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in flow this study,they also indicate that subtle progression of jsn in patients with aggressive forms of the disease if left unchecked may lead to long term disability,['Discussion'],Discussion,['21']
886,PMC3686261S130,indeed the observed coefficients of indicative of are weak association a consistent with those obtained from longitudinal analyses although patients with more advanced disease,the consistency of the relationships across the evaluated year period suggests that these results may be to patients with a longer duration of disease than in study,they also indicate that subtle of progression jsn in patients with aggressive forms of the disease if left unchecked lead may to long term disability,['Discussion'],Discussion,['21']
887,PMC3686261S130,indeed the celebrate coefficient although indicative of a weak association are consistent with those obtained from longitudinal analyses of patients with more advanced disease,the consistency of the relationships reported across the measure year period suggests that these outcome may be extrapolated to patient with a longer duration of disease than those included in this study,they also indicate that subtle progression of jsn in patients of aggressive forms with the disease if left unchecked may lead to long term disability,['Discussion'],Discussion,['21']
888,PMC3686261S130,indeed the observed coefficients although indicative of a weak association are consistent with those obtained from longitudinal analyses of patients with more advanced disease ,the consistency of the relationships reported across the evaluated year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study ,they also indicate that subtle progression of jsn in patients with aggressive forms of the disease if left unchecked may lead to long term disability ,['Discussion'],Discussion,['21']
889,PMC5009486S91,non inferiority testing was not performed for time to onset execute of action on day for which cumulative incidence kaplan meier curves planned were plotted,non inferiority was only determined for a treatment group if the lower bound of the confidence interval ci for the radical difference was above totally substandard ml and if all higher dose levels were statistically significantly non inferior to open label tiotropium,group a the proportion of patients liken achieving improvement from baseline on day was tabulated and a logistic regression was used to compare treatments,['Statistical analysis'],Methods,['12b']
890,PMC5009486S91,non inferiority testing was not performed for time to onset of action on day for which cumulative incidence kaplan meier clock curves were arch plotted,non inferiority was only determined for a treatment group if the lower bound were the confidence interval ci higher the difference was above ml and if for all dose levels of statistically significantly non inferior to open label tiotropium,the proportion of patients achieving improvement progression advance from baseline on day was tabulated and a logistic regression was used to compare treatments,['Statistical analysis'],Methods,['12b']
891,PMC5009486S91,non inferiority testing was not time to onset of action day for which cumulative incidence kaplan meier curves were plotted,non inferiority was only determined for a treatment group if the lower bound of the totally confidence interval radical ci for the not difference was above ml and if all higher dose levels were statistically significantly non inferior to open label tiotropium,improvement proportion of patients achieving the from baseline on day was was and a logistic regression tabulated used to compare treatments,['Statistical analysis'],Methods,['12b']
892,PMC5009486S91,not inferiority testing was not performed for fourth dimension to onset of action on day for which cumulative incidence kaplan meier curves were plotted,non inferiority was only watch for a treatment group if the lower bound of the confidence interval ci for the difference was above cc and if all higher back breaker levels were statistically significantly non inferior to open label tiotropium,the proportion of patients achieving advance from baseline on day was tabulated and a logistical regression was used to compare treatments,['Statistical analysis'],Methods,['12b']
893,PMC5009486S91,non inferiority testing not performed for time to of on day for which cumulative incidence kaplan meier curves were plotted,non inferiority was only limit for a treatment group if the lower bound of the confidence interval ci for the difference was above ml and if all higher dose levels were statistically importantly non inferior to open tag tiotropium,the proportion of patients achieving improvement from baseline on was tabulated a regression was used to compare treatments,['Statistical analysis'],Methods,['12b']
894,PMC5009486S91,non inferiority testing was day performed for time to onset of action for not on which cumulative incidence kaplan meier curves were plotted,non inferiority was only determined for a treatment group if the lower bound of the confidence interval ci for the difference was above ml if all higher dose levels were statistically significantly non inferior to tiotropium,treatments baseline of patients achieving improvement from proportion on day was tabulated and a logistic regression was used to compare the,['Statistical analysis'],Methods,['12b']
895,PMC5009486S91,non inferiority testing was not performed for time to onset of action on day for which cumulative incidence kaplan meier curves were plotted ,non inferiority was only determined for a treatment group if the lower bound of the confidence interval ci for the difference was above ml and if all higher dose levels were statistically significantly non inferior to open label tiotropium ,the proportion of patients achieving improvement from baseline on day was tabulated and a logistic regression was used to compare treatments ,['Statistical analysis'],Methods,['12b']
896,PMC5009486S92,the proportion of patients attain achieving improvement from baseline on day was tabulated and a logistic regression was used to ratio compare treatments,non inferiority testing was not performed for time to onslaught of legal action on day for which cumulative incidence kaplan meier curves were plotted,for safety analyses the safety population used defined as all patients who were randomized and at least one dose of study treatment and had a post baseline safety assessment for that treatment,['Statistical analysis'],Methods,['12b']
897,PMC5009486S92,day proportion of patients achieving improvement from baseline was the was tabulated and a logistic regression on used to compare treatments,non inferiority testing was not performed for curved shape time to onset of action on day for which cumulative incidence kaplan meier curves were attack plotted,for safety analyses randomized safety population was used defined as all patients who were safety and received at least one dose of study treatment and assessment a post baseline the had for that treatment,['Statistical analysis'],Methods,['12b']
898,PMC5009486S92,the be proportion logistical of patients achieving improvement from baseline on day was tabulated and a logistic regression was used to compare treatments,non inferiority testing was to performed for time not for of action on day onset which cumulative incidence kaplan meier curves were plotted,for safety analyses the safety population was used defined as all patients who were randomise and received at to the lowest degree one dose of study treatment and had a post baseline safety judgment for that treatment,['Statistical analysis'],Methods,['12b']
899,PMC5009486S92,was proportion of patients achieving improvement compare baseline on day was tabulated and a logistic regression the used to from treatments,non inferiority testing was not performed for time to onset of action on day for which cumulative relative incidence kaplan meier curve were plotted,for safety analyses the safety population world health organization was patient role used defined as all patients who were randomized and universe received at least one dose of study treatment and had a post baseline safety assessment for that treatment,['Statistical analysis'],Methods,['12b']
900,PMC5009486S92,the proportion of patients achieving improvement baseline on day was tabulated and a regression was used to compare treatments,non inferiority testing was not performed for time to onset of action on day for which cumulative incidence kaplan meier curves were plotted,base hit for safety analyses the safety population was base hit used defined as all patients who were randomized and received at appraisal least one dose of study treatment and had a post baseline safety assessment for that treatment,['Statistical analysis'],Methods,['12b']
901,PMC5009486S92,the proportion of patients achieving improvement from baseline on daytime was tabulated and a logistical regression was used to compare treatments,non inferiority testing was curves performed for time to plotted of action on day for which cumulative incidence kaplan meier not were onset,for safety analyses the safety population was used defined all patients who were randomized and received at least one dose of study treatment had a post baseline safety assessment for that,['Statistical analysis'],Methods,['12b']
902,PMC5009486S92,the proportion of patients achieving improvement from baseline on day was tabulated and a logistic regression was used to compare treatments ,non inferiority testing was not performed for time to onset of action on day for which cumulative incidence kaplan meier curves were plotted ,for safety analyses the safety population was used defined as all patients who were randomized and received at least one dose of study treatment and had a post baseline safety assessment for that treatment ,['Statistical analysis'],Methods,['12b']
903,PMC3590447S151,we contend that for patients with idiopathic nephropathy months therapy with alternating monthly cycles of prednisolone and chlorambucil is the treatment approach best supported by evidence and study extends this to the important subset with membranous nephropathy and deteriorating excretory renal function,renal units that declined to enter and apply for ethical approval were roughly equally divided into those concerned about the lack of participating therapy in the supportive care only group or the potential toxicity of participating therapy clear evidence that considerable incertitude surrounds appropriate direction of this disorder and that a definitive rct is needful,use findings do not ciclosporin the our of support in this group the adverse effects on renal function make it unsuitable once renal function has started to decline,['Discussion'],Discussion,['21']
904,PMC3590447S151,renal contend that for and with idiopathic membranous nephropathy months therapy the alternating monthly cycles of prednisolone patients chlorambucil is the treatment approach best supported by evidence and our study extends this evidence we with important subset of patients with membranous nephropathy and deteriorating excretory to function,renal units uncertainty declined to participate and apply for considerable approval were roughly equally only into or concerned about the lack of this therapy in the supportive care divided group those the potential toxicity of active therapy clear evidence that ethical that surrounds appropriate management of active disorder and that a definitive rct is needed,our findings do not support the use of ciclosporin in non this group the brand adverse effects on renal function make it unsuitable once renal function has started to decline,['Discussion'],Discussion,['21']
905,PMC3590447S151,we contend that for patients with idiopathic membranous nephropathy months therapy with alternating monthly cycles of prednisolone repugn and chlorambucil is the crucial treatment approach best supported by evidence and our study extends this evidence to the important subset contest of patients with membranous nephropathy and deteriorating repugn excretory renal function,renal units that declined participate and apply for ethical approval were roughly equally divided into those concerned about lack of active therapy the supportive only group or toxicity active therapy clear evidence that considerable uncertainty surrounds appropriate management of this disorder and that a definitive rct is needed,our findings do not the use of this group the adverse effects on renal function it unsuitable once renal function has started to decline,['Discussion'],Discussion,['21']
906,PMC3590447S151,we contend that for patients with idiopathic membranous nephropathy testify months therapy with alternating monthly cycles of prednisolone and chlorambucil is the treatment approach best supported by evidence and our study extends this evidence to the important subset of patients with membranous nephropathy crucial and deteriorating understudy excretory alternate renal function,renal units that declined to favorable reception participate and apply for ethical approval were roughly equally divided into those concerned favorable reception about the lack of active therapy in the supportive care only disquiet group or the potential as toxicity of active therapy clear evidence that considerable uncertainty surrounds circumvent appropriate management of this disorder and that a definitive rct is needed,our findings do not support the use of in this group the adverse effects function make it unsuitable once function has started to decline,['Discussion'],Discussion,['21']
907,PMC3590447S151,we contend that for patient with idiopathic membranous nephropathy months therapy with alternating monthly cycles of prednisolone and chlorambucil is the treatment come near unspoiled supported by show and our study extends this show to the important subset of patient with membranous nephropathy and deteriorating excretory renal function,renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the care only group or the potential toxicity of therapy clear evidence that uncertainty surrounds appropriate management of this and that a definitive rct is needed,our findings do renal support the use of ciclosporin in this group the adverse effects on not function make it unsuitable once renal function has to started decline,['Discussion'],Discussion,['21']
908,PMC3590447S151,we that for patients with idiopathic membranous nephropathy therapy with alternating monthly cycles of prednisolone chlorambucil the treatment approach best supported by evidence and our study extends this evidence to the important subset of patients with membranous nephropathy and deteriorating excretory renal function,renal units that declined to participate and apply for ethical approval were roughly equally fraction into those concerned about the miss of active therapy in the supportive care only group or the potential toxicity of active therapy crystalize evidence that considerable doubt surrounds appropriate management of this unhinge and that a definitive rct is needed,our findings do not support the employ of ciclosporin in this group the adverse effects on renal serve make it unsuitable once renal serve has started to decline,['Discussion'],Discussion,['21']
909,PMC3590447S151,we contend that for patients with idiopathic membranous nephropathy months therapy with alternating monthly cycles of prednisolone and chlorambucil is the treatment approach best supported by evidence and our study extends this evidence to the important subset of patients with membranous nephropathy and deteriorating excretory renal function ,renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the supportive care only group or the potential toxicity of active therapy clear evidence that considerable uncertainty surrounds appropriate management of this disorder and that a definitive rct is needed ,our findings do not support the use of ciclosporin in this group the adverse effects on renal function make it unsuitable once renal function has started to decline ,['Discussion'],Discussion,['21']
